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ABSTRACT 
Manipulation of biological targets using synthetic or naturally occurring 
organic compounds has been the focal point of medicinal chemistry. The work 
described herein centers on the synthesis of organic small molecules that are 
targeted either to cell surface receptors, to the ribosomal catalytic center or to 
human immunodeficiency virus reverse transcriptase.  
 Bleomycins (BLMs) are a family of naturally occurring glycopeptidic 
antitumor agents with an inherent selectivity towards cancer cells. DeglycoBLM, 
which lacks the sugar moiety of bleomycin, has much lower cytotoxicity in 
cellular assays. A recent study using microbbuble conjugates of BLM and 
deglycoBLM showed that BLM was able to selectively bind to breast cancer cells, 
whereas the deglyco analogue was unable to target either the cancer or normal 
cells. This prompted us to further investigate the role of the carbohydrate moiety 
in bleomycin. Fluorescent conjugates of BLM, deglycoBLM and the BLM 
carbohydrate were studied for their ability to target cancer cells. Work presented 
here describes the synthesis of the fluorescent carbohydrate conjugate. Cell 
culture assays showed that the sugar moiety was able to selectively target various 
cancer cells. A second conjugate was prepared to study the importance of the C-3 
carbamoyl group present on the mannose residue of the carbohydrate. Three 
additional fluorescent probes were prepared to improve the uptake of this 
carbohydrate moiety into cancer cells. Encouraged by the results from the 
fluorescence experiments, the sugar moiety was conjugated to a cytotoxic 
molecule to selectively deliver this drug into cancer cells.  
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 The nonsense codon suppression technique has enabled researchers to site 
specifically incorporate noncanonical amino acids into proteins. The amino acids 
successfully incorporated this way are mostly α-L-amino acids. The non-α-L-
amino acids are not utilized as substrates by ribosome catalytic center. Hoping 
that mutations near the ribosome peptidyltransferase site might alleviate its bias 
towards α-L-amino acids, a library of modified ribosomes was generated. 
Analogues of the naturally occurring antibiotic puromycin were used to select 
promising candidates that would allow incorporation of non-α-L-amino acids into 
proteins. Syntheses of three different puromycin analogues are described here.  
 The reverse transcriptase enzyme from HIV-1 (HIV-1 RT) has been a 
popular target of HIV therapeutic agents due to its crucial role in viral replication. 
The 4-chlorophenyl hydrazone of mesoxalic acid (CPHM) was identified in a 
screen designed to find inhibitors of strand transfer reactions catalyzed by HIV-1 
RT. Our collaborators designed several analogues of CPHM with different 
substituents on the aromatic ring using molecular docking simulations. Work 
presented here describes the synthesis of eight different analogues of CPHM. 
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CHAPTER 1 
INTRODUCTION 
1.1. CARBOHYDRATES 
Carbohydrates are a class of biopolymers that play an essential role in a 
range of crucial biological processes. They can be classified into four categories, 
namely monosaccharides, disaccharides, oligosaccharides and polysaccharides. 
Saccharides usually occur in nature as glycoconjugates like glycoproteins, 
proteoglycans, glycolipids, etc. Detailed determination of the functional aspects of 
these saccharides can be difficult for a number of reasons including the lack of 
facile carbohydrate sequencing techniques and efficient amplification methods.  
 The glycoconjugates that are present on cell surfaces are believed to 
participate in extracellular communication.1 Glycolipids on the cell surface are 
composed of a lipid membrane anchor that has a hydrophilic saccharide at the 
extracellular end.2 A significant number of proteins are modified post-
translationally through glycosylation.3 Glycoproteins usually have 
oligosaccharides comprising less than 15-20 monosaccharides. Proteoglycans, on 
the other hand, carry large polysaccharides (more than 100 monomers).4 In both 
cases, the sugar moiety is usually presented outside of the cell while the protein 
spans the membrane.5 Interactions of these surface carbohydrates with 
extracellular carbohydrates or receptor proteins are implicated in immune 
recognition, cell adhesion, cell migration, cellular recognition, and signaling 
events.6 Many diseases such as bacterial and viral infection, inflammation and 
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cancer have been associated with an abnormal expression of cell surface 
carbohydrates.7  
 Due to their crucial role in a range of biological processes, considerable 
effort has been dedicated to understanding protein–carbohydrate interactions.8 
Proteins that function by binding to carbohydrates can be broadly classified into 
three categories such as enzymes (glycosidases and glycosyltransferases), 
carbohydrate binding antibodies and lectins. Lectins recognize specific 
carbohydrate ligands to mediate biological phenomena like cell attachment, 
migration and invasion.9 Along with other receptors, lectins are an integral part of 
the innate immune system.10 Lectins utilize specific sugar motifs displayed by 
microorganisms to identify the pathogens and trigger an immune response.11 The 
carbohydrate ligands they interact with can be polysaccharides, oligosaccharides 
or even simple monosaccharides.12 For example, mannose-binding lectin (MBL) 
plays a crucial role in immune response by binding to specific oligosaccharides 
and monosaccharides present on the cell surface of many bacteria.13  
 Frequently, these proteins bind to multiple carbohydrate ligands 
simultaneously to achieve the desired affinity and specificity. Mechanistically, 
there are two pathways that can lead to enhancement of binding affinity due to 
polyvalency.14 If the protein has multiple binding sites, a multivalent ligand can 
potentially act as a chelating agent and give rise to stronger binding compared to a 
monomeric ligand. The structure of the spacer that carries all the ligands can be 
very important for efficient chelation. Another mechanism is called statistical 
rebinding.15 A multivalent ligand can increase the effective concentration of the 
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monovalent ligand near the binding site. This causes a decrease in the off-rate of 
protein–ligand interaction.  Plant lectins such as concanavalin A (con A) and 
wheat germ agglutinin (WGA) are examples of carbohydrate binding proteins that 
bind to multiple mannose and GlcNAc residues, respectively.16 The cholera toxin 
is a member of the AB5 family of toxins that binds to multiple sugars 
simultaneously.17 Bacterial adhesion lectins such as FimH (from E. coli), LecB 
(from P. aeruginosa) also involve in polyvalent interactions with host cell-
carbohydrates.18 Many multivalent carbohydrate-based ligands have been 
developed targeting these proteins for diagnostic or therapeutic purposes. Popular 
scaffolds used to produce multivalent systems have included cyclodextrins, 
calixerenes and dendritic spacers.19 More recently, gold nanoparticles, quantum 
dots and carbon nanotubes have been prepared that were equipped with several 
carbohydrates.20  
 Protein–carbohydrate interactions play an important role during cellular 
transformations. The state of glycosylation of glycoproteins and glycolipids on 
the cell-surface is regulated by glycosyltransferases and glycosidases. The level of 
expression of these enzymes can change dramatically depending on cell 
metabolism, activation and malignant transformation.21 Tumor cells express an 
altered distribution and composition of glycan epitopes (called tumor antigens) on 
their cell surface.22 This helps cancer cells escape recognition by immune cells 
during tumor development and metastasis.23 Glycoproteins such as 
carcinoembryonic antigen (CEA) and MUC1 have been used as biomarkers for 
certain types of cancer.24 Cancer cells also produce unusual levels of several 
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carbohydrate binding proteins such as galectins and selectins. These lectins have 
been implicated in cancer progression, metastasis, apoptotic resistance and 
angiogenesis.9 
Altered expression of cell surface glycans on tumor cells is a biomarker 
for disease diagnosis. Plant lectins that recognize cancer-specific glycan changes 
in tumor biopsies have been utilized to assess cancer prognoses and metastasis.25 
The lectins Helix pomatia agglutinin, Ulex europaeus agglutinin I and leucocyte-
agglutinating phytohaemagglutinin have been used for the diagnosis of breast and 
colorectal cancers, respectively.26 On the other hand, carbohydrate based ligands 
have been developed to inhibit carbohydrate-binding proteins that are involved in 
tumor growth, metastasis and angiogenesis.9  
 
1.2. BLEOMYCINS 
There are several anti-cancer drugs that have a sugar moiety attached to 
the cytotoxic core.27 It has been shown that the presence of sugar moieties causes 
a significant increase in cytotoxicity.28 DNA binding molecules such as 
epirubicin, esperamicin A1, and chromomycin A3 belong to this class.27 
Bleomycins are a family of glycopeptidic antitumor agents that are used clinically 
in combination chemotherapy against malignant lymphomas and squamous cell 
carcinomas. Umezawa and coworkers first isolated bleomycin from Streptomyces 
verticillus in 1966.29 Since its discovery bleomycin (BLM) quickly gained 
attention because of its ability to selectively target various cancer cells.30 As 
shown in Figure 1.1, the BLMs have four distinct structural domains, including an 
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N-terminal metal binding domain, linker domain, C-terminal bithiazole domain 
and the carbohydrate domain, the last consisting of D-mannose and L-gulose. The 
clinically used bleomycin mixture, called blenoxane has BLM A2 and BLM B2 as 
its major constituents.31 BLM targets 5ʹ′-GC-3ʹ′ and 5ʹ′-GT-3ʹ′sequences in DNA 
and causes oxidative DNA damage. In vitro experiments have shown it can also 
damage RNA and RNA–DNA heteroduplexes.32 
 
Figure 1.1. Structural domains of bleomycin.33 
 
1.3. INCORPORATION OF UNNATURAL AMINO ACIDS INTO 
PROTEINS 
Techniques that allow the manipulation of protein structure are invaluable 
for understanding the correlation between protein structure and function, and for 
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generating proteins with novel properties. Site directed mutagenesis of DNA has 
been used to replace a specific residue of a protein with another desired amino 
acid. Recently site-specific incorporation of noncanonical amino acids has drawn 
significant attention because of its potential applications in studies of protein 
stability and folding, protein–ligand and protein–protein interactions. This 
strategy enables researchers to introduce a range of new functionalities other than 
those found in 20 proteinogenic amino acids.  
The translation of a protein requires the sequential condensation of 
specific amino acids according to the nucleotide sequence of the respective 
mRNA. There are 64 codons and 61 of them code for the natural amino acids. 
These leave three that are called nonsense codons or stop codons. The amino 
acids are assigned to a particular codon by the use of tRNAs which have an 
anticodon loop. The enzymes that activate a particular tRNA with its cognate 
amino acid are called aminoacyl-tRNA synthetases (aa-RSs).34 Although the 
genetic code is nearly universal, aa-RSs from one species generally do not readily 
aminoacylate tRNAs from other species.35 The process of peptide bond formation 
is catalyzed by the ribosome and includes four steps: initiation, elongation, 
termination and recycling. Ribosome, mRNA, initiator tRNA, initiation factors 
and guanosine triphosphate form the initiation complex. Then the next aminoacyl-
tRNA (aa-tRNA) is introduced into the ribosome catalytic center with the help of 
elongation factors. The new aminoacyl-tRNA pairs with the next codon in the 
mRNA and the amino acid from the initiator tRNA is transferred to it at the 
peptidyltransferase center. Then the next tRNA is introduced and the elongation 
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cycle is repeated until the ribosome encounters one of the three stop codons. The 
stop codon causes release of the peptide from the last aminoacyl-tRNA and the 
ribosomal apparatus with the help of release factors. Finally, the ribosome is 
recycled for another round of protein production. 
Incorporation of unnatural amino acids has been attempted using both 
chemical and biosynthetic methods. Initial efforts involved chemical modification 
of certain amino acids within a biochemically expressed protein. This method 
often lacked the desired specificity and selectivity.36 Solid phase peptide 
synthesis, in combination with native chemical ligation, can be used to 
incorporate almost any noncanonical amino acid. This strategy, however, is 
limited to smaller proteins (~200 residues) and restricted by the requirement for 
amino acid residues that can participate in the native ligation.37 On the other hand, 
first of the biosynthetic strategies involved growing bacteria in the presence of 
noncanonical α-amino acids. The unnatural amino acids incorporated were close 
structural analogues of the natural ones that the bacteria were unable to 
synthesize.38  
Incorporation of unnatural amino acids into proteins at predetermined 
positions was achieved by the use of suppressor tRNA technology.39 At first, a 
stop codon such as TAG (the amber stop codon) was introduced at the desired 
position of the gene of interest. Then a suppressor tRNA, having CUA as the 
anticodon, was misacylated with the amino acid of interest.40 The misacylated 
suppressor tRNA recognized the stop codon in the mRNA and mediated the 
incorporation of the amino acid using an in vitro protein synthesizing system. 
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Both chemical and biosynthetic approaches have been utilized for the 
misacylation of tRNA.41  
Hecht and coworkers first achieved tRNA chemical misacylation by 
ligating the aminoacylated dinucleotide pCpA to a tRNA lacking the last two 
nucleotides at its 3ʹ′ end, using T4 RNA ligase.42 Schultz and colleagues later used 
aminoacylated pdCpA, containing a deoxycytidine, to overcome the synthetic 
difficulties for aminoacylation of pCpA.43 Aminoacyl-pdCpAs are now used 
routinely to produce tRNAs misacylated with unnatural amino acids. As the 
chemically misacylated tRNAs cannot be regenerated in the cell, a stoichiometric 
amount is consumed during protein synthesis. An alternative strategy for 
misacylating tRNAs involves the evolution of an orthogonal tRNA:aa-RS pair. 
Pairs from different organisms have been used for this purpose.44 In addition, 
directed evolution has allowed the isolation of specific tRNA:aa-RS pairs selected 
for aminoacylation of various noncanonical amino acids.44  
 
1.4. ANTI-HIV THERAPIES 
 Human immunodeficiency virus (HIV) induces acquired immune 
deficiency syndrome (AIDS) in humans by gradually damaging the host immune 
system.45 Since its discovery, substantial effort has been made to develop anti-
HIV therapies. The drugs currently approved by the Food and Drug 
Administration (FDA) for anti-HIV treatment can be classified into six categories 
including non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside 
reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), fusion 
	   9 
inhibitors (FIs), CCR5 antagonists, and integrase inhibitors (INIs). Drugs 
belonging to each class block a crucial step of the viral life cycle.46  
 The life cycle of HIV starts by its recognition of the CD4 receptors on the 
host cell surface.47 Following interaction with the chemokine co-receptor CXCR4 
or CCR5 the viral envelope is fused with the cell membrane, causing the release 
of the viral RNA into the cytoplasm of the host cell. The enzyme reverse 
transcriptase then synthesizes double stranded viral DNA from the viral RNA 
templates. The double stranded DNA is incorporated into the host genome with 
the help of integrase. The cellular transcription and translation machinery then 
produces viral proteins and viral RNA. Finally the virion is assembled and it buds 
off from the host cell as a Gag-Pol polyprotein. This polyprotein is subsequently 
cleaved by viral protease to generate mature virion particles.  
 The nucleoside reverse transcriptase inhibitors (NRTIs) are nucleoside 
analogues that lack 2ʹ′ and 3ʹ′ OH groups. Inside the cell, these compounds are 
converted to their triphosphate forms and participate in the reverse transcription 
process, resulting in chain termination.48 The first of these three phosphorylations 
is believed to be the slowest. NRTIs already equipped with a phosphoramidate 
group are being developed as pro-drugs to bypass the first phosphorylation step.49 
The incorporated NRTIs can also be cleaved from the 3ʹ′-end of the growing DNA 
in the drug resistant HIV strains. To reduce the occurrence of drug resistance, 
phosphonate groups have been attached at the 5ʹ′-end of the nucleoside inhibitors. 
Once incorporated, phosphonate esters are harder to repair as compared to 
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phosphodiester linkages.50 At present there are seven NRTIs approved by the 
FDA for clinical use.  
 Non-nucleoside reverse transcriptase inhibitors (NNRTIs) bind to an 
allosteric pocket of HIV RT near its polymerase active site.51 Binding of these 
inhibitors causes conformational changes in the architecture of the active site, 
resulting in diminished polymerase activity. Rapid emergence of drug resistance 
has plagued the clinical use of NNRTIs targeted against HIV.52 Various new 
drugs belonging to this class are being developed for use against the drug-resistant 
strains. Five FDA-approved NNRTIs are used currently for the treatment of HIV-
infected patients.  
 The FDA has approved as many as eight protease inhibitors (PIs) for 
clinical use against HIV. During replication, the viral proteins are initially 
expressed as polymeric precursors gag and gag-pol. HIV protease then cleaves the 
polyproteins to form mature virions.53 This enzyme, having two aspartic acid 
residues at the catalytic center, behaves like an aspartic acid protease.54 Most of 
the protease inhibitors are non-hydrolyzable transition state analogues of the 
peptide hydrolysis reaction. Appearance of drug resistance and significant toxicity 
has limited the use of PIs. New inhibitors are being designed to overcome these 
problems. 
 During the anchoring of the virion on the host cell surface, glycoprotein 
gp120 interacts with host cell surface receptors and releases the fusion peptide 
gp41. This peptide catalyzes the fusion of the host cell membrane and virion 
envelope.55 The fusion inhibitors (FIs) mimic the gp41 peptide and block the 
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fusion process. Currently enfuvirtide is the only FDA-approved FI.56 The cost of 
production and emergence of resistance are the major obstacles for new fusion 
inhibitors to overcome in clinical trials.      
 The cellular targeting process of HIV commences with the interaction 
between CD4 receptors on the cell surface and gp120 viral protein. This binding 
causes conformational changes in gp120 exposing a new site for interaction with 
cellular chemokine co-receptors such as CXCR4 and CCR5.57 Antagonists of 
these co-receptors can be used to block the HIV infection process. Maraviroc, a 
CCR5 antagonist, is the only drug approved for clinical use from this class. 
 Integrase inhibitors (INIs) block the process of integration of proviral 
DNA into the host cell chromosome. This step is catalyzed by the viral enzyme 
integrase. Integrase is also responsible for the processing of the newly reverse-
transcribed viral cDNA.58 There is only one integrase inhibitor, raltegravir, which 
is currently approved by the FDA.  
 Most of these drugs are used in combinations. Although these drugs have 
significantly improved the state of morbidity and mortality in HIV-infected 
patients, rapid emergence of drug resistance and cytotoxicities have been their 
dose limiting factors. The discovery of new candidates with low toxicity, high 
bioavailability and new modes of action are always desirable.   
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CHAPTER 2 
SYNTHESIS OF BLEOMYCIN-DISACCHARIDE CONJUGATES FOR 
SELECTIVE TARGETING OF CANCER CELL LINES 
2.1. INTRODUCTION  
The exact roles of the carbohydrate moiety in the cytotoxic activity of 
bleomycins (BLMs) still require definition. Reports in the literature indicate 
stronger cytotoxicity of bleomycin relative to deglycoBLM in cellular and in vivo 
assays.59 The carbamoyl group present on the D-mannose of the disaccharide has 
been implicated as the sixth metal binding site of BLM.60 However, this 
hypothesis cannot explain the fact that in cell free systems deglycoBLM retains 
significant DNA cleaving activity. In addition, in order to induce DNA damage, 
the metal ion chelated by BLM binds molecular oxygen, which necessitates a free 
binding site on the metal ion.61 DeglycoBLM analogues have even been utilized 
previously as synthetically expedient models to determine the DNA damage 
profiles of the corresponding BLM analogues.62  
Due to their inherent selectivity towards tumor cells,63 BLM–metal 
complexes such as 57Co-BLM and 111In-BLM have been used as in vivo 
radioactive tumor-imaging agents.64 The Co-BLM complex, however, was not 
usable clinically due to the extended half-life (270 days) of 57Co and the rapid 
excretion rate of the complex. 111In-BLM complex was too weak to be useful in 
vivo.64  A new imaging agent, BLEDTA, was developed in which an 
ethylenedinitrilotetraacetic acid (EDTA) moiety was attached to the C-terminal 
end of BLM A2. 111In-BLEDTA successfully imaged various carcinomas in 
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patients. Notably, 111In-deglycoBLEDTA was ineffective in similar imaging 
experiments.65 This result hints at the carbohydrate domain being involved in the 
cellular recognition and uptake of BLM.  
The above results prompted our lab to further investigate the role played 
by the carbohydrate domain in the tumor cell recognition process. A detailed 
understanding of tumor cell recognition and uptake might lead to identification of 
particular cell-surface receptors and the participating structural domains in 
bleomycin. The structural domain(s) of BLM directly responsible for tumor 
targeting could be further exploited to develop selective tumor imaging 
agents/targeted drug delivery vehicles. The tumor targeting ability of BLM and 
deglycoBLM were studied through imaging experiments involving cells treated 
with microbubbles conjugated to bleomycins.66 Originally used as contrasting 
agents in ultrasonography, microbubbles are lipid membranes encapsulating a 
gaseous core containing some inert gas such as air, nitrogen, or a 
perfluorocarbon.67 The microbubble surface was modified with streptavidin. BLM 
A5, deglycoBLM A5 and BLM-disaccharide were conjugated to biotin (Figure 
2.1) and were conjugated to the microbubbles through streptavidin–biotin 
binding. The targeted microbubbles were then incubated with cultured MCF-7 
breast carcinoma cells and MCF-10A non-cancerous breast cells and visualized 
through a Zeiss Axiovert 200M microscope. BLM and BLM-disaccharide-
conjugated microbubbles adhered selectively to the cancer cells but not to the 
“normal” cells.66  
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Figure 2.1. Biotin conjugates of bleomycin A5, deglycobleomycin A5 and BLM-
disaccharide. 
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disaccharide itself to adhere to the tumor cells established that this domain is 
sufficient for tumor targeting. As the microbubbles were modified with multiple 
BLMs or sugars the observed interaction with the cell surface receptors might 
have been facilitated by polyvalency.  
The microbubble experiment established the role of the disaccharide 
domain in tumor cell surface binding by BLM but this technique is limited to cell 
surface interactions. The possible mechanism of cell uptake of bleomycin, 
whether by passive diffusion or active transport, cannot be resolved using this 
technique. Accordingly, we employed fluorescently labeled BLMs and analogues, 
in conjunction with fluorescence microscopy, to address these issues. Typically, 
fluorescence microscopy experiments require fluorescent reporter molecules (e.g., 
dye) which are tagged to analytes, and the resulting fluorescent conjugates are 
incubated with the target cell lines in vitro. A fluorescence microscope is then 
used to visualize the fluorescence signal from the probe, permitting its location to 
be determined.  
There are several factors to be considered while choosing the fluorescent 
probe. First, the conjugation reaction should lead to a product that has a known 
number of reporter molecules attached to the analyte in a structurally defined 
fashion so that meaningful quantitative data can be extracted from the imaging 
experiments. Fluorescent dyes can bind nonspecifically to cells and can also 
possess their own cell-uptake mechanisms. Ideally the fluorescent reporter 
molecule should not be able to bind to or enter the cell on its own. This can be 
easily tested using a control probe without the analyte. Usually the dye and the 
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analyte molecule are connected through a linker of sufficient length so that the 
interaction of the analyte with the cell surface is unperturbed by the dye. Another 
significant issue associated with fluorescent microscopy in cellular systems is the 
occurrence of autofluorescence, which results in very high background signals.68 
Autofluorescence can be avoided either by using a reporter with very high signal 
strength or by employing a dye that emits outside of the range of cellular 
autofluorescence wavelengths.  
After much trial and error, we focused on Cy5** as the reporter of choice. This 
dye was conjugated with BLM A5 and deglycoBLM A5 (Figure 2.2) and these 
probes were incubated with breast, prostate, colon and lung cell lines (both cancer 
and non-cancerous). Cy5**COOH, used as the control, showed no binding/uptake 
by any of these cell lines. BLM-Cy5** showed selective association/uptake by all 
of the cancer cell lines mentioned above. DeglycoBLM-Cy5** had minimal 
association with the cells. The work described herein further explored the role of 
the disaccharide domain in the binding/uptake of bleomycins, with the goal of 
utilizing the acquired knowledge for application in targeted tumor imaging and 
drug delivery.  
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Figure 2.2. Structure of Cy5**-conjugates with BLM, deglycoBLM and the 
BLM-disaccharide. 
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is described in Scheme 2.1. The C-4 and C-6 OH groups of methyl α-D-
mannopyranoside were protected as a benzylidene acetal. Selective protection at 
C-2 with dibutyl tin oxide followed by alkylation at C-3 with benzyl bromide 
gave compound 2.4. Treatment with acetic anhydride in presence of catalytic 
H2SO4 resulted in the acetylated product 2.5 in 86% yield. Reductive 
debenzylation followed by activation as the p-nitrophenyl carbonate provided 
compound 2.7. Ammonolysis of the carbonate gave 3-O-carbamoylmannose 
intermediate 2.8 in 91% yield. The anomeric acetate was selectively removed 
with the acetate salt of hydrazine. The resulting free hydroxyl group was 
subsequently activated as a diphenyl phosphate ester using DMAP and 
chlorodiphenyl phosphate to obtain the activated mannose monosaccharide 2.10 
in 75% yield. 
 
Scheme 2.1. Synthesis of the activated mannose monosaccharide (2.10).69 
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Synthesis of the requisite gulose moiety (Scheme 2.2) was achieved 
following Dondoni’s method.69 L-Xylose (2.11) was protected as diethylthioacetal 
2.12. The aldehyde was regenerated from 2.12 by treatment with HgO/HgCl2 and 
immediately treated with 2-(trimethylsilyl)thiazole (2.13) to avoid decomposition. 
Desilylation of the addition product with TBAF provided intermediate 2.14 in 
57% yield from compound 2.12. The free hydroxyl group was then benzylated to 
obtain compound 2.15. The thiazole moiety was converted to the aldehyde. 
Intermediate 2.16 was immediately treated with aq AcOH to permit cyclization 
and the free OH groups were acetylated with acetic anhydride to afford compound 
2.17 in 52% yield. Debenzylation with Pd/C gave the appropriately protected 
acceptor 2.18 in 88% yield. 
 
Scheme 2.2. Synthesis of the gulose acceptor (2.18).69 
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disaccharide 2.19 in 62% yield (Scheme 2.3). Selective deprotection of the 
anomeric OH group followed by activation as the diphenyl phosphate ester 2.20 
proceeded in 84% yield. The glycosyl phosphate was subjected to TMSOTf 
mediated coupling with linker 2.21 to give compound 2.22 in 80% yield. The 
linker was synthesized from 2-(2-aminoethoxy)ethanol by treatment with CBzCl 
and triethylamine. Complete deacetylation with NaOMe-MeOH, followed by 
reductive removal of the CBz group, afforded the BLM-disaccharide linker 2.23. 
Finally, compound 2.23 was condensed with the succinimidyl ester 2.24 (prepared 
from the corresponding carboxylic acid) to obtain the BLM-disaccharide-Cy5** 
2.1 in 42% yield. 
 
Scheme 2.3. Synthesis of BLM-disaccharide-Cy5** (2.1).69 
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DecarbamoylBLM-disaccharide-Cy5** 2.30 lacked the carbamoyl group 
at C-3 of the mannose residue. The purpose of synthesizing this fluorescent 
conjugate was to test whether the C-3 carbamoyl group played any role in tumor 
targeting. It was synthesized from disaccharide 2.27 (Scheme 2.4).70 Synthesis of 
compound 2.27 commenced with peracetylation of α-D-mannopyranoside. 
Selective deacetylation of the anomeric OH group and subsequent activation with 
chlorodiphenyl phosphate in the presence of DMAP and triethylamine afforded 
the glycosyl donor 2.26. Coupling of the activated ester and glycosyl acceptor 
2.18 was promoted by TMSOTf and afforded the disaccharide 2.27 in 60% yield. 
The disaccharide was subjected to selective deprotection at the anomeric position 
followed by activation as diphenyl phosphate ester 2.28. Coupling of 2.28 with 
linker 2.21 proceeded in 70% yield. Compound 2.29 was subjected to complete 
deacetylation followed by CBz deprotection. The intermediate was treated with 
Cy5**COOSu to afford the decarbamoylBLM-disaccharide-Cy5** 2.30.  
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Scheme 2.4. Synthesis of decarbamoylBLM-disaccharide-Cy5** (2.30).70 
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disaccharide (2.36) in 76% yield. Reductive deprotection of the CBz group 
followed by condensation with succinimidyl ester 2.24 provided the Boc 
protected fluorescent conjugate 2.38. The Boc groups were removed by treatment 
with 60% aq CF3COOH to afford the fluorescent conjugate 2.39, having two 
primary amino groups, in 67% yield.  
 
Scheme 2.5. Synthesis of Cy5**-L-lysyl-L-lysyl-BLM-disaccharide (2.39). 
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The dipeptide in the conjugate 2.39, containing two L-lysines, might be 
susceptible to peptidases present inside the cells or in the cell culture media. 
Conjugate 2.48 was synthesized to overcome this problem by replacing the L-
lysines with their D-enantiomers (Scheme 2.6). Methylation of the commercially 
available Nα-CBz-Nε-Boc-D-lysine (2.40) proceeded in 87% yield. The CBz group 
was removed reductively to give compound 2.42 having a free amine. Coupling of 
this free amine with the protected lysine 2.40 was promoted by HATU affording 
the protected dipeptide ester 2.43 in 84% yield. The methyl ester was cleaved 
using LiOH in aq THF to obtain the dipeptide 2.44. BLM-disaccharide linker 2.23 
was then condensed with this dipeptide linker in the presence of HATU. 
Compound 2.45 was then subjected to reductive deprotection of the CBz group 
and the product was condensed with succinimidyl ester 2.24 to afford compound 
2.47 in 26% yield. Removal of the Boc groups with 60% aq TFA generated the 
fluorescent probe 2.48 in 62% yield. 
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Scheme 2.6. Synthesis of Cy5**-D-lysyl-D-lysyl-BLM-disaccharide (2.48). 
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CF3COOH in CH2Cl2 proceeded in quantitative yield to produce tri-acid 2.54. The 
tri-succinimidyl ester 2.55 was prepared by the use of N-hydroxysuccinimide and 
DCC in THF. Compound 2.22 (Scheme 2.3) was subjected to hydrogenolysis of 
the CBz and the free amine intermediate 2.56 was immediately coupled with the 
activated tri-ester 2.55 to produce the trimerBLM-disaccharide 2.57 in 81% yield. 
Deprotection of acetyl and CBz groups was followed by condensation with 
Cy5**COOSu (2.24) to obtain the trimerBLM-disaccharide-Cy5** 2.59 in 15% 
yield. 
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Scheme 2.7. Synthesis of trimerBLM-disaccharide-Cy5** (2.59). 
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Compound 2.23 was condensed with APA to provide the APA-BLM-disaccharide 
conjugate 2.62 in 37% yield. Conjugate 2.65 was designed to be a tumor selective 
drug delivery vehicle. Once inside the cell, the cellular esterases should release 
the cytotoxic drug, in this case APA, from the conjugate. The synthesis started 
with the esterification of APA with tert-butyl 6-hydroxyhexanoate (2.63) to 
obtain compound 2.64 in 60% yield. The tert-butyl group was removed by the use 
of CF3COOH in dichloromethane and the resulting acid was condensed with 
compound 2.23 to afford the conjugate 2.65 in 53% yield. 
 
Scheme 2.8. Synthesis of APA-BLM-disaccharide conjugates 2.62 and 2.65. 
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Scheme 2.9 describes the synthesis of a bleomycin A5 analogue 2.68 in 
which the disaccharide is attached to deglycoBLM via a polyamine linker. The 
acetylated disaccharide 2.19 was activated as the p-nitrophenyl carbonate (2.67) 
by selective deacetylation of the anomeric OH with acetate salt of hydrazine 
followed by treatment with p-nitrophenyl chloroformate in the presence of 
DMAP. The carbonate was then coupled with deglycoBLM-Cu(II) complex. The 
resulting intermediate was deprotected by the use of hydrazine to afford 
compound 2.68 in 39% yield.  
 
Scheme 2.9. Synthesis of bleomycin A5 analogue 2.68. 
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elimination of the interference arising from cellular autofluorescence. The 
presence of four sulfonates in the dye molecule (Figure 2.2) makes it highly 
soluble in aqueous media and also impermeable to the cell membrane on its own. 
All these characteristics made Cy5** a perfect dye candidate for our study. The 
cells were cultured on 16-well glass chamber slides until the cell confluence was 
about 70%. The fluorescent conjugates were then incubated with the cells at 37 
°C for 24 h. The cells were washed with PBS and fixed with 4% 
paraformaldehyde at 37 °C for 5 min. After drying for 24 h the slides were 
imaged using a Zeiss Axiovert 200M inverted microscope equipped with a 300-w 
xenon lamp (Shutter), ET-CY5 cyanine filter (Chroma) and an AxioCam MRm 
camera.  
The microbubble experiment had shown that both BLM and the BLM-
disaccharide adhered selectively to MCF-7 human breast cancer cells compared to 
MCF-10A normal breast cells.66 On the other hand deglycoBLM did not adhere to 
either of the two cell lines. Similar results were obtained when we treated the 
same two cell lines with the fluorescent conjugates BLM-Cy5**, deglycoBLM-
Cy5** and BLM-disaccharide-Cy5** (Figure 2.3). BLM bound to the MCF-7 
cells but not to noncancerous MCF-10A cells. DeglycoBLM bound minimally to 
either cell lines. The BLM-disaccharide also targeted the cancer cells selectively 
although the uptake was much lower than BLM itself. The free dye Cy5**, used 
as a control, showed no binding/uptake in any of the cell lines. 
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Figure 2.3. Relative uptake of Cy5** dye conjugates in human breast cancer cells 
(MCF-7) and human breast cells (MCF-10A). Cultured cells were incubated with 
50 µM of each of the fluorescent conjugates at 37 °C for 1 h. The cells were 
washed with PBS and were fixed with 4% paraformaldehyde at 37 °C for 5 min. 
The slide was dried for 1 h and imaged with a Zeiss Axiovert 200M inverted 
microscope. Dr. Alan Yu carried out this experiment. 
 
Similar profiles of cell uptake were observed for these fluorescent 
conjugates in prostate, lung, colon cancer cells and the respective non-cancerous 
cells (data not shown). The above results suggested that the disaccharide moiety 
in BLM is absolutely essential for its selective uptake into cancer cells. Further 
support came from the uptake-inhibition experiments described in Figure 2.4. The 
binding of BLM-Cy5** was reduced in MCF-7 cells when the cells were pre-
incubated with 50 mM BLM-disaccharide (2.69)72 (Figure 2.4) in comparison 
with its binding to cells with no pre-incubation (panel a, Figure 2.4). Not 
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surprisingly, the BLM-disaccharide was also able to inhibit the binding of BLM-
disaccharide-Cy5** (2.1) to DU-145 prostate cancer cells (panel b, Figure 2.4).  
	  
	  
Figure 2.4. Inhibition of binding of BLM-Cy5** by MCF-7 cells and binding of 
BLM-disaccharide-Cy5** by DU-145 cells by BLM-disaccharide. Cultured cells 
were incubated with a 50 mM solution of either BLM-disaccharide (2.69) or D-
glucamine at 37 °C for 2 h. (a) The MCF-7 cells were subsequently treated with a 
50 µM solution of BLM-Cy5** at 37 °C for 1 h and (b) the DU-145 cells were 
subsequently treated with a 20 µM solution of BLM-disaccharide-Cy5** (2.1) at 
37 °C for 1 h. The cells were washed with PBS and fixed with 4% 
paraformaldehyde at 37 °C for 5 min. The slide was dried for 1 h and imaged with 
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a Zeiss Axiovert 200M inverted microscope. Dr. Alan Yu carried out this 
experiment. 
 
The carbohydrate domain in BLM contains a carbamoyl group at C-3 in 
the mannose residue. In the next experiment four different types of cancer cells 
such as prostate, lung, glioma and astrocytoma cells were treated with either 
BLM-disaccharide-Cy5** (2.1) or decarbamoylBLM-disaccharide-Cy5** (2.30). 
As shown in Figure 2.5, the decarbamoylBLM-disaccharide-Cy5** had very low 
binding to each of the four cancer cell lines compared to the BLM-disaccharide. 
Clearly, the carbamoyl group plays an important role in the binding of the BLM-
disaccharide (and possibly bleomycin) to various cancer cell lines. 	   
	  
Figure 2.5. Relative binding of BLM-disaccharide-Cy5** (2.1) and 
decarbamoylBLM-disaccharide-Cy5** (2.30) to human prostate cancer (DU-
145), lung cancer (A549), glioma (C6, ATCC CCL-107), astrocytoma (SW-1783, 
ATCC HTB-13) cell lines. Cultured cells were incubated with 25 µM of each of 
the two fluorescent conjugates at 37 °C for 1 h. The cells were washed with PBS 
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and were fixed with 4% paraformaldehyde at 37 °C for 5 min. The slide was dried 
for 1 h and imaged with a Zeiss Axiovert 200M inverted microscope. Dr. Alan Yu 
carried out this experiment. 
 
Although BLM-disaccharide can target the cancer cells selectively on its 
own, cancer cell association was relatively low. Our next objective was to 
improve its cellular association so that it can be developed as a tumor selective 
imaging agent or as a targeted delivery vehicle for cytotoxic drugs. The cell 
membrane impermeability of the Cy5** molecule might also hinder the uptake of 
the BLM-disaccharide-Cy5**. Bleomycin A5, on the other hand, has several 
amines that could become protonated in the cellular media. This would certainly 
reduce the overall net negative charge on the BLM-Cy5** molecule and facilitate 
its uptake. To introduce positive charge into the disaccharide conjugate 2.1, probe 
2.39, having a L-lysyl-L-lysine dipeptide was synthesized. Incubating DU-145 
prostate cancer cells with 2.39, however, did not afford any significant increase in 
cell binding/uptake (Figure 2.6). Small peptides are known to be prone to 
degradation mediated by peptidases present in cellular media. To avoid 
degradation, we sought to replace the L-lysyl-L-lysine dipeptide in 2.39 with D-
lysyl-D-lysine. The resulting fluorescent conjugate 2.48 showed improved uptake 
in DU-145 cells compared to BLM-disaccharide-Cy5** (Figure 2.6).  
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Figure 2.6. Relative binding of Cy5**-L-lysyl-L-lysyl-BLM-disaccharide (2.39) 
and Cy5**-D-lysyl-D-lysyl-BLM-disaccharide (2.48) in human prostate cancer 
(DU-145), and normal (PZ-HPV-7) cells. Cultured cells were incubated with a 25 
µM solution of each of the fluorescent conjugates at 37 °C for 1 h. The cells were 
washed with PBS and were fixed with 4% paraformaldehyde at 37 °C for 5 min. 
The slide was dried for 1 h and imaged with a Zeiss Axiovert 200M inverted 
microscope. This experiment was carried out by Dr. Alan Yu. 
 
Another strategy to boost the binding of the BLM-disaccharide involved 
the use of a multivalent linker. This prompted us to synthesize the trimerBLM-
disaccharide-Cy5** (2.59) having three BLM-disaccharides connected to Cy5** 
through a branched linker. Binding of this conjugate was studied in DU-145 cells 
and was compared with the binding of BLM-disaccharide-Cy5** and BLM-
Cy5**. It is clear from Figure 2.7 that introduction of polyvalency greatly 
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facilitated the binding of the fluorescent conjugate 2.59 by prostate cancer cells. 
Notably, the binding of this conjugate by noncancerous prostate cells was still 
very low. 
 
Figure 2.7. Uptake of trimerBLM-disaccharide-Cy5** (2.59) in human prostate 
cancer (DU-145), and normal (PZ-HPV-7) cells. Cultured cells were incubated 
with a 25 µM solution of each of the fluorescent conjugates at 37 °C for 1 h. The 
cells were washed with PBS and were fixed with 4% paraformaldehyde at 37 °C 
for 5 min. The slide was dried for 1 h and imaged with a Zeiss Axiovert 200M 
inverted microscope. Dr. Alan Yu carried out this experiment. 
 
2.3 DISCUSSION 
2.3.1. Chemistry 
The synthesis of the disaccharide 2.19 was achieved using published 
procedures with slight modifications.69 Commercially available mannose 
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derivative 2.2 was protected as benzylidene acetal 2.3 (Scheme 2.1). To 
selectively alkylate at C-3, compound 2.3 was first protected with dibutyltin oxide 
and then treated with benzyl bromide to afford compound 2.4. The acetylated 
intermediate 2.5 was prepared by the use of acetic anhydride in the presence of a 
catalytic amount of H2SO4. The benzyl protecting group was removed under 
reductive conditions and the hydroxyl intermediate 2.6 was activated with p-
nitrophenyl chloroformate to afford carbonate 2.7. The carbamoyl group was 
introduced at the C-3 position by treatment with ammonia. This reaction was 
complete in 1.5 h and started to generate side products when continued longer 
than 3 h. Acetylated carbamoyl mannose 2.8 was then treated with the acetate salt 
of hydrazine for deprotection of the C-1 OH group. Once the starting material was 
consumed, it was necessary to quench this reaction by the addition of ethyl acetate 
to avoid formation of undesired by-products. A DMAP–triethylamine mixture 
was employed for the activation of compound 2.9 to avoid the frequently 
observed deprotonation of the carbamoyl group when nBuLi is used.  
Synthesis of the gulose derivative 2.18 was completed following reported 
procedures starting from L-xylose (Scheme 2.2). L-Xylose was protected as the 
thioacetal (2.12). The aldehyde functional group was regenerated by the use of 
HgO and HgCl2 and immediately treated with 2-trimethylsilylthiazole (2.13) to 
afford the hydroxylated intermediate 2.14 having the desired stereochemistry. The 
OH group was benzylated and thiazole 2.15 was converted to the benzylated 
gulose residue 2.17 via formation of the aldehyde 2.16. Reductive debenzylation 
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of 2.17 afforded compound 2.18 which was used in crude form without any 
chromatographic purification.   
Compound 2.18 was coupled with compound 2.10 in the presence of 
TMSOTf (Scheme 2.3). The reaction mixture was stirred at 0 °C for 17 min to 
obtain the best yield of product 2.19. Disaccharide 2.19 was then deprotected at 
the anomeric position using conditions similar to those used for the preparation of 
2.9. In this case, however, the crude intermediate was used directly in the next 
step to avoid loss of material during silica gel column chromatography. The 
activation of the anomeric OH group afforded much higher yields of the desired 
product 2.20 when DMAP–triethylamine was used instead of nBuLi. The 
phosphate ester was coupled with the linker alcohol 2.21 in the presence of 
TMSOTf to afford compound 2.22 as mixture of anomers. Treatment of 2.22 with 
NaOMe affected complete deacetylation. The acidic ion exchange resin Dowex 
50W was used to quench the remaining NaOMe. The deacetylated intermediate 
was subjected directly to catalytic hydrogenation which removed the CBz group 
in 30 min. The disaccharide linker 2.23 was condensed with the succinimidyl 
ester of the dye (2.24) to obtain BLM-disaccharide-Cy5** (2.1). The succinimidyl 
ester was prepared from the corresponding dye carboxylic acid following a 
reported procedure.76  
The decarbamoyl analogue 2.30 was prepared following a similar 
synthetic strategy (Scheme 2.4). Methyl α-D-mannopyranoside was acetylated in 
the presence of acetic anhydride and a catalytic amount of H2SO4. Compound 
2.25 was then subjected to anomeric deprotection followed by activation as the 
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diphenyl phosphate 2.26. The phosphate ester was coupled with gulose derivative 
2.18 to obtain the decarbamoyl disaccharide 2.27. This disaccharide was then 
coupled with the linker alcohol 2.21 via anomeric deacetylation and diphenyl 
phosphate activation. Compound 2.29 was then subjected to complete 
deacetylation, reductive removal of the CBz protecting group and condensation 
with succinimidyl ester 2.24 to afford decarbamoylBLM-disaccharide-Cy5** 
(2.30). 
The synthesis of Cy5**-L-lysyl-L-lysyl-BLM-disaccharide (2.39) 
involved attaching the linker disaccharide 2.23 at the C-terminus of lysyllysine 
followed by coupling of the dye at the N-terminus (Scheme 2.5). Synthesis of the 
dipeptide commenced with methylation and subsequent Fmoc deprotection of 
Fmoc-L-lys(Boc)-OH to afford compound 2.32. Compound 2.32 was then 
condensed with a second molecule of Fmoc-L-lys(Boc)-OH. The Fmoc group was 
exchanged for the CBz group and the methyl ester 2.34 was saponified to provide 
compound 2.35. Compound 2.35 was then condensed with the disaccharide linker 
2.23; the product was purified by reversed phase HPLC. The CBz group was 
subsequently removed and crude intermediate 2.37 was pure enough to be 
condensed with the activated ester of Cy5** (2.24). Finally the Boc groups were 
removed by the use of aq CF3COOH. Cy5**-D-lysyl-D-lysyl-BLM-disaccharide 
was synthesized following a similar synthetic route (Scheme 2.6). CBz-D-
lys(Boc)-OH was protected as the methyl ester (2.41). The CBz group was 
deprotected and compound 2.42 was coupled to another molecule of CBz-D-
lys(Boc)-OH. The resulting methyl ester (2.43) was subjected to saponification 
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and condensation with the disaccharide linker 2.23 to afford compound 2.45. The 
CBz group was subsequently removed and the crude intermediate 2.46 was 
condensed with activated ester 2.24. Removal of the Boc groups afforded dye 
conjugate 2.48. 
Synthesis of the branched linker 2.55 started with Michael addition of 
nitromethane to tert-butyl acrylate (Scheme 2.7). The branched nitro compound 
2.50 was converted to the respective amine (2.51) and subsequently coupled with 
protected β-alanine 2.52. The tert-butyl esters were removed by the use of 
HCOOH. Triacid 2.54 was activated as tri-succinimidyl ester 2.55 in the presence 
of N-hydroxysuccinimide and DCC. This compound was purified by 
recrystallization from ethanol because purification attempts by silica gel column 
chromatography lead to degradation of the desired product. Preparation of 
compound 2.56 by hydrogenation of compound 2.22 gave inconsistent results, 
most probably due to the extreme sensitivity of this reaction toward any catalyst 
poison. The condensation of 2.56 with compound 2.55 proceeded in reasonable 
yield. Compound 2.57 was then subjected successively to complete deacetylation 
and catalytic hydrogenation to obtain intermediate 2.58. Coupling of 2.58 with 
compound 2.24 produced trace amounts of trimerBLM-disaccharide-Cy5** (2.59) 
when aq phosphate buffer was used as the solvent. Addition of a small amount of 
DMSO to the reaction gave better yields of the conjugate 2.59, possibly due to the 
greater solubility of compound 2.58 in aq DMSO.  
The cytotoxic core of the anticancer drug methotrexate, 4-amino-4-deoxy-
10-N-methylpropanoic acid (APA) (2.61), was synthesized by following reported 
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procedures from compound 2.60 (Scheme 2.8).71 The disaccharide linker 2.23 was 
coupled with compound 2.61 to afford the APA-BLM-disaccharide conjugate 
2.62. Synthesis of APA ester-BLM-disaccharide (2.65) commenced with 
esterification of APA with alcohol 2.63. The tert-butyl ester was cleaved by the 
use of CF3COOH and the resulting intermediate was condensed with the 
disaccharide linker 2.23 to give conjugate 2.65. 
To attach the BLM-disaccharide at the C-terminus of deglycoBLM, 
disaccharide 2.19 was first deacetylated at C-1 by the use of acetate salt of 
hydrazine (Scheme 2.9). Compound 2.66 was then activated as p-nitrophenyl 
carbonate 2.67. The carbonate was then treated with deglycoBLM, which had 
been protected as the Cu(II) complex.  The coupled product was deacetylated by 
the use of hydrazine to afford the BLM A5 analogue 2.68. 
 
2.3.2. Biological Evaluation 
The obvious difference in cytotoxicities of BLM and deglycoBLM in 
cellular or in vivo assays strongly suggest that the carbohydrate moiety in BLM 
plays a key role in cellular targeting or uptake. The study involving microbubbles 
conjugates of BLM, deglycoBLM and BLM-disaccharide clearly showed that the 
BLM-disaccharide moiety was necessary for cell surface binding. The issue of 
cellular uptake, however, required further investigation.  
Fluorescent conjugates of BLM, deglycoBLM and BLM-disaccharide 
were prepared to compare their cell binding/uptake profiles in different cell lines. 
The conjugates were first tested in breast cells where the microbubble study had 
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shown a selective binding of BLM and BLM-disaccharide to MCF-7 breast 
cancer cells and not to normal MCF-10A breast cells. As expected, BLM-Cy5** 
and BLM-disaccharide-Cy5** were selectively bound by MCF-7 cells and not by 
MCF-10A normal breast cells (Figure 2.3). The dye conjugate deglyco BLM-
Cy5**, which lacked the carbohydrate moiety, did not bind to or enter the cells 
from either of the two cell lines. The dye Cy5**COOH, used as a negative 
control, also did not show any binding/uptake. Similar pattern of cellular 
binding/uptake of these fluorescent conjugates was observed in several other cell 
lines (data not shown). These results confirmed that the disaccharide moiety in 
BLM is essential for cancer cell targeting and uptake.  
Although BLM-disaccharide was able to selectively target the cancer cells, 
its binding/uptake was lower than that of the BLM conjugate. One possible reason 
for the observed difference in uptake between BLM and BLM-disaccharide could 
be the difference in formal charges on these fluorescent conjugates in the cellular 
media (pH ~ 7). BLM-disaccharide-Cy5** would have four net negative charges 
arising from the four sulfonate groups. This would certainly cause a significant 
repulsion from the negatively charged cell membrane, thus hindering cell surface 
interactions and uptake. The bleomycin molecule, on the other hand, contains 
several amine groups that should be at least partially protonated at pH 7, thus 
reducing the overall negative charge on BLM-Cy5**. In fact, the polyamine tail 
in BLM A5 has been implicated in its very high uptake in certain cancer cells that 
overexpress polyamine receptors.73  
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The inhibition experiments described in Figure 2.4 were performed to 
investigate whether the selective uptake of BLM and BLM-disaccharide in cancer 
cells is mediated by cell surface receptor that recognizes the BLM-disaccharide 
moiety. The cells were preincubated with high concentrations (50 mM) of 
disaccharide 2.69 to effectively saturate any cell surface receptor. The uptake of 
BLM-Cy5** and BLM-disaccharide-Cy5** was then studied in these 
preincubated cells. Pretreatment of the cancer cells with 2.69 blocked the uptake 
of both of the dye conjugates, suggesting that the carbohydrate moiety of BLM 
might be involved in the cellular recognition process. When the cells were 
preincubated with D-glucamine there was no inhibition of uptake of the Cy5** 
conjugates. Further studies are required to identify this potential receptor that 
preferentially interacts with the BLM-disaccharide.   
The carbamoyl moiety present on the mannose residue of BLM-
disaccharide is quite uncommon among naturally occurring carbohydrates. The 
fluorescent conjugate decarbamoylBLM-disaccharide-Cy5** was prepared to 
define the importance of the carbamoyl group in the cancer cell recognition 
process. The uptake of this conjugate was compared with that of BLM-
disaccharide-Cy5** in four different cancer cell lines. It is obvious from Figure 
2.5 that the carbamoyl group is indispensible for uptake of the fluorescent 
conjugate into cancer cells. Presumably, this group participates actively in the 
interaction of the BLM-disaccharide with potential cell surface receptors.  
Having clearly established the ability of the BLM-disaccharide to target 
cancer cells, it was of interest to employ this sugar as a tumor imaging agent or a 
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drug delivery vehicle. The BLM-disaccharide itself was not suitable for these 
applications due to its relatively low uptake. This prompted us to manipulate the 
linker region of the BLM-disaccharide-Cy5** conjugate to allow optimal uptake 
of the disaccharide. Two different strategies were employed. The first approach 
was directed towards reducing the formal net negative charge on the dye 
conjugate by introducing lysine residues in the linker. Another strategy involved 
the use of polyvalency by employing a branched linker. 
The dye conjugate Cy5**-L-lysyl-L-lysyl-BLM-disaccharide (2.39) has a 
L-lysyl-L-lysine dipeptide inserted between the disaccharide and the dye. The side 
chain amine groups should be protonated at pH ~ 7. This should help reduce the 
electrostatic repulsion between the dye conjugate and the negatively charged cell 
membrane and improve its uptake. Figure 2.6 shows that introduction of the 
dipeptide did not result in any significant increase in uptake in DU-145 prostate 
cancer cells. The reason for the low uptake could be the hydrolytic degradation of 
the dipeptide by the peptidases present in the cell culture media. Cy5**-D-lysyl-
D-lysyl-BLM-disaccharide (2.48) was synthesized to overcome this problem. The 
dipeptide present in this molecule consists of two D-lysines and should be 
resistant to peptidase activities. Figure 2.6 shows that introduction of two D-
lysines caused almost a twofold increase in binding/uptake. Once again, none of 
the conjugates showed any significant binding to normal cell lines, suggesting that 
their selectivity for the cancer cells was still intact. 
The trimerBLM-disaccharide-Cy5** (2.59) connects three sugars to a 
single Cy5** molecule through a branched linker. The binding/uptake profile of 
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this conjugate was examined in DU-145 prostate cancer cells and was found to be 
almost 2.5 times that of BLM-disaccharide-Cy5**. This result suggests that the 
potential receptor on the cell surface probably interacts with multiple sugar 
residues simultaneously. The conjugate 2.59 probably increases the local 
concentration of the BLM-disaccharide around the dye molecule, thereby 
facilitating a polyvalent interaction with the cell surface receptor. High selectivity 
towards cancer cells makes this conjugate a potential candidate for further 
development as an in vivo tumor imaging agent or as a targeted drug delivery 
vehicle.     
 
2.4. EXPERIMENTAL 
All the chemicals were purchased from Aldrich Chemical Co., Sigma 
Chemical Co or TCI America and used without further purification. 
Dichloromethane was dried by distillation from calcium hydride and 
tetrahydrofuran was dried by distillation from sodium. All reactions involving air 
or moisture sensitive reagents or intermediates were performed under an argon 
atmosphere. Flash chromatography was carried out using Silicycle 200–400 mesh 
silica gel. Analytical thin layer chromatography (TLC) was carried out using 0.25 
mm EM Silica Gel 60 F250 plates that were visualized by irradiation (254 nm) or 
by staining with Hanessian’s stain (cerium molybdate). 1H and 13C NMR spectra 
were obtained using an Inova 400 MHz Varian instrument. Chemical shifts were 
reported in parts per million (ppm, δ) referenced to the residual 1H resonance of 
the solvent (CDCl3, 7.26 ppm). 13C spectra were referenced to the residual 13C 
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resonance of the solvent (CDCl3, 77.16 ppm). Splitting patterns were designated 
as follows: s, singlet; br, broad; d, doublet; dd, doublet of doublet; dt doublet of 
triplet; m, multiplet. HPLC was performed using an Agilent 1100 series 
instrument. High resolution mass spectra were obtained at the Arizona State 
University High Resolution Mass Spectrometry Laboratory or at the Michigan 
State University Mass Spectrometry Facility. 
 
Methyl 4,6-O-Benzylidene-α-D-mannopyranoside (2.3).69 
To a solution containing 5.08 g (26.2 mmol) of methyl-α-D-mannopyranoside in 
62 mL of DMF were added 4.10 mL (27.3 mmol) of benzaldehyde dimethyl 
acetal and a catalytic amount of p-TsOH. The reaction mixture was swirled at 60 
°C for 1 h under diminished pressure and was then poured into a stirred mixture 
containing 120 mL of ethyl acetate and 100 mL of satd aq NaHCO3. The organic 
layer was washed with three 50-mL portions of brine, dried (Na2SO4) and 
concentrated under diminished pressure to afford a crude, colorless oil. The 
residue was purified by flash chromatography on a silica gel column (25 × 4 cm). 
Elution with 2:1 hexanes–ethyl acetate afforded compound 2.3 as a colorless 
solid: yield 5.05 g (68%); silica gel TLC Rf 0.31 (1:1 ethyl acetate–hexanes); 1H 
NMR (CDCl3) δ 2.90 (s, 2H), 3.38 (s, 3H), 3.78 (m, 2H), 3.87 (m, 1H), 3.98 (m, 
2H), 4.25 (m, 1H), 4.72 (d, 1H), 5.55 (s, 1H), 7.36 (m, 3H) and 7.47 (m, 2H); 13C 
NMR (CDCl3) δ 55.2, 63.3, 68.8, 69.0, 71.1, 79.0, 101.6, 102.4, 126.5, 128.6, 
129.5 and 137.4. 
OO OMe
OH
OH
OPh
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Methyl 4,6-O-Benzylidene-3-O-benzyl-α-D-mannopyranoside (2.4).69  
To a solution containing 2.40 g (8.52 mmol) of 2.3 in 71 mL of MeOH was added 
2.34 g (9.35 mmol) of Bu2SnO and the reaction mixture was heated to reflux for 
1.5 h to afford a clear solution. The solvent was concentrated under diminished 
pressure and the resulting solid was dried under vacuum overnight. The white 
residue was dissolved in 71 mL of DMF, treated with 2.03 mL (1.4 g, 17.0 mmol) 
of BnBr, and heated to 100 °C for 45 min. The reaction mixture was cooled to 
room temperature and poured into a stirred mixture of 100 mL of ethyl acetate 
and 70 mL of satd aq NaHCO3. The organic phase was separated and washed with 
60 mL of brine, dried (Na2SO4) and concentrated under diminished pressure. The 
residue was purified by flash chromatography on a silica gel column (25 × 4 cm). 
Elution with 30% ethyl acetate in hexanes afforded compound 2.4 as a colorless 
oil: yield 2.10 g (66%); silica gel TLC Rf 0.30 (30% ethyl acetate in hexanes); 1H 
NMR (CDCl3) δ 3.06 (s, 1H), 3.36 (s, 3H), 3.79 (m, 3H), 4.05 (m, 2H), 4.27 (m, 
1H), 4.70 (m, 2H), 4.84 (m, 1H), 5.62 (s, 1H) and 7.28-7.52 (m, 10H); 13C NMR 
(CDCl3) δ 54.9, 63.3, 68.8, 69.8, 73.0, 75.7, 78.8, 101.2, 101.6, 126.1, 127.8, 
128.2, 128.4, 128.4, 128.9, 137.6 and 138.0. 
 
1,2,4,6-Tetra-O-acetyl-3-O-benzyl-α-D-mannopyranose (2.5).69 
OO OMe
OH
OBn
OPh
OAcO OAc
OAc
OBn
AcO
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To a solution containing 0.80 g (4.40 mmol) of intermediate 2.4 in 13 mL of 
Ac2O was added a catalytic amount of H2SO4 and the solution was stirred at room 
temperature for 1 h. The reaction mixture was poured into a stirred mixture of 100 
mL of ethyl acetate and 60 mL of satd aq NaHCO3. The organic phase was 
separated and washed with 30 mL of brine, dried (Na2SO4) and concentrated 
under diminished pressure. The residue was purified by flash chromatography on 
a silica gel column (24 × 3 cm). Elution with 2:1 hexanes–ethyl acetate afforded 
the mannose derivative 2.5 as a yellow oil: yield 0.81 g (86%); silica gel TLC Rf 
0.34 (30% ethyl acetate in hexanes); 1H NMR (CDCl3) δ 2.02 (s, 3H), 2.07 (s, 
3H), 2.11 (s, 3H), 2.15 (s, 3H), 3.83 (dd, 1H, J = 9.7 and 3.4 Hz), 3.90 (m, 1H), 
4.04 (m, 1H), 4.19 (m, 1H), 4.41 (m, 1H), 4.64 (m, 1H), 5.24 (m, 1H), 5.34 (dd, 
1H, J = 3.4 and 2.1 Hz), 6.09 (d, 1H, J = 2.0 Hz) and 7.24-7.37 (m, 5H); 13C 
NMR (CDCl3) δ 14.4, 21.0, 21.1, 21.1, 62.6, 67.1, 67.2, 71.9, 71.7, 74.3, 91.2, 
128.0, 128.2, 128.6, 137.6, 168.3, 169.8, 170.2 and 171.0. 
 
1,2,4,6-Tetra-O-acetyl-α-D-mannopyranose (2.6).69 
To a solution containing 0.88 g (2.00 mmol) of compound 2.5 in 24 mL of ethyl 
acetate was added a catalytic amount of Pd(OH)2/C and the reaction was 
maintained under 1 atm of H2(g) overnight. The catalyst was removed by 
filtration through a pad of Celite and the filtrate was concentrated under 
diminished pressure. The residue was purified by flash chromatography on a silica 
gel column (20 × 3 cm). Elution with 75% ethyl acetate in hexanes afforded 
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compound 2.6 as a colorless oil: yield 550 mg (79%); silica gel TLC Rf 0.11 (1:1 
ethyl acetate–hexanes); 1H NMR (CDCl3) δ 2.04 (s, 3H), 2.09 (s, 3H), 2.13 (s, 
3H), 2.15 (s, 3H), 2.97 (s, 1H), 3.95 (m, 1H), 4.04 (m, 1H), 4.09 (m, 1H), 4.19 
(dd, 1H, J = 12.3 and 4.8 Hz), 5.07 (m, 1H), 5.13 (m, 1H) and 5.99 (m, 1H); 13C 
NMR (CDCl3) δ 20.7, 20.8, 62.3, 68.0, 68.6, 70.3, 70.9, 90.4, 168.2, 170.3, 170.8 
and 170.9. 
 
1,2,4,6-Tetra-O-acetyl-3-O-((p-nitrophenyl)carbamoyl)-α-D-mannopyranose 
(2.7).69  
To a solution containing 0.55 g (1.60 mmol) of 2.6 in 5.6 mL of pyridine were 
added 0.77 g (6.30 mmol) of DMAP and 1.30 g (6.30 mmol) of p-nitrophenyl 
chloroformate. The reaction mixture was stirred at 40 °C for 2 h at which time it 
was poured into a two-phase solution of 40 mL of ethyl acetate and 10 mL of 
H2O. The organic layer was washed successively with three 10-mL portions of 1 
N HCl, 10 mL of satd aq NaHCO3 and 10 mL of brine. The solution was dried 
(Na2SO4) and concentrated under diminished pressure. The residue was purified 
by flash chromatography on a silica gel column (20 × 3 cm). Elution with 50% 
ethyl acetate in hexanes afforded compound 2.7 as a yellow oil: yield 0.66 g 
(81%); silica gel TLC Rf 0.58 (1:1 ethyl acetate–hexanes); 1H NMR (CDCl3) δ 
2.07 (s, 3H), 2.09 (s, 3H), 2.14 (s, 3H), 2.17 (s, 3H), 4.08 (m, 2H), 4.25 (m, 1H), 
O OAc
OAc
O
AcO
O
O
NO2
OAc
	   50 
5.15 (dd, 1H), 5.41 (m, 2H), 6.11 (s, 1H), 7.34 (d, 2H) and 8.23 (d, 2H); 13C NMR 
(CDCl3) δ 20.6, 20.9, 61.8, 64.9, 67.4, 70.5, 74.1, 90.5, 121.8, 125.2, 145.5, 
151.6, 155.1, 167.8, 169.3, 169.9 and 170.5. 
 
1,2,4,6-Tetra-O-acetyl-3-O-carbamoyl-α-D-mannopyranose (2.8).69 
To a solution of 0.51 g (1.31 mmol) of carbonate 2.7 in 27 mL of anh CH2Cl2 was 
added 15 mL of THF that had been saturated with NH3 (g). The solution was 
stirred at room temperature for 1.5 h (at which time silica gel TLC analysis 
indicated that the reaction was complete). The solution was concentrated under 
diminished pressure. The residue was purified by flash chromatography on a silica 
gel column (14 × 3 cm). Elution with 3:1 à 1:2 hexanes–ethyl acetate afforded 
compound 2.8 as a colorless oil: yield 355 mg (91%); silica gel TLC Rf 0.10 (1:1 
hexanes–ethyl acetate). 1H NMR (CDCl3) δ 2.02 (s, 3H), 2.04 (s, 3H), 2.11 (s, 
3H), 2.12 (s, 3H), 4.04 (m, 2H), 4.22 (dd, 1H, J = 12.6 and 5.0 Hz), 5.03 (br s, 
2H), 5.24 (m, 3H) and 6.03 (d, 1H, J = 1.7 Hz); 13C NMR (CDCl3) δ 20.6, 20.6, 
20.7, 61.9, 65.4, 68.6, 69.4, 70.4, 90.3, 155.2, 168.0, 169.6, 169.6 and 170.5. 
 
2,4,6-Tri-O-carbamoyl-α,β-D-mannopyranose (2.9).69 
To a solution of 365 mg (0.93 mmol) of compound 2.8 in 10.5 mL of dry DMF 
was added 120 mg (1.31 mmol) of acetate salt of hydrazine. The reaction mixture 
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was stirred at room temperature for 1 h (at which time silica gel TLC analysis 
indicated that 2.8 had been consumed) and diluted with 80 mL of ethyl acetate. 
The solution was washed with three 25-mL portions of brine and concentrated 
under diminished pressure. The residue was purified by flash chromatography on 
a silica gel column (15 × 3 cm). Elution with 1:1 hexanes–ethyl acetate afforded 
compound 2.9 as a colorless oil: yield 285 mg (87%); silica gel TLC Rf 0.24 (1:1 
hexanes–ethyl acetate). 1H NMR (CDCl3) δ 2.06 (s, 3H), 2.09 (s, 3H), 2.15 (s, 
3H), 4.15 (m, 1H), 4.23 (m, 2H), 4.83 (s, 2H) and 5.25 (m, 4H).  
 
2,4,6-Tri-O-acetyl-3-O-carbamoyl-α-D-mannopyranosyl Diphenyl Phosphate 
(2.10).69 
To a solution of 160 mg (0.46 mmol) of intermediate 2.9, 64.0 mg (0.57 mmol) of 
DMAP and 640 µL (468 mg; 4.63 mmol) of Et3N in 12 mL of CH2Cl2 at 0 °C was 
dropwise added 0.95 mL (1.23 g; 4.6 mmol) of diphenyl chlorophosphate. The 
solution was stirred at 0 °C for 1.5 h and was poured into a two-phase solution of 
EtOAc (100 mL) and saturated aq NaHCO3 (40 mL). The organic layer was 
washed with two 30-mL portions of brine, dried over Na2SO4, filtered and 
concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (15 × 3 cm). Elution with 2:1 à 1:2 
hexanes–ethyl acetate afforded the phosphate ester 2.10 as a colorless oil: yield 
201 mg (75%); silica gel TLC Rf 0.41 (2:3 hexanes–ethyl acetate). 1H NMR 
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(CDCl3) δ 1.95 (s, 3H), 2.03 (s, 3H), 2.12 (s, 3H), 3.91 (d, 1H, J = 12.4 and 2.2 
Hz), 4.08 (m, 1H), 4.17 (dd, 1H, J = 12.4 and 4.7 Hz), 4.66 (br s, 2H), 5.30 (m, 
3H), 5.87 (dd, 1H, J = 6.5 and 1.6 Hz) and 7.28 (m, 10H); 13C NMR (CDCl3) δ 
20.6, 20.7, 20.7, 61.7, 65.3, 69.0, 69.1, 69.2, 70.7, 96.0, 96.1, 120.1, 120.1, 120.2, 
120.3, 125.8, 125.9, 130.0, 129.0, 150.0, 150.1, 150.2, 150.3, 155.2, 169.5, 169.8 
and 170.6. 
 
2,3,4,5-Di-O-isopropylidene-L-xylose Diethylthioacetal (2.12).69  
To a suspension of 5.0 g (33 mmol) of L-xylose (2.11) in 3.2 mL of conc HCl was 
added with vigorous magnetic stirring, 7.4 mL (6.38 g; 0.10 mol) of ethanethiol. 
Stirring was continued at room temperature until the two-layer mixture gave a 
homogenous solution (usually after 15-20 min) which was then diluted with 120 
mL of acetone. After stirring for 5 h, the solution was neutralized with satd aq 
NH4OH solution and co-evaporated with six 20-mL portions of toluene several 
times to remove water and most of acetone-diethyl dithioketal to afford a crude 
residue. The crude residue was applied to a silica gel column (28 × 5 cm). Elution 
with 1:1 ethyl acetate–hexanes gave compound 2.12 as a colorless syrup: yield 
5.23 g (52 %); silica gel TLC Rf 0.59 (3:1 ethyl acetate−hexanes); 1H NMR 
(CDCl3) δ 1.23-1.28 (m, 6H), 1.36 (s, 3H), 1.41 (s, 6H), 1.45 (s, 3H), 2.72 (m, 
4H), 3.91 (dd, 2H, J = 9.8 and 4.5 Hz), 4.04 (m, 1H), 4.13 (dd, 1H, J = 5.3 and 
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2.1 Hz) and 4.32 (m, 2H); 13C NMR (CDCl3) δ 14.26, 14.34, 24.9, 25.3, 25.6, 
26.1, 27.1, 27.3, 53.0, 65.9, 75.2, 78.7, 80.1, 109.5 and 110.0. 
 
2-(Trimethylsilyl)thiazole (2.13).74  
A 500-mL, four-necked round bottomed flask, containing a magnetic stirring bar, 
was equipped with two 100 mL, pressure-equalizing dropping funnels and a low-
temperature thermometer. The anhydrous apparatus was filled with argon and 
kept under a slightly positive pressure of this gas during the entire reaction. The 
flask was charged with 80 mL of freshly distilled Et2O and 42 mL (67.1 mmol) of 
a 1.6 M solution of n-BuLi in hexane. One of the two dropping funnels is charged 
with 5.5 mL (10 g, 61 mmol) of 2-bromothiazole in 20 mL of Et2O and the other 
with 7.7 mL (6.6 g; 61 mmol) of chlorotrimethylsilane in 20 mL of Et2O. The 
reaction flask was cooled to −78 °C in a anhydrous acetone bath. While the 
solution in the flask was stirred, 2-bromothiazole was added dropwise over a 
period of 1 h. After 20 min of additional stirring, chlorotrimethylsilane was added 
dropwise over 30 min and the stirring was continued for 1 h at −78 °C. The 
resulting mixture was then allowed to warm to room temperature. A satd aq 
NaHCO3 solution was added and the mixture was transferred into a 1-L separatory 
funnel. After the mixture was shaken, the organic layer is recovered and the 
aqueous layer was extracted with two 200-mL portions of Et2O. The combined 
organic layer was dried (Na2SO4), filtered, and concentrated under diminished 
pressure with the external bath temperature not exceeding 40 °C. The residue was 
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distilled from a 100 mL flask at reduced pressure in a Claisen apparatus. The 
distillation was carried out under diminished pressure at 45 °C after a forerun at 
25 °C consisting mainly of bromobutane was collected. The pure product 2.13 
was isolated as a colorless oil: yield 6.5 g (67%); 1H NMR (CDCl3) δ 0.39 (s, 
12H), 7.50 (1H, d, J = 3.0 Hz) and 8.09 (1H, d, J = 2.9 Hz); 13C NMR (CDCl3) δ 
1.03, 127.3, 145.6 and 174.2. 
 
(1S)-((4R,4'S)-2,2,2',2'-Tetramethyl-[4,4'-bi(1,3-dioxolan)]-5-yl)(thiazol-2-
yl)methanol (anti-6) (2.14).69 
To a stirred solution containing 5.01 g (14.8 mmol) of thioacetal 2.12 in 50 mL of 
acetone diluted with 5 mL of water were added 7.6 g (35 mmol) of yellow 
mercury(II) oxide and 7.6 g (28 mmol) of mercuric(II) chloride. The reaction 
mixture was stirred at 55 °C for 2 h and then allowed to cool to room temperature. 
The solvent was filtered through a pad of Celite and the filtrate was concentrated 
under diminished pressure to afford a crude residue. The crude residue was 
suspended in three 60-mL portions of dichloromethane and filtered through a pad 
of Celite. The filtrate was washed with 40 mL of 1 M aq KI, dried (Na2SO4) and 
then concentrated under diminished pressure to afford 2,3,4,5-di-O-
isopropylidene-aldehydo-L-xylose: crude yield 2.8 g. The crude aldehyde was 
used for the next reaction immediately without further purification.  
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To a stirred solution containing 2.8 g (12.2 mmol) of crude aldehyde in 38 
mL of anhydrous dichloromethane cooled to −20 °C was added 2.5 mL (2.46 g; 
15.7 mmol) of 2-(trimethylsilyl)thiazole (2.13) dropwise over a period of 15 min. 
The solution was stirred at 0 °C for 1 h and then concentrated under diminished 
pressure to afford a crude residue. The crude residue was dissolved in 50 mL of 
anhydrous THF and treated with 3.8 g (12 mmol) of n-Bu4NF3H2O at room 
temperature for 30 min, then concentrated under diminished pressure. The residue 
was dissolved in 300 mL of dichloromethane. The solution was washed with three 
80-mL portions of water and dried (Na2SO4) and then concentrated under 
diminished pressure to yield 2.14 as a crude residue. Repeated recrystallization of 
the crude residue from cyclohexane afforded intermediate 2.14 as a colorless 
crystals: yield 2.7g (57% over two steps); silica gel TLC Rf 0.49 (1:1 ethyl 
acetate−hexanes); 1H NMR (CDCl3) δ 1.28 (s, 3H), 1.36 (s, 6H), 1.40 (s, 3H), 
3.67 (t, 1H, J = 6.6 Hz), 3.81 (m, 2H), 4.12 (dd, 1H, J = 7.2 and 3.6 Hz), 4.32 (m, 
1H), 4.56 (br s, 1H), 5.10 (d, 1H, J = 5.5 Hz), 7.30 (d, 1H, J = 3.2 Hz) and 7.71 
(d, 1H, J = 3.2 Hz); 13C NMR (CDCl3) δ 25.6, 26.1, 27.07, 27.13, 65.7, 71.7, 
75.5, 77.4, 79.8, 109.5, 110.2, 119.7, 142.1 and 170.9. 
 
2-((1S)-(Benzyloxy)((4R,4'S)-2,2,2',2'-tetramethyl-[4,4'-bi(1,3-dioxolan)]-5-
yl)methyl)thiazole (2.15).69 
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To a solution containing 2.65 g (8.40 mmol) of compound 2.14 in anhydrous 
DMF, cooled to 0 °C, was added 0.67 g (60% dispersion in oil, 17 mmol) of NaH 
portionwise and the reaction mixture was stirred for 0.5 h. To this solution was 
added 1.50 mL (2.16 g, 12.6 mmol) of benzyl bromide and the reaction mixture 
stirred at room temperature for 0.5 h. The reaction mixture was quenched by the 
addition of 1.5 mL methanol, stirred for 10 min and then diluted with 50 mL of 
distilled water. The aqueous layer was extracted with three 140-mL portions of 
ether. The combined organic layer was dried (Na2SO4) and concentrated under 
diminished pressure to afford a crude residue. The crude residue was purified by 
flash chromatography on a silica gel column (25 × 4 cm). Elution with 6:1 ethyl 
acetate−hexanes gave 2.15 as colorless solid: yield 2.8 g (82%); silica gel TLC Rf 
0.36 (9:1 toluene−methanol); 1H NMR (CDCl3) δ 1.20 (s, 3H), 1.25 (s, 3H), 1.29 
(s, 3H), 1.33(s, 3H), 3.65(m, 1H), 3.77 (m, 1H), 3.91 (m, 1H), 3.97 (m, 1H), 4.35 
(dd, 1H, J = 7.3 and 2.5 Hz), 4.47 (m, 2H), 4.80 (d, 1H, J = 4.8 Hz), 7.24 (m, 5H), 
7.32 (d, 1H, J = 3.2 Hz) and 7.78 (d, 1H, J = 3.2 Hz); 13C NMR (CDCl3) δ 14.0, 
25.5, 26.03, 26.05, 26.7, 27.0, 65.5, 72.2, 75.5, 77.7, 78.5, 79.4, 109.4, 110.3, 
120.1, 127.9, 128.1, 128.3, 136.8, 142.4 and 168.9. 
 
3,4:5,6-Di-O-isopropylidene-2-O-(benzyl)-aldehydo-L-gulose (2.16).69 
A solution containing 3.80 g (9.30 mmol) of O-benzyl ether 2.15 and 17.4 g of 
activated 4Å Molecular Sieves dissolved in 93 mL of anhydrous acetonitrile was 
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stirred at room temperature for 10 min and then 1.37 mL (2.05 g; 12.1 mmol) of 
methyl triflate was added dropwise. The suspension was stirred at room 
temperature for 15 min and then concentrated under diminished pressure to afford 
the crude N-methylthiazolium salt. To a stirred solution of the crude N-
methylthiazolium salt in 93 mL of methanol cooled to 0 °C was added 0.75 g 
(20.0 mmol) of sodium borohydride. The reaction mixture was stirred at room 
temperature for 5 min and then diluted with 31 mL of acetone. The solvent was 
filtered through a pad of Celite and concentrated under diminished pressure to 
afford a crude mixture of thiazolidines. The crude mixture obtained was dissolved 
in 87 mL of acetonitrile and 8.7 mL of water and treated under vigorous stirring 
with 5.98 g (74.8 mmol) of CuO and 1.62 g (9.34 mmol) of CuCl2•2H2O. The 
reaction mixture was stirred at 20 °C for 15 min and filtered through a pad of 
Celite and then concentrated under diminished pressure to remove acetonitrile and 
most of the water (bath temperature not exceeding 40 °C) to afford a crude 
residue. The brown residue was triturated with four 310-mL portions of ether and 
the liquid phase separated and filtered through a pad of Florisil (60−100 mesh) to 
afford a colorless solution. After a further washing of the Florisil with 310 mL of 
ethyl acetate, the combined organic layer was concentrated under diminished 
pressure to yield the crude aldehyde 2.16 as a brown syrup which was used 
immediately for the next reaction without further purification: crude yield 2.23 g. 
 
1,3,4,6-Tetra-O-acetyl-2-O-benzyl-L-gulopyranose (2.17).69 
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A solution containing 2.23 g (6.36 mmol) of crude aldehyde 2.16 was dissolved in 
35 mL of glacial acetic acid and 9 mL of distilled water and stirred at 100 °C for 
40 min. The cooled reaction mixture was then concentrated by co-evaporation 
three times with portions of toluene to afford the crude 2-O-benzyl-L-gulose as a 
mixture of β-pyranose, α-pyranose and furanose forms. A solution of the crude 
residue and 0.76 g (6.36 mmol) of 4-(N, N-dimethylamino)pyridine in 16 mL of 
pyridine and 16 mL of acetic anhydride was stirred at room temperature for 12 h 
and concentrated under diminished pressure to yield a brown syrup. The crude 
residue was purified by flash chromatography on a silica gel column (30 × 4 cm). 
Elution with 3:1 ethyl acetate−hexanes gave 2.17 as a yellow oil: yield 2.14 g 
(52% from compound 2.15); silica gel TLC Rf  0.44 (1:1 ethyl acetate−hexanes); 
1H NMR (CDCl3) δ2.01 (s, 3H), 2.05 (s, 3H), 2.08 (s, 3H), 2.11 (s, 3H), 3.64 (dd, 
1H, J = 8.3 and 4.9 Hz), 4.04 (m, 2H), 4.28 (m, 1H), 4.55 (m, 2H), 4.95 (dd, 1H, J 
= 3.9 and 2.5 Hz), 5.44 (m, 1H), 5.89 (d, 1H, J =8.3 Hz) and 7.28 (m, 5H). 
 
1,3,4,6-Tetra-O-acetyl-L-gulopyranose (2.18).69 
To a solution containing 1.73 g (3.95 mmol) of 2.17 in 27 mL of ethyl acetate was 
added a catalytic amount of 10% Pd/C and the reaction mixture was stirred at 
room temperature overnight under 1 atm of H2 (g). The solvent was filtered 
through a pad of Celite and the filtrate concentrated under diminished pressure to 
afford 2.18 as a mixture of β-pyranose, α-pyranose and furanose forms which was 
used in the next reaction without further purification: yield 1.21 g (88%); silica 
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gel TLC Rf 0.52 (ethyl acetate); 1H NMR (CDCl3) δ 1.91 (s, 3H), 2.00 (s, 3H), 
2.03 (s, 6H), 3.32 (br s, 1H), 3.80 (dd, 1H, J = 8.4 and 3.5 Hz), 3.94 (m, 1H), 4.02 
(m, 1H), 4.16 (m, 1H), 4.85 (m, 1H), 5.19 (t, 1H, J = 3.6 Hz) and 5.70 (d, 1H, J = 
8.4 Hz); 13C NMR (CDCl3) δ 20.4, 20.5, 20.6, 20.8, 61.6, 66.2, 67.5, 69.5, 70.9, 
92.1, 169.4, 169.5, 169.7 and 170.5. 	  
 
1,3,4,6-Tetra-O-acetyl-2-O-(2,4,6-tri-O-acetyl-3-O-carbamoyl-α-D-
mannopyranosyl)-α-L-gulopyranoside (2.19).69 
To a round bottom flask containing 200 mg (0.34 mmol) of 2.10 was added a 
solution of 95.0 mg (0.27 mmol) of 2.18 in 3.8 mL of anhydrous CH2Cl2. The 
solution was cooled to 0 °C and to it was added 98.0 µL (120 mg; 0.55 mmol) of 
TMSOTf dropwise and the reaction mixture was stirred at 0 °C for 17 min at 
which time it was poured into a two-phase solution of EtOAc (60 mL) and 
saturated aq NaHCO3 (25 mL). The organic layer was washed with two 20-mL 
portions of brine, dried (Na2SO4), filtered and concentrated under diminished 
pressure. The residue was purified by flash chromatography on a silica gel 
column (25 × 2 cm). Elution with 3:2 à 1:3 hexanes–ethyl acetate afforded the 
disaccharide 2.19 as a colorless oil: yield 115 mg (62%); silica gel TLC Rf 0.38 
(1:4 hexanes–ethyl acetate); 1H NMR (CDCl3) δ 2.05 (s, 3H), 2.06 (s, 3H), 2.07 
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(s, 3H), 2.14 (s, 6H), 2.16 (s, 3H), 2.20 (s, 3H), 3.98 (dd, 1H, J = 8.4 and 3.3 Hz), 
4.19 (m, 2H), 4.38 (m, 1H), 4.85 (s, 2H), 5.13 (m, 7H), 5.45 (m, 1H) and 5.88 (d, 
1H, J = 8.4 Hz); 13C NMR (CDCl3) δ 14.4, 20.9, 21.0, 21.0, 21.2, 21.3, 60.6, 61.6, 
62.3, 65.7, 66.1, 67.9, 69.3, 69.4, 69.9, 71.5, 90.8, 95.2, 155.4, 168.9, 169.5, 
169.6, 170.0, 170.7 and 170.8. 
 
3,4,6-Tri-O-acetyl-2-O-(2,4,6-tri-O-acetyl-3-O-carbamoyl-α-D-
mannopyranosyl)-α-L-gulopyranosyl Diphenyl Phosphate (2.20).69 
To a solution containing 112 mg (0.165 mmol) of 2.19 in 0.8 mL of anhydrous 
DMF was added 21 mg (0.23 mmol) of acetate salt of hydrazine. The reaction 
mixture was stirred at room temperature for 1 h and quenched by the addition of 
60 mL of ethyl acetate. The organic layer was washed with three 10-mL portions 
of brine and dried (Na2SO4). The solvent was filtered and then concentrated under 
diminished pressure to afford the deacetylated intermediate as a crude residue 
which was used for next reaction without further purification. 
To a solution of 115 mg of the crude residue, 26 mg (0.21 mmol) of 
DMAP and 242 µL (177 mg, 1.75 mmol) of Et3N in 16.5 mL of anhydrous 
CH2Cl2 at 0 °C was added 0.33 mL (428 mg, 1.59 mmol) of diphenyl 
chlorophosphate dropwise. The solution was stirred at 0 °C for 1.5 h and was then 
poured into a two-phase solution of EtOAc (80 mL) and saturated aq NaHCO3 
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soln (30 mL). The organic layer was washed with three 25-mL portions of H2O, 
two 25-mL portions of brine, then dried over Na2SO4, filtered, and concentrated 
under diminished pressure. The residue was purified by flash chromatography on 
a silica gel column (22 × 2 cm). Elution with 1:1 à 1:3 hexanes–ethyl acetate 
afforded compound 2.20 a colorless oil: yield 121 mg (84%); 1H NMR (CDCl3) δ 
1.70 (s, 3H), 1.97 (s, 3H), 2.05 (s, 3H), 2.11 (s, 3H), 2.13 (s, 3H), 2.19 (s, 3H), 
4.13 (m, 5H), 4.31 (m, 2H), 4.76 (s, 2H), 4.96 (m, 1H), 4.98 (m, 1H), 5.18 (m, 
3H), 5.43 (m, 1H), 5.69 (m, 1H) and 7.25 (m, 10H); 13C NMR (CDCl3) δ 20.2, 
20.6, 20.7, 61.1, 61.7, 65.3, 65.4, 67.3, 69.0, 69.8, 71.5, 95.3, 96.1, 120.1, 120.2, 
125.5, 129.6, 129.8, 129.9, 155.0, 169.2, 169.3, 169.7, 170.3 and 170.5. 
 
3,4,6-Tri-O-acetyl-2-O-(2,4,6-tri-O-acetyl-3-O-carbamoyl-α-D-
mannopyranosyl)-α-L-gulopyranosyl benzyl 2-(2-ethoxy)ethylcarbamate 
(2.22).75 
To a solution of 78 mg (91 µmol) of 2.20 and 19 mg (79 µmol) of 2.21 in 2.4 mL 
of anhydrous CH2Cl2 was added 28 µL (34 mg, 0.16 mmol) of TMSOTf at 0 °C. 
The reaction mixture was stirred at 0 °C for 17 min, at which time it was poured 
into a two-phase solution of EtOAc (50 mL) and saturated aq NaHCO3 (20 mL). 
The organic layer was washed with two 20-mL portions of brine, dried (Na2SO4), 
filtered and concentrated under diminished pressure. The residue was purified by 
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flash chromatography on a silica gel column (25 × 2 cm).  Elution with 15:32:1 à 
11:36:1 hexanes–ethyl acetate–methanol afforded compound 2.22 as a colorless 
oil: yield 62 mg (80%); silica gel TLC Rf 0.30 (1:4 hexanes–ethyl acetate); 1H 
NMR (CDCl3) δ 2.03 (s, 6H), 2.07 (s, 3H), 2.09 (s, 3H), 2.11 (s, 3H), 2.12 (s, 3H), 
3.54 (m, 8H), 3.83 (m, 1H), 3.96 (m, 1H), 4.05 (m, 4H), 4.25 (m, 1H), 4.46 (m, 
1H), 4.69 (s, 1H), 4.91 (m, 1H), 5.12 (m, 8H), 5.61 (m, 1H) and 7.34 (m, 5H); 13C 
NMR (CDCl3) δ 20.6, 20.7, 20.8, 29.6, 40.9, 62.1, 62.5, 63.7, 65.5, 66.1, 66.6, 
67.6, 68.5, 69.1, 69.6, 69.7, 70.0, 70.3, 70.6, 97.0, 97.1, 128.1, 128.2, 128.4, 
136.5, 156.5, 169.3, 169.5, 169.8 and 170.5.   
 
Cy5** Carboxylic Acid Succinimidyl Ester (2.24).76 
To a 1.5 mL vial containing 0.50 mg (57 nmol) of Cy5**COOH were added a 
solution of 5 mg (16.6 µmol) of TSTU in 100 µL of DMF and a solution of 6 µL 
(34.4 µmol) of DIPEA in 60 µL of DMF. The mixture was shaken at room 
temperature for 2.5 h, diluted with ethyl acetate and centrifuged. The supernatant 
was discarded, the pellet was washed with ethyl acetate and dried under 
O
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diminished pressure to afford Cy5** carboxylic acid succinimidyl ester 
(Cy5**COOSu) (2.24) as dark blue solid: yield 0.55 mg (100%); mass spectrum 
(MALDI) 984.55 (M)+(C42H54N3O16S4+ requires 984.24). 
 
BLM-disaccharide-Cy5** (2.1).77 
To a solution of 8.0 mg (9.3 µmol) of 2.22 in 2 mL of dry MeOH was added 0.2 
mL of a 25% w/w solution of NaOMe in MeOH and the mixture was shaken at 
room temperature for 2 h. Fifty mg of Dowex 50W resin was added and the 
mixture was shaken at room temperature for 30 min. The mixture was filtered, 
diluted to 5 mL with methanol and a catalytic amount of 10% Pd/C was added. H2 
gas was bubbled through the solution for 30 min, the mixture was filtered and 
concentrated to obtain compound 2.23 as colorless foam: yield 3.5 mg (80%). 
Compound 2.23 was dissolved in 2 mL of 0.2 M aq sodium phosphate buffer 
solution (pH ~ 8). One hunderd µL (175 µg; 0.37 µmol) of this solution was 
added to a vial containing 110 µg (0.112 µmol) of Cy5** carboxylic acid 
succinimidyl ester 2.24 and the mixture was shaken at room temperature 
overnight in the dark. The crude reaction mixture was purified on an Econosil C18 
reversed phase semi-preparative (250 × 10 mm, 10 µm) HPLC column using 
0.1% aq TFA and CH3CN mobile phases. A linear gradient was employed (1 à 
55% CH3CN in 0.1% aq TFA) over a period of 30 min at a flow rate of 3 mL/min. 
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Fractions containing the desired product eluted at 16.1 min (monitoring at 651 
nm) and were collected, frozen, and lyophilized to give BLM-disaccharide-Cy5** 
(2.1) as a blue solid: yield 62 µg (42%); mass spectrum (MALDI), m/z 1379.59 
(M)+ (theoretical m/z 1379.36). 
 
Penta-O-acetyl-α-D-mannopyranose (2.25).78  
To a solution containing 1.09 g (5.60 mmol) of 1-O-methyl-α-D-mannopyranose 
in 18 mL of Ac2O was added a catalytic amount of H2SO4, and the solution was 
stirred at room temperature for 12 h. The reaction mixture was poured into a 
stirred mixture of 150 mL of ethyl acetate and 80 mL of satd aq NaHCO3. The 
organic phase was separated and washed with 40 mL of satd aq NaHCO3, 30 mL 
of brine, then dried (Na2SO4) and concentrated under diminished pressure. The 
residue was purified by flash chromatography on a silica gel column (16 × 3 cm). 
Elution with 4:1 hexanes–ethyl acetate afforded 2.25 as a light yellow oil: yield 
2.10 g (96%); silica gel TLC Rf 0.64 (30% ethyl acetate in hexanes); 1H NMR 
(CDCl3) δ1.86 (s, 3H), 1.91 (s, 3H), 1.95 (m, 3H), 2.04 (m, 6H), 3.94 (m, 2H), 
4.13 (m, 1H), 5.12 (s, 1H), 5.20 (m, 2H) and 5.94 (s, 1H); 13C NMR (CDCl3) δ 
20.40, 20.43, 20.47, 20.53, 20.6, 61.9, 65.3, 68.1, 68.6, 70.4, 76.8, 77.2, 77.5, 
167.8, 169.3, 169.5, 169.7 and 170.3. 
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2,3,4,6-Tetra-O-acetyl-α-D-mannopyranose (2.26).79  
To a solution of 300 mg (0.77 mmol) 2.25 in 10 mL of dry DMF was added 99.0 
mg (1.07 mmol) of acetate salt of hydrazine. The reaction was stirred at room 
temperature for 1 h until analysis by silica gel TLC indicated it was complete. The 
reaction mixture was diluted with 50 mL of ethyl acetate and washed with three 
20-mL portions of brine. The aq layer was re-extracted with three 30-mL portions 
of ethyl acetate. The combined organic layer was dried (Na2SO4) and 
concentrated under diminished pressure. The residue was co-evaporated with 
portions of toluene several times, then dried and dissolved in 40 mL of dry 
CH2Cl2. To the solution were added 117 mg (0.96 mmol) of DMAP and 1.14 mL 
(0.834 g; 8.19 mmol) of Et3N. The reaction mixture was stirred for 10 min, 
followed by the addition of 1.49 mL (1.93 g; 7.19 mmol) of diphenyl 
chlorophosphate dropwise at 0 °C. The solution was stirred at 0 °C for 1 h and 
was poured into a two-phase solution of EtOAc (200 mL) and saturated aq 
NaHCO3 soln (80 mL). The organic layer was washed with two 50-mL portions 
of brine, dried over Na2SO4, filtered, and concentrated under diminished pressure. 
The residue was purified by flash chromatography on a silica gel column (15 × 3 
cm). Elution with 3:1 à 2:1 hexanes–ethyl acetate afforded compound 2.26 as a 
colorless oil: yield 258 mg (58% over two steps); silica gel TLC Rf 0.41 (3:1 
hexanes–ethyl acetate); 1H NMR (CDCl3) δ 1.96 (s, 3H), 1.99 (s, 3H), 2.03 (s, 
3H), 2.15 (s, 3H), 3.91 (dd, 1H, J = 2.04 and 12.43 Hz), 4.07 (m, 1H), 4.17 (m, 
1H), 5.32 (m, 3H), 5.87 (m, 1H), 7.23, (m, 6H) and 7.36 (m, 4H). 
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1,3,4,6-Tetra-O-acetyl-2-O-(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-α-L-
gulopyranoside (2.27).70  
To a solution of 51 mg (0.15 mmol) of 2.18 100 mg (0.17 mmol) of 2.26 in 1.3 
mL of dry CH2Cl2 at 0 °C was added 53.0 µL (65.2 mg; 0.29 mmol) of TMSOTf 
dropwise and the reaction mixture was stirred at 0 °C for 17 min at which time it 
was poured into a two-phase solution of EtOAc (60 mL) and saturated aq 
NaHCO3 (30 mL). The organic layer was washed with two 20-mL portions of 
brine, dried (Na2SO4), filtered and concentrated under diminished pressure. The 
residue was purified by flash chromatography on a silica gel column (25 × 2 cm). 
Elution with 3:1 à 1:1 hexanes–ethyl acetate afforded the disaccharide 2.27 as a 
colorless oil: yield 60 mg (60%); silica gel TLC Rf 0.36 (1:2 hexanes–ethyl 
acetate); 1H NMR (CDCl3) δ 1.93 (s, 3H), 1.99 (s, 3H), 2.01 (s, 3H), 2.10 (m, 
12H), 2.15 (s, 3H), 3.95 (dd, 1H, J = 8.4, 3.0 Hz), 4.09 (m, 4H), 4.18 (t, 2H, J = 
3.8 Hz), 4.32 (t, 1H, J = 6.5 Hz), 4.94 (s, 1H), 4.97 (d, 1H, J = 3.7 Hz), 5.05 (m, 
1H), 5.11 (dd, 1H, J = 10.0 and 3.3 Hz), 5.23 (t, 1H, J = 10.0 Hz), 5.40 (t, 1H, J = 
3.3 Hz) and 5.85 (d, 1H, J = 8.4 Hz); 13C NMR (CDCl3) δ 20.7, 20.78, 20.84, 
20.9, 61.4, 62.2, 65.6, 65.8, 67.7, 68.7, 68.9, 69.3, 69.7, 71.4, 90.7, 95.1, 168.7, 
169.32, 169.35, 169.5, 169.6, 169.9, 170.5 and 170.6. 
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3,4,6-Tri-O-acetyl-2-O-(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-α-L-
gulopyranosyl Diphenyl Phosphate (2.28).77 
To a solution of 30 mg (44 µmol) of compound 2.27 in 1 mL of dry DMF was 
added 5.5 mg (60 µmol) of acetate salt of hydrazine and the reaction mixture was 
stirred for 1 h at which time analysis by silica gel TLC indicated complete 
consumption of the disaccharide. The solution was diluted with 40 mL of EtOAc 
and washed with three 15-mL portions of brine, dried over Na2SO4, filtered and 
concentrated under diminished pressure. The residue was co-evaporated with 
toluene, dried under diminished pressure and dissolved in 5 mL of dry CH2Cl2. To 
the solution were added 6.5 mg (54 µmol) of DMAP and 65 µL (47 mg; 0.5 
mmol) of Et3N; the mixture was stirred for 10 min, followed by addition of 86.0 
µL (111 mg; 0.41 mmol) of diphenyl chlorophosphate dropwise at 0 °C. The 
solution was stirred at 0 °C for 1 h and was then poured into a two-phase solution 
of EtOAc (50 mL) and saturated aq NaHCO3 soln (20 mL). The organic layer was 
washed with two 15-mL portions of brine, dried over Na2SO4, filtered, and 
concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (22 × 2 cm). Elution with 2:1 à 1:1 
hexanes–ethyl acetate afforded the activated ester 2.28 as a colorless oil: yield 28 
mg (73% over two steps); silica gel TLC Rf 0.28 (1:2 hexanes–ethyl acetate); 1H 
O
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NMR (CDCl3) δ 1.70 (s, 3H), 1.94 (s, 3H), 1.99 (s, 3H), 2.08 (s, 3H), 2.13 (s, 3H), 
2.15 (s, 3H), 2.21 (s, 3H), 4.00 (m, 3H), 4.13 (m, 2H), 4.33 (dd, 2H, J = 15.5 and 
8.8 Hz), 4.99 (m, 2H), 5.14 (m, 1H), 5.24 (m, 2H), 5.44 (s, 1H), 5.71 (t, 1H, J = 
7.3 Hz) and 7.28 (m, 10H); 13C NMR (CDCl3) δ 20.2, 20.60, 20.61, 20.65, 20.7, 
61.1, 61.8, 65.3, 65.5, 67.4, 68.6, 69.0, 69.1, 71.0, 71.6, 95.4, 96.1, 120.2, 120.2, 
125.6, 125.7, 129.6, 129.9, 150.0, 150.3, 169.2, 169.3, 169.4, 169.5, 169.6, 170.3 
and 170.5; mass spectrum (ESI), m/z 869.2253 (M + H)+ (C38H46O21P requires 
m/z 869.2264) 
 
3,4,6-Tri-O-acetyl-2-O-(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-α,β-L-
gulopyranosyl benzyl 2-(2-ethoxy)ethylcarbamate (2.29).77 
To a solution of 26 mg (30 µmol) of phosphate ester 2.28 and 6.5 mg (27 µmol) of 
the alcohol 2.21 in 1.0 mL of anhydrous CH2Cl2 was added 10 µL (12.3 mg; 54 
µmol) of TMSOTf at 0 °C. The reaction was stirred at 0 °C for 17 min and was 
then poured into a two-phase solution of EtOAc (50 mL) and saturated aq 
NaHCO3 (20 mL). The organic layer was washed with two 20-mL portions of 
brine, dried (Na2SO4), filtered and concentrated under diminished pressure. The 
residue was purified by flash chromatography on a silica gel column (25 × 2 cm).  
Elution with 32:16:1 à 12:12:1 hexanes–ethyl acetate–methanol afforded 
compound 2.29 a colorless oil: yield 18 mg (70%); silica gel TLC Rf 0.80 
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(12:12:1 hexanes–ethyl acetate–methanol); 1H NMR (CDCl3) δ 1.97 (s, 3H), 2.02 
(s, 3H), 2.04 (s, 3H), 2.08 (s, 3H), 2.10 (s, 3H), 2.12 (s, 3H), 2.14 (s, 3H), 3.40 
(m, 2H), 3.61 (m, 3H), 3.68 (m, 2H), 3.85 (m, 1H), 3.97 (m, 1H), 4.18 (m, 5H), 
4.27 (m, 4H), 4.47 (t, 1H, J = 6.4 and 6.4 Hz), 4.92 (d, 1H, J = 3.7 Hz), 5.01 (m, 
2H), 5.09 (s, 2H), 5.15 (s, 1H), 5.28 (m, 3H), 5.45 (s, 1H) and 7.33 (m, 5H); 13C 
NMR (CDCl3) δ 20.61, 20.62, 20.70, 20.75, 20.8, 29.7, 40.9, 62.1, 62.5, 63.7, 
65.5, 6.0, 66.6, 68.6, 68.6, 69.1, 69.2, 70.1, 70.3, 70.6, 97.0, 97.1, 128.05, 128.15, 
128.5, 136.5, 156.4, 169.3, 169.5, 169.6, 169.8, 169.9, 170.52 and 170.53; mass 
spectrum (ESI), m/z 858.3036 (M + H)+ (C38H52NO21 requires m/z 858.3026) 
 
Decarbamoyl BLM-disaccharide-Cy5** (2.30). 
To a solution of 5.0 mg (5.8 µmol) of compound 2.29 in 2 mL of dry MeOH was 
added 0.2 mL of a 25% w/w solution of NaOMe in MeOH and the mixture was 
shaken at room temperature for 2 h. Fifty mg of Dowex 50W resin was added and 
the mixture was shaken at room temperature for 30 min. The mixture was filtered, 
diluted to 5 mL with methanol and catalytic amount of Pd/C was added. H2 gas 
was bubbled through the solution for 30 min and the mixture was filtered through 
a pad of Celite. The filtrate was concentrated to obtain the free amine as a 
colorless oil: crude yield 2 mg (73%). Two (2.0) mg of this compound was 
dissolved in 1 mL of 0.2 M aq sodium phosphate buffer solution (pH ~ 8). One 
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hundred µL of this solution was added to a vial containing 110 µg of Cy5** 
carboxylic acid succinimidyl ester (2.24) and the mixture was shaken at room 
temperature overnight in the dark. The crude reaction mixture was purified on an 
Econosil C18 reversed phase semi-preparative (250 × 10 mm, 10 µm) HPLC 
column using 0.1% aq TFA and CH3CN mobile phases. The column was washed 
with 1 à 55% CH3CN in 0.1% aq TFA over a period of 30 min at a flow rate of 3 
mL/min. Fractions containing the desired product eluted at 16.05 min (monitoring 
at 651 nm) and were collected, frozen, and lyophilized to give the dye conjugate 
2.30 as a blue solid: yield 34 µg (7%); mass spectrum (MALDI), m/z 1336.99 
(M)+ (theoretical 1336.35); mass spectrum (ESI), m/z 647.6858 (M – K – 2H)2– 
(C54H77N3O25S4 requires m/z 647.6870). 
 
Nε-Boc-L-Lysine Methyl Ester (2.32).80 
To a mixture of 160 mg (0.34 mmol) of Nα-Fmoc-Nε-Boc-L-lysine (2.31) and 94 
mg (0.68 mmol) of K2CO3 in 4 mL of anhydrous DMF was added 64.0 µL (145 
mg; 1.0 mmol) of CH3I at room temperature. The reaction mixture was stirred at 
50 °C for 2 h. The cooled reaction mixture was diluted with 50 mL of diethyl 
ether. The organic layer was washed with 20 mL of H2O, 20 mL of 0.1 N aq HCl 
and 15 mL of brine. The ether layer was dried (Na2SO4) and concentrated under 
diminished pressure. The crude Nα-Fmoc-Nε-Boc-L-lysine methyl ester was then 
dissolved in 3 mL of a solution of 20% piperidine in anhydrous DMF and the 
H2N
O
BocHN
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reaction mixture was stirred at room temperature for 1 h. The reaction mixture 
was concentrated under diminished pressure and the residue was purified by flash 
chromatography on a silica gel column (8 × 3 cm).  Elution with 25:1 à 15:1 
chloroform–methanol afforded compound 2.32 as a colorless oil: yield 82 mg 
(92%); silica gel TLC Rf 0.46 (20:1 chloroform–methanol); 1H NMR (CDCl3) δ 
1.32–1.77 (m, 15H), 3.10 (d, 2H, J = 6.1 Hz), 3.43 (dd, 1H, J = 9.6 and 3.7 Hz), 
3.70 (s, 3H) and 4.58 (s, 1H); 13C NMR (CDCl3) δ 22.8, 28.4, 29.8, 34.4, 40.3, 
51.9, 54.2, 79.0, 155.9 and 176.4. 
 
Nα-Fmoc-Nε-Boc-L-lysyl-Nε-Boc-L-lysine Methyl Ester (2.33). 
To a solution of 60.0 mg (0.23 mmol) of compound 2.32, 108 mg (0.23 mmol) of 
compound 2.31 and 99.0 mg (0.46 mmol) of 1,8-bis(dimethylamino)naphthalene 
(proton sponge) in 4 mL of anhydrous DMF was added 131 mg (0.35 mmol) of 
HATU. The reaction mixture was stirred at room temperature for 16 h. The 
reaction mixture was concentrated under diminished pressure and the residue was 
diluted in 50 mL of diethyl ether. The ether layer was washed with three 15-mL 
portions of 1 N aq HCl, 20 mL of satd aq NaHCO3 soln and 20 mL of brine. The 
organic layer was then dried (Na2SO4) and concentrated under diminished 
pressure. The residue was purified by flash chromatography on a silica gel 
column (15 × 3 cm).  Elution with 2:1 à 1:1 hexanes–ethyl acetate afforded 
compound 2.33 as a colorless oil: yield 110 mg (67%); silica gel TLC Rf 0.42 (1:1 
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hexanes–ethyl acetate); 1H NMR (CDCl3) δ 1.41 (m, 26H), 1.66 (m, 2H), 1.84 (m, 
2H), 3.06 (m, 4H), 3.66 (s, 3H), 4.40 (m, 4H), 4.54 (dd, 1H, J = 12.4 and 7.4 Hz), 
4.82 (s, 2H), 5.81 (s, 1H), 6.92 (d, 1H, J = 6.1 Hz), 7.27 (m, 2H), 7.37 (t, 2H, J = 
7.5 Hz), 7.58 (d, 2H, J = 7.3 Hz) and 7.73 (d, 2H, J = 7.5 Hz); 13C NMR (CDCl3) 
δ 22.3, 22.5, 28.47, 28.48, 29.4, 29.6, 31.5, 32.3, 39.9, 40.0, 47.1, 52.2, 52.4, 54.6, 
67.2, 79.1, 119.98, 120.01, 125.16, 125.21, 127.1, 127.7, 141.28, 141.29, 143.8, 
143.9, 156.20, 156.24, 156.3, 171.9 and 172.6; mass spectrum (ESI), m/z 
711.3976 (M + H)+ (C38H55N4O9 requires m/z 711.3964).   
 
Nα-CBz-Nε-Boc-L-lysyl-Nε-Boc-L-lysine Methyl Ester (2.34).81 
To a solution of 110 mg (0.15 mmol) of compound 2.33 in 2 mL of anhydrous 
DMF was added 0.4 mL of piperidine and the solution was stirred at room 
temperature for 1 h. The reaction mixture was concentrated under diminished 
pressure and the residue was co-evaporated with three 10-mL portions of toluene. 
To a solution of the residue in 3 mL of dry THF were added 0.22 mL (0.16 mg; 
1.60 mmol) of anhydrous triethylamine and 0.11 mL (0.13 g, 0.77 mmol) of 
benzyl chloroformate. The reaction mixture was stirred at room temperature for 5 
h. The reaction mixture was diluted with 60 mL of diethyl ether, washed with two 
20-mL portions of water and 20 mL of brine. The ether layer was dried (Na2SO4) 
and concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (15 × 3 cm).  Elution with 2:1 à 1:2 
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hexanes–ethyl acetate afforded the methyl ester 2.34 as a colorless oil: yield 82 
mg (85%); silica gel TLC Rf 0.50 (1:1 hexanes–ethyl acetate); 1H NMR (CDCl3) δ 
1.30–1.53 (m, 26H), 1.67 (dd, 3H, J = 13.7 and 7.1 Hz), 1.83 (m, 2H), 3.06 (s, 
4H), 3.72 (s, 3H), 4.21 (d, 1H, J = 5.8 Hz), 4.67 (m, 3H), 5.10 (s, 2H), 5.64 (s, 
1H), 6.75 (d, 1H, J = 6.9 Hz) and 7.32 (m, 5H); 13C NMR (CDCl3) δ 22.4, 22.5, 
27.8, 28.5, 29.3, 29.5, 29.6, 31.7, 39.9, 40.1, 52.1, 54.8, 67.1, 79.2, 128.2, 128.3, 
128.6, 136.3, 156.2, 156.3, 156.4,171.9 and 172.7. 
 
Nα-CBz-Nε-Boc-L-lysyl-Nε-Boc-L-lysine (2.35).82 
To a solution containing 82.0 mg (0.13 mmol) of compound 2.34 in 1.2 mL of 
THF was added a solution of 13 mg of LiOH (0.53 mmol) in 0.6 mL of water. 
The reaction mixture was stirred at room temperature for 2 h.  The reaction 
mixture was diluted with 10 mL of Et2O and 25 mL of water and the phases were 
separated.  The cooled aqueous phase (ice bath) was acidified to pH ~ 3 with 5% 
aq NaHSO4 soln and extracted with three 20-mL portions of ethyl acetate. The 
combined organic layer was then washed with 10 mL of brine, dried over 
anhydrous Na2SO4, filtered and concentrated under diminished pressure to afford 
the acid 2.35 as a colorless oil: yield 62 mg (77%); silica gel TLC Rf 0.27 (1:3 
hexanes–ethyl acetate); 1H NMR (CD3OD) δ 1.44 (s, 26H), 1.68 (m, 2H), 1.86 
(m, 2H), 3.01 (m, 4H), 4.14 (m, 1H), 4.38 (m, 1H), 5.09 (s, 2H) and 7.33 (m, 5H); 
13C NMR (CD3OD) δ 24.0, 24.1, 28.8, 30.4, 30.5, 32.3, 32.9, 41.0, 41.1, 53.4, 
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53.5, 56.2, 67.6, 79.8, 128.8, 129.0, 129.4, 138.2, 158.4, 158.49, 158.53, 174.9 
and 175.1.  
 
Nα-CBz-Nε-Boc-L-lysyl-Nε-Boc-L-lysyl-BLM-disaccharide (2.36). 
To a solution of 5.0 mg (10 µmol) of compound 2.23, 4.5 mg (7.4 µmol) of the 
dipeptide 2.35 and 6.4 mg (30 µmol) of 1,8-bis(dimethylamino)naphthalene 
(proton sponge) in 0.2 mL of anhydrous DMF was added 5.6 mg (15 µmol) of 
HATU. The reaction mixture was stirred at room temperature for 16 h. The 
reaction mixture was purified on an Econosil C18 reversed phase semi-preparative 
(250 × 10 mm, 10 µm) HPLC column using 0.1% aq TFA and CH3CN mobile 
phases. The column was washed with 1 à 55% CH3CN in 0.1% aq TFA over a 
period of 30 min at a flow rate of 3 mL/min. Fractions containing the desired 
product eluted at 29.8 min (monitoring at 220 nm) and were collected, frozen, and 
lyophilized to give compound 2.36 as a colorless solid: yield 6 mg (76%); mass 
spectrum (ESI), m/z 1063.5287 (M + H)+ (C47H79N6O21 requires m/z 1063.5293). 
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Nα-Cy5**-Nε-Boc-L-lysyl-Nε-Boc-L-lysyl-BLM-disaccharide (2.38). 
H2 (g) was bubbled through a solution of 4.5 mg (4.2 µmol) of compound 2.36 in 
2 mL of methanol for 10 min, and the reaction mixture was stirred for 30 min 
under a hydrogen atmosphere. The reaction mixture was filtered and the filtrate 
was concentrated under diminished pressure to obtain compound 2.37 as colorless 
solid: crude yield 4.2 mg. Two (2.0) mg of the amine 2.37 was dissolved in 0.8 
mL of 0.2 M aq sodium phosphate buffer solution (pH ~ 8). Two hundred µL (0.5 
mg; 0.54 µmol) of this solution was added to a vial containing 100 µg (0.10 µmol) 
of Cy5** carboxylic acid succinimidyl ester (2.24) and the mixture was shaken at 
room temperature overnight in the dark. The crude reaction mixture was purified 
on an Econosil C18 reversed phase semi-preparative (250 × 10 mm, 10 µm) HPLC 
column using 0.1% aq TFA and CH3CN mobile phases. A linear gradient was 
employed (99:1 0.1% aq TFA–CH3CN à 45:55 0.1% aq TFA–CH3CN) over a 
period of 30 min at a flow rate of 3 mL/min. Fractions containing the desired 
product eluted at 20.2 min (monitoring at 651 nm) and were collected, frozen, and 
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lyophilized to give the dye conjugate 2.38 as a blue solid: yield 50 µg (27%); 
mass spectrum (ESI), m/z 897.3375 (M – 3H)2– (C77H118N8O32S4 requires m/z 
897.3373). 
 
Nα-Cy5**-L-lysyl-L-lysyl-BLM-disaccharide (2.39). 
A solution of 32 µg (18 nmol) of 2.38 in 200 µL of 60% aq TFA was shaken at 
room temperature for 40 min and was purified on an Econosil C18 reversed phase 
semi-preparative (250 × 10 mm, 10 µm) HPLC column using 0.1% aq TFA and 
CH3CN mobile phases. A linear gradient was employed (99:1 0.1% aq TFA–
CH3CN à 45:55 0.1% aq TFA–CH3CN) over a period of 30 min at a flow rate of 
3 mL/min. Fractions containing the desired product eluted at 16.1 min 
(monitoring at 651 nm) and were collected, frozen, and lyophilized to afford the 
dye conjugate 2.39 as a blue solid: yield 19 µg (67%); mass spectrum (ESI), m/z 
797.2850 (M – 3H)2– (C67H102N8O28S4 requires m/z 797.2850). 
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Nα-CBz-Nε-Boc-D-lysine Methyl Ester (2.41).83 
To a mixture of 149 mg (0.39 mmol) of Nα-CBz-Nε-Boc-D-lysine (2.40) and 108 
mg (0.78 mmol) of K2CO3 in 4 mL of anhydrous DMF was added 73.0 µL (0.17 
g; 1.2 mmol) of CH3I at room temperature. The reaction mixture was stirred at 50 
°C for 2 h. The cooled reaction mixture was diluted with 50 mL of diethyl ether. 
The organic layer was washed with 20 mL of H2O, 20 mL of 0.1 N aq HCl and 15 
mL of brine. The ether layer was dried (Na2SO4) and concentrated under 
diminished pressure. The residue was purified by flash chromatography on a silica 
gel column (12 × 3 cm).  Elution with 3:1 à 1:1 hexanes–ethyl acetate afforded 
compound 2.41 as a colorless oil: yield 134 mg (87%); silica gel TLC Rf 0.31 (3:1 
hexanes–ethyl acetate); 1H NMR (DMSO-d6) δ 1.31−1.67 (m, 15H), 2.87 (m, 
2H), 3.62 (m, 1H), 3.99 (s, 3H), 5.03 (s, 2H), 6.78 (m, 1H), 7.71 (m, 1H) and 7.36 
(m, 5H). 
  
Nε-Boc-D-lysine Methyl Ester (2.42).83 
H2 (g) was bubbled through a mixture of 134 mg (0.34 mmol) of compound 2.41 
and a catalytic amount of Pd/C in 8 mL of methanol for 10 min. The reaction 
mixture was stirred under an atmosphere of H2 for 30 min and filtered through a 
pad of Celite. The filtrate was concentrated under diminished pressure to obtain 
compound 2.42 as a colorless oil: yield 79 mg (89%); silica gel TLC Rf 0.46 (20:1 
chloroform–methanol); 1H NMR (CDCl3) δ 1.32−1.77 (m, 15H), 3.10 (d, 2H, J = 
H2N
O
BocHN
O
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6.1 Hz), 3.43 (dd, 1H, J = 9.6 and 3.7 Hz), 3.70 (s, 3H) and 4.58 (s, 1H); 13C 
NMR (CDCl3) δ 22.8, 28.4, 29.8, 34.4, 40.3, 51.9, 54.2, 79.0, 155.9 and 176.4. 
 
Nα-CBz-Nε-Boc-D-lysyl-Nε-Boc-D-lysine Methyl Ester (2.43). 
To a solution of 79 mg (0.30 mmol) of compound 2.42, 109 mg (0.29 mmol) of 
compound 2.40 and 123 mg (0.57 mmol) of 1,8-bis(dimethylamino)naphthalene 
(proton sponge) in 4 mL of anhydrous DMF was added 163 mg (0.43 mmol) of 
HATU. The reaction mixture was stirred at room temperature for 16 h. The 
reaction mixture was concentrated under diminished pressure and the residue was 
diluted in 80 mL of diethyl ether. The ether layer was washed with three 25-mL 
portions of 1 N aq HCl, 30 mL of satd aq NaHCO3 soln and 20 mL of brine. The 
organic layer was dried (Na2SO4) and concentrated under diminished pressure. 
The residue was purified by flash chromatography on a silica gel column (15 × 3 
cm).  Elution with 2:1 à 1:1 hexanes–ethyl acetate afforded the methyl ester 2.43 
as a colorless oil: yield 150 mg (84%); silica gel TLC Rf 0.50 (1:1 hexanes–ethyl 
acetate); 1H NMR (CDCl3) δ 1.30−1.53 (m, 26H), 1.67 (dd, 3H, J = 13.7 and 7.1 
Hz), 1.83 (m, 2H), 3.06 (s, 4H), 3.72 (s, 3H), 4.21 (d, 1H, J = 5.8 Hz), 4.67 (m, 
3H), 5.10 (s, 2H), 5.64 (s, 1H), 6.75 (d, 1H, J = 6.9 Hz) and 7.32 (m, 5H); 13C 
NMR (CDCl3) δ 22.4, 22.5, 27.8, 28.5, 29.3, 29.5, 29.6, 31.7, 39.9, 40.1, 52.1, 
54.8, 67.1, 79.2, 128.2, 128.3, 128.6, 136.3, 156.2, 156.3, 156.4,171.9 and 172.7; 
N
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mass spectrum (ESI), m/z 623.3652 (M + H)+ (C31H51N4O9 requires m/z 
623.3650). 
 
Nα-CBz-Nε-Boc-D-lysyl-Nε-Boc-D-lysine (2.44). 
To a solution containing 145 mg (0.37 mmol) of the methyl ester 2.34 in 3.2 mL 
of THF was added a solution of 35 mg of LiOH (1.47 mmol) in 1.6 mL of water. 
The reaction mixture was stirred at room temperature for 2 h.  The mixture was 
diluted with 20 mL of Et2O and 35 mL of water and the phases were separated. 
The cooled aqueous phase (ice bath) was acidified to pH ~ 3 with 5% aq NaHSO4 
and extracted with three 30-mL portions of ethyl acetate. The combined organic 
layer was washed with 20 mL of brine, dried over anhydrous Na2SO4, filtered and 
concentrated under diminished pressure to afford the free acid 2.44 as a colorless 
oil: yield 129 mg (91%); silica gel TLC Rf 0.27 (1:3 hexanes–ethyl acetate); 1H 
NMR (CDCl3) δ 1.24−1.96 (m, 30H), 3.04 (d, 4H, J = 5.1 Hz), 4.25 (m, 2H), 4.89 
(s, 1H), 5.06 (d, 2H, J = 12.7 Hz), 6.05 (m, 1H), 7.25 (m, 5H) and 10.55 (br s, 
1H); 13C NMR (CDCl3) δ 22.5, 22.6, 28.5, 29.5, 31.5, 32.4, 40.2, 52.3, 54.8, 67.0, 
79.4, 128.1, 128.2, 128.6, 136.4, 156.4, 156.5, 158.0, 172.4 and 174.9; mass 
spectrum (ESI), m/z 609.3495 (M + H)+ (C30H49N4O9 requires m/z 609.3494). 
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Nα-CBz-Nε-Boc-D-lysyl-Nε-Boc-D-lysyl-BLM-disaccharide (2.45). 
To a solution of 3.0 mg (6.3 µmol) of compound 2.23, 3.8 mg (6.2 µmol) of 
compound 2.44 and 4.5 µL (3.2 mg; 25 µmol) of DIPEA in 0.15 mL of anhydrous 
DMF was added 4.8 mg (13 µmol) of HATU. The reaction mixture was stirred at 
room temperature for 16 h. The reaction was purified on an Econosil C18 reversed 
phase semi-preparative (250 × 10 mm, 10 µm) HPLC column using 0.1% aq TFA 
and CH3CN mobile phases. A linear gradient was employed (99:1 0.1% aq TFA–
CH3CN à 45:55 0.1% aq TFA–CH3CN) over a period of 30 min at a flow rate of 
3 mL/min. Fractions containing the desired product eluted at 29.8 min 
(monitoring at 220 nm) and were collected, frozen, and lyophilized to give 2.45 as 
a colorless solid: yield 2.5 mg (37%); mass spectrum (ESI), m/z 1063.5280 (M + 
H)+ (C47H79N6O21 requires m/z 1063.5293). 
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Nα-Cy5**-Nε-Boc-D-lysyl-Nε-Boc-D-lysyl-BLM-disaccharide (2.47). 
H2 gas was bubbled through a solution of 1.5 mg (4.2 µmol) of compound 2.45 in 
2 mL of methanol for 10 min, and the reaction mixture was stirred for 30 min 
under a hydrogen atmosphere. The reaction mixture was filtered and the filtrate 
was concentrated under diminished pressure to afford compound 2.46 as a 
colorless solid: yield 1.1 mg. To 1.1 mg (1.2 µmol) of 2.46 was added 0.44 mL of 
0.2 M aq sodium phosphate buffer solution (pH ~ 8). Two hundred µL (0.5 mg; 
0.54 µmol) of this solution was added to a vial containing 110 µg (0.11 µmol) of 
Cy5** carboxylic acid succinimidyl ester (2.24) and the mixture was shaken at 
room temperature overnight in the dark. The crude reaction mixture was purified 
on an Econosil C18 reversed phase semi-preparative (250 × 10 mm, 10 µm) HPLC 
column using 0.1% aq TFA and CH3CN mobile phases. A linear gradient was 
employed (99:1 0.1% aq TFA−CH3CN à 45:55 0.1% aq TFA−CH3CN) over a 
period of 30 min at a flow rate of 3 mL/min. Fractions containing the desired 
product eluted at 20.1 min (monitoring at 651 nm) and were collected, frozen, and 
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lyophilized to give the dye conjugate 2.47 as a light blue solid: yield 52 µg (26%); 
mass spectrum (ESI), m/z 897.3370 (M – 3H)2– (C77H118N8O32S4 requires m/z 
897.3373). 
 
Nα-Cy5**-D-lysyl-D-lysyl-BLM-disaccharide (2.48). 
A solution of 45 µg (25 nmol) of 2.47 in 200 µL of 60% aq TFA was shaken at 
room temperature for 40 min and was purified on an Econosil C18 reversed phase 
semi-preparative (250 × 10 mm, 10 µm) HPLC column using 0.1% aq TFA and 
CH3CN mobile phases. A linear gradient was employed (99:1 0.1% aq TFA–
CH3CN à 45:55 0.1% aq TFA–CH3CN) over a period of 30 min at a flow rate of 
3 mL/min. Fractions containing the desired product eluted at 16.2 min 
(monitoring at 651 nm) and were collected, frozen, and lyophilized to give 2.48 as 
a blue solid: yield 25 µg (62%); mass spectrum (ESI), m/z 797.2845 (M – 3H)2– 
(C67H102N8O28S4 requires m/z 797.2850). 
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4-(2-tert-Butoxycarbonyl-ethyl)-4-nitro-heptanedioic Acid Di-tert-butyl Ester 
(2.50).84 
To a solution of 2.14 mL (2.43 g; 39.8 mmol) of nitromethane in 10 mL of 
dimethoxyethane at 65 °C was added 0.4 mL of 40% aq tetrabutylammonium 
hydroxide soln and the reaction mixture was heated to 75 °C. To the reaction 
mixture was added dropwise 18.2 mL (125 mmol) of tert-butyl acrylate (2.49). To 
this mixture was added 0.8 mL of 40% aq tetrabutylammonium hydroxide soln in 
portions over a period of 1 h. The reaction mixture was stirred at 75 °C for 2 h. 
The reaction mixture was concentrated under diminished pressure and the residue 
was diluted in 100 mL of diethyl ether. The ether layer was washed with two 30-
mL portions of 10% aq citric acid soln, two 30-mL portions of sat aq NaHCO3 
soln, 20 mL of brine, then dried over anhydrous Na2SO4, filtered and concentrated 
under diminished pressure. The residue was recrystallized from absolute ethanol 
to afford compound 2.50 as colorless needles: yield 16.1 g (91%); mp 92-94 °C, 
lit84 mp 98-100 °C 1H NMR (CDCl3) δ 1.43 (s, 27H) and 2.19 (m, 12H); 13C 
NMR (CDCl3) δ 28.2, 29.9, 30.5, 81.3, 92.3 and 171.2. 
 
4-Amino-4-(2-tert-butoxycarbonylethyl)heptanedioic Acid Di-tert-butyl Ester 
(2.51).84 
A mixture of 1.02 g (2.29 mmol) of compound 2.50, ~6 mL of T1-Raney Ni 
(suspension in ethanol) and 18 mL of absolute ethanol was shaken in a Parr 
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shaker at room temperature and 52 psi H2 for 72 h. The reaction mixture was 
filtered through a pad of Celite and the filtrate was concentrated under diminished 
pressure to afford the amine 2.51 as a waxy solid which was used directly in the 
next step: yield 0.88 g (92%); silica gel TLC Rf 0.14 (1:3 hexanes–ethyl acetate); 
1H NMR (CDCl3) δ 1.42 (s, 27H), 1.58 (t, 6H, J = 8.4 Hz) and 2.22 (t, 6H, J = 8.4 
Hz); 13C NMR (CDCl3) δ 28.0, 29.9, 34.4, 52.3, 80.3 and 173.0. 
 
4-(3-Benzyloxycarbonylaminopropionylamino)-4-(2-tert-butoxycarbonyl-
ethyl)-heptanedioic Acid Di-tert-butyl Ester (2.53). 
To a solution of 0.84 g (2.02 mmol) of compound 2.51 and 0.43 g (1.91 mmol) of 
CBz-β-alanine (2.52) in 15 mL of dry DMF were added 0.74 g (1.95 mmol) of 
HATU and 0.82 g (3.82 mmol) of proton sponge. The resulting yellow mixture 
was stirred at room temperature for 16 h. The reaction mixture was concentrated 
under diminished pressure and the residue was dissolved in 80 mL of ethyl 
acetate. The ethyl acetate layer was washed with two 40-mL portions of 2 M aq 
HCl, two 30-mL portions of H2O, and 20 mL of brine, then dried over anhydrous 
Na2SO4, filtered and concentrated under diminished pressure. The residue was 
purified by flash chromatography on a silica gel column (12 × 3 cm). Elution with 
1:1 hexanes–ethyl acetate gave compound 2.53 as a colorless solid: yield 1.17 g 
(98%); silica gel TLC Rf 0.40 (1:1 hexanes–ethyl acetate); 1H NMR (CDCl3) δ 
1.42 (s, 27H), 1.94 (t, 6H, J = 8.0 Hz), 2.19 (t, 6H, J = 8.4 Hz), 2.34 (m, 2H), 3.44 
HN
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(m, 2H), 5.09 (s, 2H), 5.57 (brs, 1H), 5.99 (brs, 1H) and 7.32 (m, 5H); 13C NMR 
(CDCl3) δ 28.1, 29.8, 30.0, 36.8, 37.3, 57.8, 66.6, 80.8, 128.0, 128.5, 136.7, 
156.6, 170.9 and 172.9; mass spectrum (ESI), m/z 621.3753 (M + H)+ 
(C33H53N2O9 requires m/z 621.3746). 
 
4-(3-Benzyloxycarbonylaminopropionylamino)-4-(2-carboxy-ethyl)-
heptanedioic Acid (2.54). 
A solution of 1.21 g (1.93 mmol) of 2.53 in 25 mL of formic acid was stirred at 
room temperature for 12 h. The reaction mixture was concentrated under 
diminished pressure. The residue was co-evaporated with six 10-mL portions of 
toluene to afford the tri-acid 2.54 as colorless oil: yield 0.91 g (100%); 1H NMR 
(CD3OD) δ 2.01 (m, 6H), 2.26 (m, 6H), 2.40 (m, 2H), 3.36 (m, 2H), 5.07 (s, 2H) 
and 7.31 (m, 5H); 13C NMR (DMSO-d6) δ 28.1, 29.0, 36.2, 37.3, 56.4, 65.2, 
127.71, 127.75, 137.2, 156.0, 170.0 and 174.5; mass spectrum (ESI), m/z 
453.1886 (M + H)+ (C21H29N2O9 requires m/z 453.1868). 
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4-(3-Benzyloxycarbonylaminopropionylamino)-4-[2-(2,5-dioxo-pyrrolidin-1-
yloxycarbonyl)-ethyl]-heptanedioic Acid Bis-(N-hydroxysuccinimide) Ester 
(2.55). 
To a solution of 0.48 g (1.06 mmol) of compound 2.54 and 0.44 g (3.82 mmol) of 
N-hydroxysuccinimide in 9 mL dry THF at 0 °C was added dropwise a solution of 
0.83 g (4.03 mmol) of DCC in 2 mL of dry THF. The resulting reaction mixture 
was stirred at 5 °C for 16 h. The reaction mixture was concentrated under 
diminished pressure and the residue was suspended in 10 mL of acetonitrile. The 
suspension was filtered and the filtrate was concentrated under diminished 
pressure. The residue was the purified by crystallization from absolute ethanol to 
afford 2.55 as a colorless crystals: yield 366 mg (46%); 1H NMR (CD3CN) δ 2.08 
(m, 6H), 2.31 (m, 2H), 2.58 (m, 6H), 2.74 (s, 12H), 3.28 (m, 2H), 5.02 (s, 2H), 
5.73 (brs, 1H), 6.10 (brs, 1H) and 7.32 (m, 5H); 13C NMR (CD3CN) δ 25.9, 26.3, 
29.5, 37.0, 37.9, 58.0, 66.7, 128.6, 128.7, 129.3, 138.3, 157.2, 169.8, 171.0 and 
172.1; mass spectrum (ESI), m/z 744.2342 (M + H)+ (C33H38N5O15 requires m/z 
744.2359). 
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TrimerBLM-disaccharide (2.57). 
H2 gas was bubbled through a mixture containing 18 mg (21 µmol) of 2.22 and a 
catalytic amount of Pd/C in 5 mL of dry THF for 45 min. The reaction mixture 
was filtered through a pad of Celite and the filtrate was concentrated under 
diminished pressure to obtain crude 2.56 as a colorless oil, which was used 
immediately in the next step: crude yield 14 mg; mass spectrum (MALDI) m/z 
725.28 (M + H)+ (theoretical m/z 725.26).  
To a solution containing 14 mg (19 µmol) of 2.56 and 20 µL (15 mg, 0.14 
mmol) of triethylamine in 1.5 mL of dry DMF was added 1.6 mg (2.2 µmol) of 
2.55 and the mixture was stirred at room temperature for 20 h. The reaction 
mixture was concentrated under diminished pressure. The residue was purified by 
flash chromatography on a silica gel column (14 × 1 cm).  Elution with 32:15:1 à 
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11:10:1 chloroform–acetone–methanol afforded trimerBLM-disaccharide 2.57 as 
a colorless oil: yield 4.5 mg (81%); silica gel TLC Rf 0.60 (4:4:1 chloroform–
acetone–methanol); mass spectrum (MALDI), m/z 2595.11 (M + Na)+ (theoretical 
m/z 2594.90); mass spectrum (ESI), m/z 1297.4575 (M + H + Na)2+ 
(C108H155N8O63Na requires m/z 1297.4529). 
 
TrimerBLM-disaccharide-Cy5** (2.59). 
To a solution of 5.0 mg (1.94 µmol) of 2.57 in 2 mL of dry MeOH was added 0.3 
mL of a 25% w/w solution of NaOMe in MeOH. The reaction mixture was 
shaken at room temperature for 2 h. One hundred mg of Dowex 50W resin was 
added and the mixture was shaken at room temperature for 30 min. The mixture 
was filtered, diluted to 5 mL with methanol and a catalytic amount of Pd/C was 
added. H2 gas was bubbled through the mixture for 30 min and the mixture was 
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filtered. The filtrate was concentrated to obtain compound 2.58 as colorless solid: 
crude yield 2.6 mg (80%). To 110 µg (0.11 µmol) of Cy5**COOSu (2.24) was 
added 100 µL of 0.2 M aq sodium phosphate buffer (pH ~ 8). This solution was 
added to a vial containing 0.56 mg (0.34 µmol) of 2.58 in 40 µL of DMSO and 
the mixture was shaken at room temperature overnight in the dark. The crude 
reaction mixture was purified on an Econosil C18 reversed phase semi-preparative 
(250 × 10 mm, 10 µm) HPLC column using 0.1% aq TFA and CH3CN mobile 
phases. A linear gradient was employed (99:1 0.1% aq TFA–CH3CN à 45:55 
0.1% aq TFA–CH3CN) over a period of 30 min at a flow rate of 3 mL/min. 
Fractions containing the desired product eluted at 14.8 min (monitoring at 651 
nm) and were collected, frozen, and lyophilized to give the trimerBLM-
disaccharide-Cy5** 2.59 as a blue solid: yield 43 µg (15%); mass spectrum 
(MALDI), m/z 2588.4 (M)+ (theoretical m/z 2587.8); mass spectrum (ESI), m/z 
848.6223 (M – 4H)3– (C102H167N10O56S4 requires m/z 848.6215). 
 
4-Amino-4-deoxy-10-N-methylpteroic Acid (APA, 2.61).71  
A mixture of 249 mg (0.59 mmol) dibromotriphenylphosphorane and 45.0 mg 
(0.20 mmol) 2,4-diamino-6-(hydroxymethyl)pteridine hydrochloride (2.60) in 1.5 
mL of anhydrous dimethylacetamide was stirred at room temperature for 24 h 
under an argon atmosphere. To the reaction mixture were added 41 mg (0.27 
mmol) of 4-(methylamino)benzoic acid and 0.16 mL (116 mg, 0.90 mmol) of 
N
NN
N
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DIPEA and the reaction mixture was stirred at room temperature for 48 h, and 
then at 60 °C for 24 h. The cooled reaction mixture was poured into 25 mL of 
0.33 M aq NaOH and the precipitate was filtered. The filtrate was adjusted to pH 
5.5 with 10% acetic acid and the resulting precipitate was collected through 
filtration, washed with water and dried under diminished pressure at 80 °C 
overnight to obtain 2.61 as an orange solid: yield 42 mg (56%); silica gel TLC Rf 
0.47 (5:4:1 chloroform–methanol–water); 1H NMR (DMSO-d6) δ 3.19 (s, 3H), 
4.76 (s, 2H), 6.61 (s, 2H), 6.78 (d, 2H, J = 8.9 Hz), 7.72 (d, 2H, J = 8.7 Hz) and 
8.56 (s, 1H). 
 
APA-BLM-disaccharide (2.62). 
To a solution containing 3.5 mg (7.4 µmol) of 2.23, 2.5 mg (7.6 µmol) of 2.61 and 
3.0 µL (2.2 mg; 17 µmol) of DIPEA in 0.12 mL of anhydrous DMSO was added 
4.3 mg (11 µmol) of HATU. The reaction mixture was stirred at room temperature 
for 16 h. The reaction mixture was purified on an Econosil C18 reversed phase 
semi-preparative (250 × 10 mm, 10 µm) HPLC column using 0.1% aq TFA and 
CH3CN mobile phases. A linear gradient was employed (99:1 0.1% aq TFA–
CH3CN à 45:55 0.1% aq TFA–CH3CN) over a period of 30 min at a flow rate of 
3 mL/min. Fractions containing the desired product eluted at 26.5 min 
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(monitoring at 292 nm) and were collected, frozen, and lyophilized to give APA-
BLM-disaccharide conjugate 2.62 as a yellow solid: yield 2.2 mg (37%); mass 
spectrum (ESI), m/z 780.3168 (M + H)+ (C32H46N9O14 requires m/z 780.3159). 
 
4-Amino-4-deoxy-10-N-methylpteroic Acid 6-(tert-Butoxy)-6-oxohexyl Ester 
(2.64). 
To a solution of 36 mg (0.2 mmol) of 2.63, 12 mg (37 µmol) of 2.61 and 45 mg 
(0.4 mmol) of DMAP in 1 mL of anhydrous DMSO was added 39 mg (0.2 mmol) 
of DCC and the reaction mixture was stirred at room temperature for 24 h. The 
reaction mixture was filtered and the filtrate was purified on a C18 reversed phase 
semi-preparative (250 × 10 mm, 10 µm) HPLC column using 0.1% aq TFA and 
CH3CN mobile phases. A linear gradient was employed (99:1 0.1% aq TFA–
CH3CN à 1:99 0.1% aq TFA–CH3CN) over a period of 30 min at a flow rate of 3 
mL/min. Fractions containing the desired product eluted at 25.8 min (monitoring 
at 292 nm) and were collected, frozen, and lyophilized to give 2.64 as a yellow 
solid: yield 11 mg (60%); 1H NMR (CD3CN) δ 1.40 (m, 9H), 1.58 (m, 2H), 1.70 
(m, 2H), 2.19 (t, 2H, J = 7.3 Hz), 3.24 (s, 3H), 4.19 (t, 2H, J = 6.4 Hz), 4.84 (s, 
2H), 5.45 (s, 2H), 6.79 (m, 2H), 7.26 (s, 1H), 7.72 (s, 1H), 7.8 (m, 2H) and 8.73 
(s, 1H); mass spectrum (ESI), m/z 496.2676 (M + H)+ (C25H34N7O4 requires m/z 
496.2667). 
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APA ester-BLM-disaccharide (2.65). 
A solution containing 2.8 mg (5.6 µmol) of compound 2.64 in 1:1 TFA–CH2Cl2 
was shaken at room temperature for 1 h and concentrated under diminished 
pressure. The residue was co-evaporated with five 2-mL portions of toluene and 
dissolved in 0.1 mL of anhydrous DMSO. To this solution were added 2.9 mg 
(6.2 µmol) of 2.23, 2.0 µL (1.5 mg; 12 µmol) of DIPEA and 3.5 mg (9.3 µmol) of 
HATU. The reaction mixture was stirred at room temperature for 16 h. The 
reaction was purified on an Econosil C18 reversed phase semi-preparative (250 × 
10 mm, 10 µm) HPLC column using 0.1% aq TFA and CH3CN mobile phases. A 
linear gradient was employed (99:1 0.1% aq TFA–CH3CN à 45:55 0.1% aq 
TFA–CH3CN) over a period of 30 min at a flow rate of 3 mL/min. Fractions 
containing the desired product eluted at 20.7 min (monitoring at 292 nm) and 
were collected, frozen, and lyophilized to give APA-BLM-disaccharide conjugate 
2.65 as a yellow solid: yield 2.2 mg (53%); mass spectrum (ESI), m/z 894.3853 
(M + H)+ (C32H46N9O14 requires m/z 894.3840). 
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3,4,6-Tri-O-acetyl-2-O-(2,4,6-tri-O-acetyl-3-O-carbamoyl-α-D-
mannopyranosyl)-α,β-L-gulopyranoside (2.66).69 
To a solution of 83.0 mg (0.12 mmol) of 2.19 in 2 mL of dry DMF was added 
15.0 mg (0.16 mmol) of acetate salt of hydrazine at 0 °C. The solution was 
warmed to room temperature and stirred for 1 h at which time analysis by silica 
gel TLC indicated that the starting material had been completely consumed. The 
reaction mixture was diluted with 50 mL of EtOAc and washed with three 15-mL 
portions of brine, then dried over Na2SO4, filtered and concentrated under 
diminished pressure. The residue was purified by flash chromatography on a silica 
gel column (20 × 2 cm). Elution with 1:3 hexanes–ethyl acetate afforded 
compound 2.66 as a colorless oil: yield 55 mg (70%); silica gel TLC Rf 0.30 (1:2 
hexanes–ethyl acetate); 1H NMR (CDCl3) δ 2.02 (s, 3H), 2.04 (s, 3H), 2.09 (s, 
3H), 2.10 (s, 3H), 2.12 (s, 3H), 2.15 (s, 3H), 3.73 (dd, 1H, J = 8.0 and 3.4 Hz), 
4.12 (m, 3H), 4.34 (m, 1H), 4.95 (m, 5H), 5.10 (m, 1H), 5.16 (d, 1H, J = 3.3 Hz), 
5.25 (m, 1H) and 5.37 (m, 1H). 
 
1-O-((p-Nitrophenyl)carbamoyl)- 3,4,6-tri-O-acetyl-2-O-(2,4,6-tri-O-acetyl-3-
O-carbamoyl-α-D-mannopyranosyl)-α,β-L-gulopyranoside (2.67). 
To a solution of 25 mg (39 µmol) of compound 2.66 in 1 mL of dry acetonitrile 
were added 7.0 mg (58 µmol) of DMAP and a solution of 12 mg (58 µmol) of p-
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nitrophenyl chloroformate in 125 µL of acetonitrile. The mixture was stirred at 
room temperature for 1 h at which time silica gel TLC analysis showed complete 
consumption of the starting material. The reaction mixture was concentrated 
under diminished pressure, diluted in 30 mL ethyl acetate, and then washed with 
10 mL of H2O, 10 mL of 1 N aq HCl and 10 mL of brine. The ethyl acetate layer 
was dried over Na2SO4, filtered and concentrated under diminished pressure. The 
residue was purified by flash chromatography on a silica gel column (15 × 2 cm).  
Elution with 1:1 à 1:2 hexanes–ethyl acetate afforded the carbonate 2.67 as a 
colorless oil: yield 28 mg (92%); silica gel TLC Rf 0.38 (2:3 hexanes–ethyl 
acetate); 1H NMR (CDCl3) δ 1.94 (s, 3H), 2.06 (s, 3H), 2.10 (s, 3H), 2.15 (s, 3H), 
2.16 (s, 3H), 2.21 (s, 3H), 4.11 (m, 6H), 4.41 (m, 1H), 4.69 (br s, 2H), 5.04 (m, 
2H), 5.16 (m, 2H), 5.29 (m, 1H), 5.48 (m, 1H) 5.83 (d, 1H, J = 8.4 Hz), 7.47 (dd, 
1H, J = 6.8 and 2 Hz) and 8.31 (dd, 1H, J = 6.8 and 2 Hz); 13C NMR (CDCl3) δ 
20.78, 20.84, 20.95, 61.4, 62.0, 65.6, 65.9, 67.5, 69.2, 69.7, 69.8, 70.0, 72.0, 95.3, 
95.5, 122.09, 125.6, 146.0, 151.1, 155.1, 155.2, 169.3, 169.3, 169.6, 169.8, 170.5 
and 170.7; mass spectrum (ESI), m/z 825.1821 (M + Na)+ (C32H38N2O22Na 
requires m/z 825.1808). 
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Cu(II)deglycoBLM-disaccharide 2.68. 
To a solution containing 1.0 mg (1.2 μmol) of compound 2.67 and 1.0 mg (0.9 μmol) of Cu(II)deglycobleomycin in 0.5 mL of anhydrous DMF was added 5.0 
µL (3.7 mg; 36 μmol) of dry triethylamine and the mixture was shaken at room 
temperature for 3 h. Fifty µL (51 mg; 1.59 mmol) of hydrazine was added and the 
reaction mixture was shaken at room temperature for 1 h and then concentrated 
under diminished pressure. The mixture was diluted with 0.2 mL of 1:1 0.1% aq 
TFA–CH3CN and purified on an Alltech Alltima C18 reversed phase semi-
preparative (250 × 10 mm, 5 µm) HPLC column using 0.1% aq TFA and CH3CN 
mobile phases. A linear gradient was employed (99:1 0.1% aq TFA–CH3CN à 
50:50 0.1% aq TFA–CH3CN) over a period of 35 min at a flow rate of 3 mL/min. 
Fractions containing the desired product eluted at 17.0 min and were collected, 
frozen, and lyophilized to give 2.68 as a colorless solid: yield 0.53 mg (39%); 
mass spectrum (MALDI-TOF), m/z 1484.9 (M – Cu + H)+ (theoretical m/z 
1484.6); mass spectrum (ESI), m/z 742.7995 (M – Cu + 2H)2+ (C58H91N19O23S2 
requires m/z 742.7983). 
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Bleomycin-disaccharide (2.69).72  
To a solution of 20 mg (29 µmol) of compound 2.19 in 10 mL of dry MeOH was 
added 0.5 mL of a 25% w/w solution of NaOMe in MeOH. The mixture was 
shaken at room temperature for 2 h. One hundred mg of Dowex 50W resin was 
added and the mixture was shaken at room temperature for 30 min. The mixture 
was filtered and concentrated to obtain compound 2.69 as colorless syrup: 10 mg 
(88%); mass spectrum (MALDI), m/z 408.31 (M + Na)+ (theoretical m/z 408.11). 
Cell Growth Conditions.   
MCF-7 cells (ATCC HBT-22) were grown in RPMI 1640 (Gibco, Grand Island, 
NY) supplemented with 10% fetal bovine serum (HyClone, South Logan, UT) 
and 1% penicillin-streptomycin mix antibiotic supplement (Cellgro, 
Manassas,VA). MCF-10A cells (ATCC CRL-10317) were grown in MEGM 
(Invitrogen, Grand Island, NY) supplemented with 100 ng/mL cholera toxin 
(Sigma-Aldrich) and 1% penicillin-streptomycin mix antibiotic supplement. DU-
145 (ATCC HTB-81) and PZ-HPV-7 (ATCC CRL-2221) prostate cells were 
grown in MEM (Gibco, Grand Island, NY) supplemented with 10% fetal bovine 
serum (HyClone) and 1% penicillin-streptomycin mix antibiotic supplement. Cell 
lines were maintained at 37 °C under a humidified atmosphere of 5% CO2 and 
95% air. Dr. Alan Yu carried out this experiment. 
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Fluorescence Microscopy.   
Fluorescence images were obtained using a Zeiss Axiovert 200M inverted 
microscope fitted with an AxioCam MRm camera equipped with a 300-w xenon 
lamp (Sutter, Novato, CA), Cy5 and Cy7 cyanine filter (Chroma, Bellows Falls, 
VT). Adherent cancer cells were grown on 16-well Lab-Tek glass chamber slides 
at a cell density of 5000 cells/well (Thermo Scientific, Waltham, MA) at 37 °C 
for 48 h. Cells were rinsed twice with phosphate buffered saline (PBS) when the 
cell confluence was about 70%, then the medium was replaced with RPMI 1640 
(no phenol red). The dye-labeled conjugates were subsequently added to the final 
desired concentrations. The cells were incubated at 37 °C for 1 h, washed with 
PBS, then fixed with 4% paraformaldehyde at 37 °C for 5 min. Finally the slide 
was mounted with Prolong Antifade Gold reagent with DAPI (Invitrogen), then 
covered with a glass coverslip and dried for 24 h before fluorescence microscope 
imaging analysis. All images were recorded and target cells counted using a 40× 
oil objective. For comparative studies, the exposure time and laser intensity were 
kept identical for accurate intensity measurements. Pixel intensity was quantified 
using AxioVision Release 4.7 version software, and the mean pixel intensity was 
generated as gray level. Dr. Alan Yu carried out this experiment. 
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CHAPTER 3 
SYNTHESIS OF PUROMYCIN ANALOGUES 
3.1. INTRODUCTION 
Site-specific incorporation of unnatural amino acids into proteins has been 
facilitated by the use of suppressor tRNAs misacylated with these amino acids.39 
Several α-L-analogues of natural amino acids, containing various side chains, 
were successfully incorporated into proteins albeit with varying yields of the 
modified protein. Studies have been conducted to better understand the structural 
constraints placed upon amino acid residues that can be utilized by the 
ribosome.85 Incorporation efficiencies of α-L-amino acids with large side chains, 
as well as α-hydroxy acids,86 α-hydrazino amino acids87 and α-aminooxy acids88 
were quite low. This suggests that the peptidyl transferase center (PTC) is at least 
partially selective in accepting individual amino acids during protein synthesis.  
Using the same technique, incorporation of α-D-amino acids was not 
successful as well.89 Naturally occurring peptides containing D-amino acids are 
produced either by nonribosomal synthesis or by post-translational 
modifications.90 To facilitate the incorporation of D-amino acids into proteins, 
Dedkova et al. re-engineered regions of 23S rRNA in an effort to make the PTC 
better able to utilize D-aminoacyl-tRNAs.91 Mutated 23S rRNA genes were 
introduced into bacteria and the colonies expressing modified ribosomes were 
examined for their ability to incorporate D-amino acids. A number of colonies 
containing modified ribosomes were then used to successfully incorporate the D-
amino acids into firefly luciferase and dihydrofolate reductase (DHFR). Notably, 
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these clones retained the ability to express functional wild-type proteins in vitro 
when unmodified mRNAs were used. The utility of this technique is limited, 
however, due to its laborious and low-throughput nature. 
A detailed study of high-resolution structure of the PTC, conducted by 
Yonath and coworkers, revealed some possible mechanisms by which ribosomes 
could exclude D-amino acids during protein production, and the nucleotides in the 
23S rRNA putatively involved.92 When the crystal structure of the PTC in 
complex with a substrate analogue mimicking a D-aminoacyl-tRNA was studied, 
the amino group (of the amino acid) was not present within a distance and in a 
spatial orientation suitable for a peptide bond-forming reaction. Instead, the amino 
group was within a hydrogen bonding distance that would lock the group in an 
unproductive conformation. This may well be the reason that substantial structural 
changes in the PTC were required to accommodate tRNAs activated with α-D-
amino acids.91  
Puromycin is an antibiotic produced by Streptomyces alboniger (Figure 
3.1). Owing to its structural resemblance to the 3ʹ′-end of aminoacyl-tRNAs, 
puromycin can bind to the A-site of ribosomes and cause premature release of 
polypeptides by accepting the growing peptide chain from peptidyl-tRNAs in the 
ribosomal P-site.93 It was hypothesized that puromycin analogues containing non-
α-L-amino acids, rather than the normal substituent with an α-L-tyrosine moiety, 
might bind selectively to modified ribosomes capable of utilizing the 
corresponding aminoacylated suppressor tRNAs.94 
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Figure 3.1. Structure of the antibiotic puromycin. 
 
The architecture of the PTC of the selected ribosomes would have to 
accommodate the geometry of the aminoacyl-tRNAs charged with non-α-L-amino 
acids, including placing the nucleophilic N atom at the required distance and in a 
favorable orientation for successful “peptide bond” formation. Such puromycin 
analogues could then be used for identifying ribosomes having an enhanced 
ability to incorporate the desired noncanonical amino acids from a library of 
bacteria containing re-engineered ribosomes.  
In vitro experiments have shown that L-β-(4-Me)-Phe-PANS (puromycin 
aminonucleoside) and L-β-Ala-PANS was able to disrupt normal translation.95 
This suggests that β-amino acids could bind to the A-site of the PTC but that the 
distance between the activated carbonyl of the peptidyl-tRNA and the amino 
group of the aminoacyl-tRNA might not be favorable for peptide bond formation. 
Accordingly, we generated a library of ribosomes with alterations in two regions 
of the PTC.94 β-Puromycin (Figure 3.2) was chosen as the initial puromycin 
analogue to be used for selection of modified ribosomes capable of incorporating 
N
NN
N
N
O
OHHN
HO
H2N
O
O
puromyin (3.1)
	   101 
β-amino acids into proteins while maintaining the fidelity of protein synthesis for 
the incorporated natural α-amino acids. Two additional puromycin analogues 
were prepared. Dipeptidylpuromycin (3.3) was synthesized to enable the selection 
of ribosomes that could incorporate two amino acids per mRNA codon. 
Thiopuromycin (3.4) was prepared to select modified ribosomes that would 
accept α-thiocarboxylic acids during protein synthesis.  
 
Figure 3.2. Structure of puromycin analogues prepared. 
 
3.2. RESULTS 
3.2.1. Synthesis of β-Puromycin (3.2) 
The synthesis of β-puromycin was achieved by acylating the amine 
functionality of puromycin aminonucleoside (PANS) with N-Fmoc-(S)-3-amino-
4-(p-methoxyphenyl)butyric acid (3.8) (Scheme 3.1). The primary amine of L-β-
homotyrosine hydrochloride (3.5) was protected as the tert-butyl carbamate and 
the intermediate was subjected to exhaustive methylation using dimethyl sulfate 
and K2CO3 to afford compound 3.6 in 81% yield. Methylation permitted the 
protected amino acid to be isolated and purified readily. The methyl ester was 
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saponified with LiOH in aqueous THF to obtain compound 3.7 in 91% yield. The 
Boc group was removed by treatment with CF3COOH and the resulting free 
amine was re-protected with a Fmoc group. Carboxylic acid 3.8 was activated as 
the N-hydroxysuccinimidyl ester 3.9, which was subsequently condensed with 
PANS in the presence of triethylamine to provide Fmoc-protected β-puormycin 
3.10. Removal of the Fmoc group with piperdine in DMF afforded β-puromycin 
(3.2) in 61% yield for the last two steps. 
 
Scheme 3.1. Synthesis of β-puromycin (3.2).94 
 
3.2.2. Synthesis of Dipeptidylpuromycin (3.3) 
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Sriloy Dey synthesized compound 3.14 starting from methyl glycinate and 
N-Fmoc-O-methyl-L-tyrosine (Scheme 3.2). The N-hydroxysuccinimide ester 
3.14 was condensed with puromycin aminonucleoside to afford Fmoc-protected 
dipeptidylpuromycin 3.15 (Scheme 3.2). Dipeptidylpuromycin (3.3) was then 
prepared in 49% yield from 3.15 by the use of 20% piperidine in DMF.  
 
Scheme 3.2. Synthesis of dipeptidylpuromycin (3.3). 
 
3.2.3. Synthesis of Dipeptidyl-pdCpAs 3.22a and 3.22b 
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Synthesis of the requisite dipeptidyl-pdCpA (Scheme 3.3) required the 
synthesis of dipeptide 3.20. The dipeptide synthesis commenced with the 
protection of glycine as N-pentenoylglycine 3.17. This protected glycine was 
subsequently condensed with phenylalanine methyl ester (3.18) in the presence of 
HBTU and DIPEA to afford the N-protected dipeptide methyl ester 3.19 in 58% 
yield. The methyl ester was subjected to saponification in the presence of aqueous 
LiOH to produce the N-pentenoyl dipeptide 3.20 in 90% yield. The dipeptide was 
then converted to the corresponding cyanomethyl ester 3.21 in 82% yield. The 
cyanomethyl ester was used for the acylation of the dinucleotide pdCpA.96 The 
acylation reaction was promoted by the use of sonication and provided both 
mono- and bisacyl-pdCpA derivatives, 3.22a and 3.22b, respectively. 
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Scheme 3.3. Synthesis of mono-2ʹ′(3ʹ′)-O-(N-4-pentenoylglycylphenylalanyl)-
pdCpA (3.22a) and bis-2ʹ′,3ʹ′-O-(N-4-pentenoylglycylphenylalanyl)-pdCpA 
(3.22a). 
 
3.2.4. Synthesis of Thiopuromycin (3.4) 
The synthesis of thiopuromycin (3.4) started from 4-O-methyl-D-tyrosine 
3.23 (Scheme 3.4). The amino acid was subjected to diazotization in the presence 
of KBr to obtain the bromide 3.24 as a crude intermediate. Cesium thioacetate 
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combined with the bromide to afford compound 3.25 in 61% yield. The 
carboxylate was activated as N-hydroxysuccinimidyl ester 3.26 by the use of DCC 
and N-hydroxysuccinimide in THF. The activated ester was then condensed with 
PANS to afford S-acetylthiopuromycin 3.27 as mixture of epimers. The acetyl 
group was removed by the treatment with ammonia in MeOH to generate 
thiopuromycin 3.4 in 74% yield.  
 
Scheme 3.4. Synthesis of thiopuromycin (3.4). 
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β-amino acids. An iterative selection process was employed to identify modified 
ribosomes having the ability to incorporate both α- and β-amino acids into 
proteins while maintaining the fidelity of translation. The antibiotic erythromycin 
is known to bind close to the PTC.97 Thus modified ribosomes with improved 
resistance against this antibiotic compared to wild type are likely to have altered 
PTC architectures.  
 Initially, the region 2057–2063 in the 23S rRNA gene was altered to 
obtain a library of E. coli clones. These clones were grown in the presence of 3.5 
µg/mL erythromycin and the minimum inhibitory concentration (MIC) of this 
antibiotic was determined for each clone. Eight clones were chosen based on their 
MIC values. Plasmids from these clones were isolated, sequenced and 
transformed into freshly grown E. coli cells. The β-puromycin sensitivities of 
these clones were determined (Table 3.1). The modified clones with reduced 
sensitivity to erythromycin did show increased cell growth inhibition by β-
puromycin (100 µg/mL) compared to the wild-type strain. 
Table 3.1: Characterization of Erythromycin-Resistant Clones Harboring 
Plasmids with Modified rrnB Operons. 
name/no. 
of clones 
sequence in the 2057-2063 
region of 23SrRNA gene 
inhibition by 
erythromycin 
 (MIC, µg/mL) 
β-puromycin 
 (% cell growth 
inhibition) 
01/05 TGCGTGG 12.5 − 6.25 26±10 
02/02 TTGGTCG 6.25 − 3.12 15±6 
03/01 ATGGTTG 6.25 − 3.12 20±7 
04/02 AGCGTGA 6.25 − 3.12 28±13 
05/02 TCGTCCA 12.5 − 6.25 16 ±7 
06/01 AGGGACA 12.5 − 6.25 27±11 
07/01 ATTCCGG 6.25 − 3.12 16±7 
08/01 AGTGAGA 25 − 12.5 23±9 
wt GAAAGAC 1.56 − 0.78 <1 
	   108 
Dr. Larisa Dedkova carried out this experiment. 
"Reprinted with permission from (Dedkova, L. M.; Fahmi, N. E.; Paul, R.; del 
Rosario, M.; Zhang, L.; Chen, S.; Feder, G. and Hecht, S. M. Biochemistry 2012, 
51, 401.). Copyright (2012) American Chemical Society." 
The next round of mutagenesis involved alterations of the eight 23S rRNA 
variants in the regions 2582–2588, 2496–2501 or 2502–2507. Approximately 6 × 
103 clones were generated and were screened for their erythromycin resistance 
and β-puromycin sensitivity. Isolated plasmids from the selected clones were 
transformed into freshly grown E. coli cells to verify their sensitivity to both the 
antibiotics. Table 3.2 summarizes the detailed characterization of 17 clones of 
interest.  
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Table 3.2: Characterization of Selected β-Puromycin-Sensitive and 
Erythromycin-Resistant Clones. 
name 
of 
plasmid 
sequence in regions of mutagenesis sensitivity to 
first region second region β-
puromycin 
(IC50, 
µg/mL) 
erythromycin 
(MIC, 
µg/mL) 
wt 2057GAAAGAC2063 2496CACCTC2501 
2502GATGTC2507 
2582GGTTTAG2588 
>1000 3.12 – 1.56 
010102 2057TGCGTGG2063 2582TTCAAGA2588 390 ± 32 6.25 – 3.12 
030116 2057ATGGTTG2063 2582TCAACTC2588 320 ± 90 6.25 – 3.12 
030130 2057ATGGTTG2063 2582TCAGGGC2588 314 ± 20 6.25 – 3.12 
030185 2057ATGGTTG2063 2582CCCGATT2588 320 ± 90 12.5 – 6.32 
080110 2057AGTGCGG2063 2582TCAGATC2588 250 ± 50 12.5 – 6.32 
080118 2057AGTGCGG2063 2582ATGGGCT2588 450 ± 90 12.5 – 6.32 
020250 2057TTGGTCG2063 2496TCAGCG2501 260 ± 80 6.25 – 3.12 
020252 2057TTGGTCG2063 2496TCGAGA2501 230 ± 40 6.25 – 3.12 
030201 2057ATGGTTG2063 2496AGGTCT2501 290 ±100 6.25 – 3.12 
040217 2057AGCGTGA2063 2496ATAGAA2501 250 ±30 12.5 – 6.32 
060203 2057AGGGACA2063 2496ATAAAT2501 170 ± 45 6.25 – 3.12 
060233 2057AGGGACA2063 2496ACAAAT2501 220 ± 97 12.5 – 6.32 
020322 2057TTGGTCG2063 2502ACGAAG2507 145 ± 70 6.25 – 3.12 
020328 2057TTGGTCC2063 2502ACGAAG2507 130 ± 90 6.25 – 3.12 
040321 2057AGCGTGA2063 2502AGATAA2507 430 ± 85 12.5 – 6.32 
040329 2057AGCGTGA2063 2502TGGCAG2507 320 ± 98 12.5 – 6.32 
080302 2057AGTGCGG2063 2502TACAAC2507 210 ± 60 12.5 – 6.32 
Dr. Larisa Dedkova carried out this experiment. 
"Reprinted with permission from (Dedkova, L. M.; Fahmi, N. E.; Paul, R.; del 
Rosario, M.; Zhang, L.; Chen, S.; Feder, G. and Hecht, S. M. Biochemistry 2012, 
51, 401.). Copyright (2012) American Chemical Society." 
 The selected mutants were then checked for their ability to support non-
specific readthrough of mRNAs by the use of a β-galactosidase assay. The clones 
having mutations in the region 2582-2588 were excluded from subsequent 
experiments due to their lesser fidelity during protein translation. Finally, cells 
transformed by plasmids bearing the selected 23S rRNA genes were grown in the 
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presence of erythromycin and their sensitivity towards β-puromycin was 
measured (Table 3.3).  
Table 3.3:	  Characterization of Rate of Growth and β-Puromycin Sensitivity of 
Clones Having Modified Ribosomes, in the Presence of Erythromycin. 
clones doubling time, min β-puromycin inhibition 
(IC50, µg/mL) 
020322 137±32 66±20 
020328 270±25 41±6 
030201 540±120 63±10 
040217 160±80 46±2 
040321 220±90 208±130 
040329 140±25 53±14 
0403x4a 120±40 76±15 
060203 102±7 58±4 
080302 88±20 53±6 
wt no growth  
wt (no Ery) 38 ±4 >1000 
 
aDerived in analogy with 040329, but in a parallel set of experiments. Dr. Larisa 
Dedkova carried out this experiment. 
"Reprinted with permission from (Dedkova, L. M.; Fahmi, N. E.; Paul, R.; del 
Rosario, M.; Zhang, L.; Chen, S.; Feder, G. and Hecht, S. M. Biochemistry 2012, 
51, 401). Copyright (2012) American Chemical Society." 
 Five clones with acceptable growth rates in the presence of erythromycin 
and sufficient sensitivity to β-puromycin were utilized to prepare S-30 extracts. 
Each of the five S-30 preparations was used for the in vitro translation of proteins. 
The E. coli DHFR gene was modified to incorporate a TAG codon corresponding 
to position 10 of DHFR. The ability of the S-30 systems to suppress this stop 
codon in the presence of β-alanyl-tRNACUA was measured and compared with 
their suppression efficiency in the presence of L-α-valyl-tRNACUA (Table 3.4). 
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Table 3.4:	  Characterization of DHFR Synthesis Using S-30 Systems Prepared 
from Clones with Modified Ribosomes.a 
S-30 
name 
modified ribosome suppression efficiency 
(%) 
sequence abundance 
(%) 
tRNACUA β-alanyl-
tRNACUA 
B1 (wt)  no 1.0 ± 0.4 4.0 ± 1.3 
020322 2057UUGGUCG2063 
2502ACGAAG2507 
22 1.3 ± 0.3 7.5 ± 2.3 
040329 2507AGCGUGA2063 
2502UGGCAG2507 
66 3.3 ± 0.7 12.3 ± 2.2 
0403x4 2507AGCGUGA2063 
2502AGCCAG2507 
58 3.2 ±0.2 9.7 ± 3.6 
040217 2507AGCGUGA2063 
2496AUAGAA2501 
50 0.9±0.4 4.8 ± 2.0 
060203 2507AGCGUGA2063 
2496AUAAAU2501 
53 0.8±0.5 3.8 ± 1.5 
 
aThe mRNA utilized for translation had a UAG codon corresponding to position 
10 of DHFR. The suppression efficiency reported is relative to that obtained using 
L-α-valyl-tRNACUA. Dr. Larisa Dedkova carried out this experiment. 
"Reprinted with permission from (Dedkova, L. M.; Fahmi, N. E.; Paul, R.; del 
Rosario, M.; Zhang, L.; Chen, S.; Feder, G. and Hecht, S. M. Biochemistry 2012, 
51, 401). Copyright (2012) American Chemical Society." 
 
3.2.6. Dipeptidylpuromycin (3.3) Selection of Erythromycin Resistant Clones 
of 23S rRNA 
 A solution of 100 µg/mL of dipeptidylpuromycin (3.3) was used for 
selection of 415 clones having mutated ribosomes. Clones with increased 
sensitivity (>50% inhibition of cell growth) to dipeptidylpuromycin were 
identified and the plasmids from these clones were sequenced (Table 3.5). These 
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modified ribosomes with increased sensitivity to 3.3 are expected to accept 
dipeptides from dipeptidyl-tRNAs during protein synthesis.  
Table 3.5. Characterization of Dipeptidylpuromycin-Sensitive Clones. 
clones cell-growth 
inhibition (%) 
sequence in mutagenized regions 
first region second region 
010120 65.4 2057TGCGTGG2063 2582CCGAATC2588 
080118 66.5 2057AGTGAGA2063 2582ATGGGCT2588 
020213 54 2057TTGGTCC2063 2496CACCTC2501 
020309 63.2 2057TTGGTCC2063 2502CTACGG2507 
020310 52.9 2057TTGGTCC2063 2502CGCAAT2507 
020322 77 2057TTGGTCC2063 2502ACGGAA2507 
020326 50.4 2057TTGGTCC2063 2502CTACAG2507 
020328 77 2057TTGGTCC2063 2502ACGAAG2507 
030240 56 2057TTGGTCC2063 2496AGTGGT 2501 
030247 64 2057AGCGTGA2063 2496CACCTC2501 
030248 61 2057AGCGTGA2063 2496CACCTC2501 
040228 51 2057AGCGTGA2063 2496CACCTC2501 
040322 54 2057AGCGTGA2063 2502CTGCTT2507 
040329 54 2057AGCGTGA2063 2502TGGCAG2507 
040338 56 2057AGCGTGA2063 2502ATCAGG2507 
070307 77 2057ATTCCGG2063 2502GATGTC2507 
080337 51 2057AGTGAGA2063 2502ATCCGA2507 
Dr. Larisa Dedkova carried out this experiment. 
 
3.2.7. Thiopuromycin (3.4) Selection of Erythromycin Resistant Clones of 
23S rRNA 
 A library of 264 clones was selected for their sensitivity to 100 µg/mL of 
thiopuromycin (3.4). The solution of thiopuromycin used for this assay contained 
0.3 M of 3-mercaptopropionic acid (3-MPA) to prevent disulfide formation 
during the selection experiment. Clones that exhibited >50% inhibition of cell 
growth in the presence of thiopuromycin were chosen for further characterization 
of the plasmids (Table 3.6). It was presumed that the modified ribosomes selected 
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against thiopuromycin would show enhanced ability to incorporate α-
thiocarboxylic acids into proteins. 
Table 3.6. Characterization of Thiopuromycin-Sensitive Clones. 
clones cell-growth 
inhibition (%) 
sequence in the regions of mutagenesis 
first region second region 
010342 56.1 2057TGCGTGG2063 2502GATGTC2507  
020213 84 2057TTGGTCC2063 2496CACCTC2501  
020219 51.1 2057TTGGTCC2063 2496CACCTC2501  
020220 91.8 2057TTGGTCC2063 2496CACCTC2501  
020309 83 2057TTGGTCC2063 2502CTACGG2507  
020310 61 2057TTGGTCC2063 2502CGCAAT2507 
020312 59 2057TTGGTCC2063 2502CTCCAG2507 
020322 59.4 2057TTGGTCC2063 2502ACGGAA2507  
020326 65 2057TTGGTCC2063 2502CTACAG2507  
020328 58.6 2057TTGGTCC2063 2502ACGAAG2507  
030304 57.1 2057TTGGTCC2063 2502GATGTC2507  
030307 75.1 2057TTGGTCC2063 2502GATGTC2507  
030310 57.8 2057TTGGTCC2063 2502ACGCGG2507 
030322 72 2057TTGGTCC2063 2502GATGTC2507  
030326 64.6 2057TTGGTCC2063 2502GATGTC2507  
030332 51.0 2057TTGGTCC2063 2502GATGTC2507 
030342 55.3 2057TTGGTCC2063 2502ATCTAT2507  
030343 61.5 2057TTGGTCC2063 2502GATGTC2507  
040217 54.2 2057AGCGTGA2063 2496ATAGTT2501  
040329 52 2057AGCGTGA2063 2502TGGCAG2507 
060325 52 2057AGGGACA2063 2502 TGAAGT2507  
070307 67 2057ATTCCGG2063 2502GATGTC2507  
Dr. Larisa Dedkova carried out this experiment. 
3.3. DISCUSSION 
3.3.1. Chemistry 
Boc-protection of the L-β-homotyrosine followed by methylation of the 
phenolic OH with dimethyl sulfate afforded the methyl ester 3.6. The acid was 
regenerated by the treatment of aq LiOH. The Boc protecting group was removed 
in the presence of CF3COOH. The crude residue had to be dried thoroughly by 
co-evaporation with toluene to obtain reasonable yields of the Fmoc-protected 
compound 3.8. Purification of the succinimidyl ester 3.9 by column 
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chromatography on silica gel was difficult due to contamination from 
dicyclohexylurea (DCU). Re-suspending the crude residue in acetonitrile 
followed by filtration removed most of the DCU. Condensation of the ester 3.9 
with puromycin aminonucleoside (PANS) and subsequent Fmoc deprotection was 
achieved using 20% piperidine in DMF (Scheme 3.1). 
The dipeptidylpuromycin 3.3 contains a glycine residue which connects 
the tyrosine and the aminonucleoside. Modified ribosomes selected using 
dipeptidylpuromycin should be promising candidates for accepting a dipeptide 
from dipeptidyl-tRNA during protein synthesis. The succinimidyl ester 3.14 was 
prepared by Sriloy Dey. The synthesis of analogue 3.3 from the activated ester 
3.14 was achieved in 41% yield over two steps (Scheme 3.2).  
Chemical misacylation of a suppressor tRNA with a dipeptide required the 
synthesis of dipeptidyl-pdCpA. The dipeptide consisted of glycine and 
phenylalanine. Glycine was protected as N-(4-pentenoyl)glycine (3.17) and 
condensed with phenylalanine methyl ester (Scheme 3.3). The methyl ester 3.19 
was converted to the cyanomethyl ester 3.21 via the formation of the acid 3.20. 
The cyanomethyl ester then was utilized to form pdCpA esters 3.22a and 3.22b. 
The bromide 3.24 was prepared from the amino acid 3.23 by diazotization 
in the presence of KBr (Scheme 3.4). Exclusion of aerial oxygen and ambient 
light during the reaction afforded better yields of the bromide. After extractive 
work-up the bromide was sufficiently pure to be used in the next reaction. Careful 
exclusion of oxygen from the reaction mixture was required to avoid formation of 
side products during the substitution reaction with CsSAc. The thioacetate (3.25) 
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was activated as the succinimidyl ester (3.26) which was then condensed with 
PANS. The coupling reaction afforded the product 3.27 as a mixture of epimers. 
Epimerization was unavoidable even without the presence of any base (such as 
triethylamine) in the reaction mixture. Deacetylation with methanolic ammonia 
was complete in 2 h. TCEP (tris(2-carboxyethyl)phosphine) was added to the 
reaction mixture before HPLC purification to prevent thiol oxidation. After 
lyophilization, the peaks collected from HPLC showed partial disulfide formation 
in MALDI analysis.  
3.3.2. Biological Evaluation 
A dual selection strategy was employed to identify modified ribosomes 
having an A-site architecture that would allow incorporation of β-amino acids 
during protein production. The ribosomes were initially modified in the region 
2057–2063. Ribosomes that had altered erythromycin resistance as compared to 
wild-type ribosomes were selected in the first round. These were judged more 
likely to have alterations close the PTC where erythromycin binds. Moreover, the 
erythromycin resistance allowed the modified ribosomes to be studied 
independently without inference from the wild-type ribosomes that were encoded 
by chromosomal genes in E. coli. The clones that showed improved resistance to 
erythromycin were extra-sensitive to β-puromycin in comparison with the wild-
type strain, thus validating the selection strategy.  
The next round of mutagenesis performed on these selected clones then 
afforded a large library of clones containing modified ribosomes. All of the clones 
were checked for their erythromycin resistance and sensitivity to β-puromycin. 
	   116 
Seventeen clones with the best activity profile were chosen for further 
characterization and subsequent rounds of selections. The enhanced sensitivity of 
these clones to β-puromycin (in the presence of erythromycin) suggested that they 
were heavily dependent on the modified ribosomes for survival, probably due to 
increased production of the modified ribosomes.   
To express full-length proteins with meaningful activity containing a β-
amino acid at a certain position, the altered ribosomes must retain their fidelity of 
protein synthesis involving natural (i.e. α-L) amino acids. Accordingly, next 
round of selection involved exclusion of the modified ribosomes that support 
nonspecific readthrough of a nonsense codon. The selected clones were then 
tested for their ability to express wild-type proteins in their active form from their 
wild-type mRNAs. S-30 preparations from the selected clones were then checked 
for their β-puromycin sensitivity during protein expression. Interestingly, S-30 
extract from one of the clones did not show significant β-puromycin inhibition of 
protein synthesis. 
Finally four S-30 preparation were utilized for suppressing an amber 
codon in the presence of a suppressor tRNA that was chemically misacylated with 
β-alanine. The DHFR mRNA was modified with a UAG codon at the place 
corresponding to position 10 (valine) of DHFR and was translated using the 
modified ribosomes in the presence of β-alanyl-tRNACUA. Enhanced suppression 
of the nonsense codon in the presence of β-alanyl-tRNACUA suggested 
incorporation of the noncanonical amino acid β-alanine into DHFR. The 
unmodified aminoacyl-tRNA, L-α-valyl-tRNACUA , was used as the positive 
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control and tRNACUA, bearing no amino acid was used as the negative control. 
Four of the S-30 preparations showed enhanced expression of full length protein 
in the presence of β-alanyl-tRNACUA compared to the wild-type S-30 system.   
A similar selection strategy was adopted for the other two analogues. 
Erythromycin resistant clones were selected for their sensitivity to 
dipeptidylpuromycin (3.3) and thiopuromycin (3.4). The clones with most 
favorable results were sequenced. Verification of the fidelity of protein synthesis 
and subsequent expression of proteins containing noncanonical residues using 
these modified ribosomes has recently been achieved.  
3.4. EXPERIMENTAL 
Reagents and solvents for chemical synthesis were purchased from 
Aldrich Chemical Co. or Sigma Chemical Co. and were used without further 
purification. All reactions involving air- or moisture-sensitive reagents or 
intermediates were performed under argon. Flash chromatography was performed 
using Silicycle silica gel (40–60 mesh). Analytical TLC was performed using EM 
silica gel 60 F254 plates (0.25 mm) and was visualized by UV irradiation (254 
nm). 1H and 13C NMR spectra were obtained using a 400 MHz Varian NMR 
instrument. Chemical shifts are reported in parts per million (ppm, δ) referenced 
to the residual 1H resonance of the solvent (CDCl3, δ 7.26; CD3OD, δ 3.31; 
DMSO-d6, δ 2.50). 13C NMR spectra were referenced to the residual 13C 
resonance of the solvent (CDCl3, δ 77.16; CD3OD, δ 49.00; DMSO-d6, δ 39.52). 
Splitting patterns are designated as follows: s, singlet; d, doublet; dd, doublet of 
doublets; ddd, doublet of doublet of doublet; dt, doublet of triplet; t, triplet; q, 
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quartet; m, multiplet; br, broad. High resolution mass spectra were obtained at the 
Michigan State University High Resolution Mass Spectrometry Laboratory. 
 
N-Boc-(S)-3-amino-4-(4-methoxyphenyl)butyric Acid Methyl Ester (3.6).94  
To a cooled (0 °C) solution containing 161 mg (0.68 mmol) of β-L-homotyrosine 
hydrochloride (3.5) in 2.6 mL of 1:1 dioxane–water was added 0.24 mL (176 mg; 
1.7 mmol) of triethylamine, and the reaction mixture was stirred at 0 °C for 5 min. 
Di-tert-butyl dicarbonate (237 mg, 1.09 mmol) was added, and the reaction 
mixture was stirred at 0 °C for 30 min, and then at 25 °C for 20 h. The reaction 
mixture was concentrated under diminished pressure, and the residue was diluted 
with 20 mL of water and washed with two 8-mL portions of Et2O. The cooled 
aqueous phase (ice bath) was acidified to pH ∼3 with 5% aq NaHSO4 and 
extracted with three 20-mL portions of ethyl acetate. The combined organic layer 
was washed with 10 mL of brine, dried over anhydrous Na2SO4, filtered and 
concentrated under diminished pressure to afford N-Boc-(S)-3-amino-4-(4-meth- 
oxyphenyl)butyric acid as a light yellow oil: crude yield 228 mg; silica gel TLC 
Rf 0.20 (9:1 chloroform–methanol). This compound was used directly in the next 
step without further purification. 
To a suspension containing 228 mg of the crude carboxylic acid and 470 
mg (3.41 mmol) of oven-dried K2CO3 in 4 mL of anh acetone was added 
dropwise 0.20 mL (0.27 mg; 2.0 mmol) of dimethyl sulfate, and the reaction 
BocHN
O
COOMe
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mixture was stirred at reflux for 36 h. The cooled reaction mixture was filtered 
and washed with ethyl acetate, and the combined filtrate was concentrated under 
diminished pressure. The light yellow residue was purified on a silica gel column 
(12 × 3 cm), which was eluted with 4:1 hexanes–ethyl acetate. Compound 3.6 was 
obtained as a colorless oil: yield 179 mg (81% over 2 steps); silica gel TLC Rf 
0.30 (2:1 hexanes–ethyl acetate); 1H NMR (CDCl3) δ 1.38 (s, 9H), 2.46 (dq, 2H, J 
= 15.8 and 5.7 Hz), 2.80 (m, 2H), 3.64 (s, 3H), 3.74 (s, 3H), 4.10 (m, 1H), 5.01 
(br, 1H), 6.80 (d, 2H, J = 8.4 Hz) and 7.06 (d, 2H, J = 8.4 Hz); 13C NMR (CDCl3) 
δ: 28.4, 37.5, 39.5, 49.0, 51.6, 55.2, 79.3, 113.9, 129.7, 130.3, 155.1, 158.4 and 
172.1; mass spectrum (ESI), m/z 324.1800 (M + H)+ (C17H26NO5 requires m/z 
324.1811). 
 
N-Boc-(S)-3-amino-4-(4-methoxyphenyl)butyric Acid (3.7).94  
To a solution containing 76 mg (0.27 mmol) of compound 3.6 in 2.5 mL of THF 
was added a solution of 27 mg (1.1 mmol) of LiOH in 1.25 mL of water, and the 
reaction mixture was stirred at 25 °C for 20 h. The reaction mixture was diluted 
with 10 mL of Et2O and 25 mL of water, and the phases were separated. The 
cooled aqueous phase (ice bath) was acidified to pH ∼ 3 with 5% aq NaHSO4 and 
extracted with three 20-mL portions of ethyl acetate. The combined organic layer 
was washed with 10 mL of brine, dried over anh Na2SO4, filtered, and 
concentrated under diminished pressure to afford 3.7 as a colorless solid: yield 65 
BocHN
O
COOH
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mg (91%); silica gel TLC Rf 0.17 (1:1 hexanes–ethyl acetate); 1H NMR (CD3OD) 
δ: 1.37 (s, 9H), 2.40, (m, 2H), 2.72 (m, 2H), 3.75 (s, 3H), 4.07 (m, 1H), 6.82(d, 
2H, J = 8.4 Hz) and 7.12 (d, 2H, J = 8.4 Hz); 13C NMR (CDCl3) δ 28.7, 39.5, 
40.8, 50.7, 55.6, 79.9, 114.8, 131.3, 131.5, 157.5, 159.7 and 175.0. 
 
N-Fmoc-(S)-3-amino-4-(4-methyoxyphenyl)butyric Acid (3.8).94   
A solution containing 220 mg (0.71 mmol) of 3.7 in 4.2 mL of 4:1 CH2Cl2–
CF3COOH was stirred at 25 °C for 40 min. The reaction mixture was 
concentrated under diminished pressure and the residual CF3COOH was removed 
by coevaporation with five 4-mL portions of toluene. The solid residue was 
dissolved in 4.2 mL of 10% aq Na2CO3 and a solution containing 290 mg (0.86 
mmol) of Fmoc-OSu in 4.2 mL of dioxane was added dropwise. The resulting 
mixture was stirred at 25 °C for 24 h. Water (25 mL) was added and the aqueous 
layer was washed with two 10-mL portions of ether. The cooled aqueous phase 
(ice bath) was acidified to pH ~ 3 with 5% aq NaHSO4 and extracted with three 
30-mL portions of ethyl acetate. The combined organic layer was washed with 15 
mL of brine, dried over anhydrous Na2SO4, filtered and concentrated under 
diminished pressure. Compound 3.8 was purified by precipitation from hexanes–
ethyl acetate and was obtained as a colorless solid: yield 202 mg (66%); silica gel 
TLC Rf 0.12 (1:1 hexanes–ethyl acetate); mp 178 °C; 1H NMR (DMSO-d6) δ 2.37 
(dd, 2H, J = 6.8 and 2.2 Hz), 2.66 (d, 2H, J = 6.8 Hz), 3.67 (s, 3H), 3.95 (dd, 1H, 
FmocHN
COOH
O
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J = 14.9 and 7.0 Hz), 4.16 (dd, 1H, J = 12.9 and 6.0 Hz), 4.22 (dd, 2H, J = 7.0 and 
2.9 Hz), 6.80 (d, 2H, J = 8.6 Hz), 7.08 (d, 2H, J = 8.6 Hz), 7.32 (q, 2H, J = 6.3 
Hz), 7.41 (t, 2H, J = 7.4 Hz), 7.65 (d, 2H, J = 7.5 Hz) and 7.88 (d, 2H, J = 7.5 
Hz); 13C NMR (DMSO-d6) δ 46.7, 49.8, 54.9, 65.2, 113.6, 120.1, 125.2, 127.0, 
127.6, 130.2, 130.4, 140.7, 143.8, 143.9, 155.3, 157.7 and 172.46; mass spectrum 
(ESI), m/z 432.1820 (M + H)+ (C26H26NO5 requires m/z 432.1811). 
 
N-Fmoc-(S)-3-amino-4-(4-methyoxyphenyl)butyric Acid Succinimidyl Ester 
(3.9).94   
To a suspension containing 46 mg (0.11 mmol) of 3.8 and 19.0 mg (0.16 mmol) 
of N-hydroxysuccinimide in 3 mL of anhydrous CH2Cl2 was added 33.0 mg (0.16 
mmol) of N,N'-dicyclohexylcarbodiimide and the reaction mixture was stirred at 
25 °C for 24 h. The insoluble precipitate was filtered and the filtrate was 
concentrated under diminished pressure.  The residue was suspended in 3 mL of 
ethyl acetate, filtered and the filtrate was concentrated under diminished pressure. 
The crude product was purified on a silica gel column (12 × 2 cm); elution was 
with 2:1 hexanes–ethyl acetate. Compound 3.9 was obtained as a colorless solid: 
yield 38 mg (68%); mp 172 °C; silica gel TLC Rf 0.75 (9:1 chloroform–
methanol); 1H NMR (CDCl3) δ 2.70-3.01 (m, 8H), 3.78 (s, 3H), 4.28 (dt, 4H, J = 
14.1 and 6.7 Hz), 5.35 (d, 1H, J = 8.8 Hz), 6.85 (d, 2H, J = 8.3 Hz), 7.15 (d, 2H, J 
= 8.0 Hz), 7.30 (t, 2H, J = 7.4 Hz), 7.40 (t, 2H, J = 7.4 Hz), 7.56 (dd, 2H, J = 7.4 
FmocHN
O
O
O
N
O
O
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and 3.7 Hz) and 7.76 (d, 2H, J = 7.5 Hz); 13C NMR (CDCl3) δ 25.7, 34.7, 38.7, 
47.3, 49.6, 55.4, 66.9, 114.3, 120.0, 125.3, 127.1, 127.8, 129.0, 130.5, 141.4, 
143.98, 144.02, 155.7, 158.6, 166.7 and 169.1; mass spectrum (ESI), m/z 
529.1956 (M + H)+ (C30H29N2O7 requires m/z 529.1975). 
 
9-[3’-Deoxy-3’-(N-Fmoc-(S)-3-amino-4-(4-methyoxyphenyl)butyramido)-β-D-
ribofuranosyl]-6-(N,N’-dimethylamino)purine (3.10).94   
To a solution containing 14 mg (26 µmol) of 3.9 and 3.0 µL (2.2 mg; 22 µmol) of 
Et3N in 0.6 mL of anhydrous DMF was added 5.0 mg (17 µmol) of puromycin 
aminonucleoside (PANS). The reaction mixture was stirred at 25 °C for 3.5 h (at 
which time silica gel TLC analysis showed complete consumption of 3.9). The 
solvent was concentrated under diminished pressure and the residue was purified 
on a silica gel column (14 × 2 cm); elution was with 25:1 chloroform–methanol. 
Compound 3.10 was obtained as a colorless solid: yield 12 mg (the product was 
slightly impure and was used directly in the next step); silica gel TLC Rf 0.52 (9:1 
chloroform–methanol); 1H NMR (DMSO-d6) δ 2.31 (d, 2H, J = 6.7 Hz), 2.55-
2.82 (m, 2H), 3.50 (s, 6H), 3.68 (m, 5H), 3.97 (s, 2H), 4.20 (m, 3H), 4.45 (dd, 2H, 
J = 16.1 and 8.5 Hz), 5.17 (s, 1H), 5.97 (s, 2H), 6.80 (d, 2H, J = 8.1 Hz), 7.06 (d, 
N
NN
N
N
O
OHNH
HO
O
FmocHN
O
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2H, J = 8.0 Hz), 7.18 (d, 1H, J = 8.3 Hz), 7.36 (m, 4H), 7.63 (t, 2H, J = 7.1 Hz), 
7.87 (d, 2H, J = 8.0 Hz), 7.91 (d, 1H, J = 8.0 Hz), 8.20 (s, 1H) and 8.44 (s, 1H); 
13C NMR (DMSO-d6) δ 24.9, 33.8, 47.1, 50.5, 50.6, 55.3, 60.9, 65.6, 73.6, 83.3, 
89.7, 113.9, 120.0, 120.5, 125.6, 127.4, 128.0, 130.7, 138.1, 141.1, 144.2, 144.4, 
150.0, 152.2, 154.7, 155.8, 158.0 and 170.8; mass spectrum (MALDI) m/z 708.2 
(M + H)+ (theoretical 708.3) and 730.1 (M + Na)+ (theoretical 730.3); mass 
spectrum (ESI), m/z 708.3163 (M + H)+ (C38H42N7O7 requires m/z 708.3146). 
 
9-[3’-Deoxy-3’-((S)-3-amino-4-(4-methyoxyphenyl)butyramido)-β-D-
ribofuranosyl]-6-(N,N’-dimethylamino)purine (β-Puromycin) (3.2).94   
A solution containing 12 mg (17 mmol) of 3.10 in 3 mL of 4:1 DMF–piperidine 
was stirred at 25 °C for 40 min. The solvent was concentrated under diminished 
pressure and the residue was purified by chromatography on a silica gel column 
(5 × 2 cm). Elution with 9:1 chloroform–methanol afforded 3.2 as a colorless 
solid: yield 5 mg (61% over two steps); silica gel TLC Rf 0.12 (9:1 
dichloromethane–methanol); 1H NMR (CD3OD) δ 2.42 (dd, 1H, J = 15.9 and 8.4 
Hz), 2.60 (dd, 1H, J = 15.9 and 4.2 Hz), 2.82 (m, 2H), 3.51 (s, 6H), 3.59 (m, 1H), 
3.73 (dd, 1H, J = 12.6 and 2.9 Hz), 3.77 (s, 3H), 3.94 (dd, 1H, J = 12.5 and 2.0 
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Hz), 4.17 (d, 1H, J = 7.3 Hz), 4.62 (m, 2H), 6.01 (d, 1H, J = 3.0 Hz), 6.90 (d, 2H, 
J = 8.5 Hz), 7.17 (d, 2H, J = 8.5 Hz), 8.21 (s, 1H) and 8.35 (s, 1H); 13C NMR 
(CD3OD) δ 38.8, 39.0, 40.5, 51.5, 52.0, 55.7, 62.2, 75.0, 84.8, 91.9, 115.3, 121.6, 
129.6, 131.4, 139.1, 150.6, 153.0, 156.2, 160.4 and 173.3; mass spectrum 
(MALDI) m/z 486.2 (M + H)+ (theoretical 486.2) and 508.2 (M + Na)+ 
(theoretical 508.2); mass spectrum (ESI), m/z 486.2482 (M + H)+ (C23H32N7O5 
requires m/z 486.2465). 
 
9-[3ʹ′-Deoxy-3ʹ′-(N-Fmoc-4-O-methyl-(S)-tyrosylglycyl)-β-D-ribofuranosyl]-6-
(N,Nʹ′-dimethylamino)purine (3.15). 
To a solution of 14 mg (24 µmol) of 3.14 and 4.7 mg (16 µmol) of puromycin 
aminonucleoside in 0.8 mL of dry DMF was added 3 µL (2.4 mg; 24 µmol) of 
Et3N. The reaction mixture was stirred at 25 °C for 3.5 h and then concentrated 
under diminished pressure. The residue was purified by flash chromatography on 
a silica gel column (15 × 2 cm). Elution with 1:15 methanol–chloroform afforded 
3.15 as a colorless solid: yield 10 mg (83%); 1H NMR (500 MHz, DMSO-d6) δ 
2.73 (m, 1H), 2.97 (dd, 1H, J = 13.7 and 3.7 Hz), 3.47 (br s, 6H). 3.68 (s, 3H), 
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3.74, (m, 1H), 3.82 (d, 2H, J = 5.6 Hz), 4.04 (m, 1H), 4.17 (m, 4H), 4.50 (m, 2H), 
6.01 (d, 1H, J = 2.4 Hz), 6.80 (d, 2H, J = 8.4 Hz), 7.21 (m, 2H), 7.29 (m, 2H), 
7.39 (d, 2H, J = 7.8 Hz), 7.63 (d, 3H, J = 7.8 Hz), 7.87 (d, 2H, J = 7.5 Hz), 7.96 
(d, 1H, J = 7.6 Hz), 8.25 (s, 1H) and 8.49 (s, 1H); 13C NMR (DMSO-d6) δ 29.0, 
36.5, 42.0, 46.5, 48.6, 50.3, 54.9, 56.5, 65.7, 73.2, 83.1, 89.4, 113.5, 119.6, 120.0, 
125.30, 125.31, 127.0, 127.6, 130.0, 130.2, 138.1, 140.6, 140.6, 143.7, 143.8, 
149.3, 151.1, 153.6, 155.9 157.7, 169.0 and 171.9; mass spectrum (MALDI) m/z 
751.5 (M + H)+ (theoretical m/z 751.3), m/z 773.5 (M + Na)+ (theoretical m/z 
773.3); mass spectrum (APCI), m/z 751.3201 (M + H)+ (C39H43N8O8 requires m/z 
751.3204). 
 
9-[3ʹ′-Deoxy-3ʹ′-(O-methyl-(S)-tyrosylglycyl)-β-D-ribofuranosyl]-6-(N,Nʹ′-
dimethylamino)purine (dipeptidylpuromycin) (3.3). 
A solution of 10 mg (13 µmol) of 3.15 in 1 mL of 5:1 DMF–piperidine was 
stirred at 25 °C for 40 min and concentrated under diminished pressure. The 
residue was purified by flash chromatography on a silica gel column (5 × 2 cm). 
Elution with 1:9 methanol–chloroform afforded 3.3 as a colorless solid: yield 3.1 
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mg (49%); 1H NMR (CD3OD) δ 2.85 (m, 1H), 3.07 (m, 1H), 3.51 (s, 6H), 3.76 
(m, 4H) 3.93 (m, 3H), 4.18 (m, 1H), 4.63 (m, 2H), 6.03 (d, 1H, J = 3.0 Hz), 6.87 
(d, 2H, J = 8.5 Hz), 7.17 (d, 2H, J = 8.6 Hz), 8.21 (s, 1H) and 8.36 (s, 1H); 13C 
NMR (CD3OD) δ 39.0, 39.3, 43.3, 52.1, 55.7, 62.3, 68.6, 75.1, 85.0, 92.0, 106.4, 
115.2, 121.6, 131.4, 139.2, 150.6, 153.0,156.2, 160.4 and 171.6; mass spectrum 
(MALDI) m/z 529.3 (M + H)+ (theoretical m/z 529.2), 551.3 (M + Na)+ 
(theoretical m/z 551.2); mass spectrum (APCI), m/z 529.2530 (M + H)+ 
(C24H33N8O6 requires m/z 529.2523). 
 
N-(4-pentenoyl)glycine (3.17).  
To a solution of 250 mg (3.33 mmol) of glycine in 10 mL of 10% aq Na2CO3 was 
added a solution of 1.31 g (6.66 mmol) of pentenoylsuccinimide (3.16) in 10 mL 
of dioxane. The reaction mixture was stirred at 25 °C for 12 h. The mixture was 
acidified with 1 N aq HCl and the aq layer was extracted with three 50-mL 
portions of ethyl acetate. The combined organic extract was dried (Na2SO4) and 
concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (16 × 3 cm). Elution with 1:5:50 acetic 
acid–methanol–dichloromethane afforded 3.17 as a colorless oil: yield 0.430 g 
(82%); silica gel TLC Rf 0.52 (1:10:50 acetic acid–methanol–dichloromethane); 
1H NMR (CDCl3) δ 2.37 (m, 4H), 4.05 (d, 2H, J = 5.1 Hz), 5.04 (m, 2H), 5.80 (m, 
1H), 6.58 (m, 1H) and 10.63 (br s, 1H); 13C NMR (CDCl3) δ 29.3, 35.3, 41.5, 
H
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115.9, 136.4, 172.8 and 174.0. mass spectrum (APCI), m/z 158.0815 (M + H)+ 
(C7H12NO3 requires m/z 158.0817). 
 
(N-(4-Pentenoyl)glycyl)phenylalanine Methyl Ester (3.19).  
To a solution of 0.41 g (2.60 mmol) of 3.17, 673 mg (3.13 mmol) of 3.18 and 0.55 
mL (3.95 mmol) of triethylamine in 20 mL of dry DMF was added 1.48 g (3.91 
mmol) of HBTU. The reaction mixture was stirred at 25 °C for 5 h. The mixture 
was concentrated under diminished pressure and the residue was diluted in 80 mL 
of ethyl acetate. The organic layer was washed with two 40-mL portions of 1 N aq 
HCl, 40 mL of water and 20 mL of brine, then dried (Na2SO4) and concentrated 
under diminished pressure. The residue was purified by flash chromatography on 
a silica gel column (20 × 3 cm). Elution with 1:25 methanol–dichloromethane 
afforded 3.19 as a colorless oil: yield 0.49 g (58%); silica gel TLC Rf 0.59 (9:1 
chloroform–methanol); 1H NMR (CDCl3) δ 2.28 (m, 4H), 3.02 (m, 2H), 3.64 (s, 
3H), 3.86 (m, 2H), 4.78 (m, 1H), 4.97 (m, 2H), 5.76 (m, 1H), 7.01 (t, 1H, J = 5.1 
Hz), 7.09 (m, 2H), 7.19 (m, 3H) and 7.36 (d, 1H, J = 8.0 Hz); 13C NMR (CDCl3) 
δ 29.3, 35.1, 37.7, 42.9, 52.2, 53.4, 115.4, 126.9, 128.4, 129.1, 135.9, 136.8, 
169.1, 171.7 and 173.0; mass spectrum (ESI), m/z 319.1655 (M + H)+ 
(C17H23N2O4 requires m/z 319.1652). 
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(N-(4-Pentenoyl)glycyl)phenylalanine (3.20). 
To a solution of 0.35 g (1.10 mmol) of 3.19 in 10 mL of THF was added dropwise 
a solution of 105 mg (4.39 mmol) of LiOH in 5 mL of water at 0 °C. The reaction 
mixture was stirred at 25 °C for 12 h, diluted with 30 mL of water and washed 
with two 15-mL portions of Et2O. The aqueous layer was acidified with 1 N aq 
HCl to pH ~ 2 and extracted with three 40-mL portions of ethyl acetate. The 
combined organic layer was dried (Na2SO4) and concentrated under diminished 
pressure to obtain 3.20 as a colorless solid: yield 301 mg (90%); silica gel TLC Rf 
0.25 (9:1 chloroform–methanol); 1H NMR (CD3OD) δ 2.32 (s, 4H), 3.01 (dd, 1H, 
J = 13.9 and 8.0 Hz), 3.19 (dd, 1H, J = 13.9 and 5.2 Hz), 3.82 (q, 2H, J = 16.7 
Hz), 4.68 (dd, 1H, J = 7.6 and 5.4 Hz), 4.96 (m, 1H), 5.04 (d, 1H, J = 17.0 Hz), 
5.83 (m, 1H) and 7.24 (m, 5H); 13C NMR (CD3OD) δ 29.2, 34.7, 36.9, 41.8, 52.5, 
114.4, 126.4, 128.0, 128.9, 136.7, 136.8, 169.9, 172.9 and 174.3; mass spectrum 
(APCI), m/z 305.1503 (M + H)+ (C17H23N2O4 requires m/z 305.1501). 
 
(N-(4-pentenoyl)glycyl)phenylalanine Cyanomethyl Ester (3.21). 
To a solution of 301 mg (0.99 mmol) of compound 3.20 in 18 mL anhydrous 
acetonitrile was added 0.70 mL (0.51 g; 5.06 mmol) of Et3N followed by 0.63 mL 
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(0.53 g; 9.9 mmol) of chloroacetonitrile. The reaction mixture was stirred at room 
temperature for 16 h and then concentrated under diminished pressure. The 
residue was diluted in 80 mL of ether. The ether layer was washed successively 
with 40 mL of water, 40 mL of 1 N HCl and 30 mL of brine. The organic layer 
was dried (Na2SO4) and concentrated under diminished pressure. The residue was 
purified by flash chromatography on a silica gel column (15 × 3 cm). Elution with 
1:3 hexanes–ethyl acetate afforded the ester 3.21 as a colorless oil: yield 0.28 g 
(82%); silica gel TLC Rf 0.67 (9:1 chloroform–methanol); 1H NMR (CDCl3) δ 
2.31 (m, 4H), 3.09 (m, 2H), 3.89 (m, 2H), 4.67 (m, 2H), 4.81 (m, 1H), 5.01 (m, 
2H), 5.76 (m, 1H), 6.79 (m, 1H), 7.14 (d, 2H, J = 7.7 Hz), 7.26 (m, 3H) and 7.44 
(d, 1H, J = 7.6 Hz); 13C NMR (CDCl3) δ 29.3, 35.2, 37.5, 43.1, 49.0, 53.4, 114.0, 
115.7, 127.4, 128.8, 129.2, 135.2, 136.8, 169.4, 170.2 and 173.3; mass spectrum 
(APCI), m/z 344.1607 (M + H)+ (C18H22N2O4 requires m/z 344.1610). 
 
Mono-2ʹ′(3ʹ′)-O-(N-(4-pentenoyl)glycyl)phenylalanyl-pdCpA (3.22a) and Bis-
2ʹ′ ,3ʹ′-O-(N-(4-pentenoyl)glycyl)phenylalanyl-pdCpA (3.22a). 
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A solution containing 35.0 mg (0.10 mmol) of cyanomethyl ester 3.21 and 8.0 mg 
(5.9 µmol) of the tris(tetrabutylammonium) salt of pdCpA96 in 100 µL of DMF 
was subjected to sonication at room temperature for 1 h. The reaction mixture was 
diluted with 2:1 CH3CN–50 mM NH4OAc, pH 4.5, to a total volume of 800 µL 
and purified using a semipreparative C18 reversed phase column (250 × 10 mm). 
The column was washed with 1 à 63% CH3CN in 50 mM NH4OAc, pH 4.5, over 
a period of 45 min at a flow rate of 3.5 mL/min (monitoring at 260 nm). After 
lyophilization of the appropriate fractions two compounds were obtained as 
colorless solids: mono-2ʹ′(3ʹ′)-O-(N-(4-pentenoyl)glycyl)phenylalanyl-pdCpA 
(3.22a) (retention times 18.4 and 18.8 min, for the two positional (2′,3′) isomers): 
yield 3.5 mg (64%). mass spectrum (ESI), m/z 921.2365 (M − H)− 
(C35H43N10O16P2 requires m/z 921.2339); bis-2ʹ′,3ʹ′-O-(N-(4-
pentenoyl)glycyl)phenylalanyl-pdCpA (3.22a): yield 2.0 mg (28%). mass 
spectrum (ESI), m/z 603.1809 (M – 2H)2− (C51H60N12O19P22− requires m/z 
603.1792). 
  
(S)-2-(Acetylthio)-3-(4-methoxyphenyl)propanoic Acid (3.25).98 
A solution of 400 mg (2.05 mmol) of (R)-4-O-methyltyrosine, 829 mg (6.97 
mmol) of KBr, and 0.51 mL of 48% HBr in 2 mL of water was cooled to −13 °C 
in an ice–salt water bath with argon bubbling through the solution. NaNO2 (176 
S COOH
O
O
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mg; 2.54 mmol) was added portionwise over a period of 45 min and the reaction 
mixture was allowed to warm to room temperature. The argon bubbling was 
ceased and the reaction mixture was stirred at room temperature for 20 h. The 
solution was bubbled with argon for 1 h and then extracted with three 20-mL 
portions of diethyl ether. The combined organic extract was dried (Na2SO4), 
filtered and concentrated under diminished pressure to give the bromo acid 3.24 
as a yellow oil which was used in the next step without further purification: yield 
230 mg (44%); 1H NMR (CDCl3) δ 3.20 (dd, 1H, J = 14.4 and 7.2 Hz), 3.41 (dd, 
1H, J = 14.4 and 8.0 Hz), 3.80 (s, 3H), 4.38 (dd, 1H, J = 8.0 and 7.2 Hz); 6.58 (d, 
2H, J = 8.4 Hz) and 7.50 (d, 2H, J = 8.4 Hz); 13C NMR (CDCl3) δ 39.9, 45.0, 
55.2, 114.1, 128.4, 130.2, 158.9 and 175.2. 
A suspension of 464 mg (1.42 mmol) Cs2CO3 in 3.5 mL of dry MeOH was 
bubbled with argon for 10 min and cooled to 0 °C. To this was added dropwise 
0.1 mL (92 mg; 1.5 mmol) of thioacetic acid and the mixture was stirred for 1 h 
while warming to room temperature. The solvent was concentrated under 
diminished pressure and the residue was dissolved in 1 mL of dry DMF. Bromo-
acid 3.24 (230 mg, 0.89 mmol) in 1.2 mL of DMF was added dropwise and the 
resulting solution was stirred at room temperature for 20 h. The solution was 
poured over 10 mL of 1 N HCl and extracted with three 15-mL portions of 
EtOAc. The combined organic extract was dried (Na2SO4) and concentrated under 
diminished pressure. The residue was purified by flash chromatography on a silica 
gel column (14 × 3 cm). Elution with 1:1:50 acetic acid–methanol–chloroform 
afforded 3.25 as a colorless oil: yield 0.14 g (61%); silica gel TLC Rf 0.31 (9:1 
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chloroform–methanol); 1H NMR (CDCl3) δ 2.32 (s, 3H), 2.97 (dd, 1H, J = 14.0 
and 7.6 Hz), 3.22 (dd, 1H, J = 14.2 and 7.6 Hz), 3.77 (s, 3H), 4.40 (m, 1H); 6.82 
(d, 2H, J = 8.0 Hz), 7.14 (d, 2H, J = 7.9 Hz) and 10.45 (br s, 1H); 13C NMR 
(CDCl3) δ 30.3, 36.7, 47.5, 55.3, 114.0, 129.0, 130.3, 158.8, 176.6 and 193.9. 
 
(S)-2-(Acetylthio)-3-(4-methoxyphenyl)propanoic Acid Succinimidyl Ester 
(3.26). 
To a cooled (0 °C) mixture of 110 mg (0.43 mmol) of 3.25 and 74.0 mg (0.65 
mmol) N-hydroxysuccinimide in 1.5 mL of dry THF was added dropwise a 
solution of 165 mg (0.80 mmol) of DCC in 1.5 mL of dry THF. The reaction 
mixture was stirred at room temperature overnight and then concentrated under 
diminished pressure. The residue was suspended in 4 mL of acetonitrile, filtered 
and the filtrate was concentrated under diminished pressure. The residue was 
purified by flash chromatography on a silica gel column (18 × 2 cm). Elution with 
2:1 hexanes–ethyl acetate afforded 3.26 as a colorless solid: yield 75 mg (49%); 
silica gel TLC Rf 0.42 (15:1 chloroform–methanol); 1H NMR (CDCl3) δ 2.32 (s, 
3H), 2.76 (s, 4H), 3.09 (dd, 1H, J = 11.6 and 6.0 Hz), 3.32 (dd, 1H, J = 11.2 and 
7.6 Hz), 3.76 (s, 3H), 4.63 (m, 1H); 6.86 (d, 2H, J = 7.2 Hz) and 7.23 (d, 2H, J = 
7.2 Hz); 13C NMR (CDCl3) δ 26.36, 26.39, 30.4, 36.8, 45.7, 55.9, 114.8, 129.3, 
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131.5, 159.9, 168.3, 170.7 and 193.7; mass spectrum (APCI), m/z 352.0863 (M + 
H)+ (C16H18NO6S requires m/z 352.0855). 
 
9-[3′-Deoxy-3′-(2-(acetylthio)-3-(4- methoxyphenyl)propanamido)-β-D-
ribofuranosyl]-6-(N,N′- dimethylamino)purine (3.27). 
To a solution of 20 mg (57 µmol) of compound 3.26 and 7.0 mg (24 µmol) of 
puromycin aminonucleoside in 1.0 mL of dry DMF was added 3 µL (2.4 mg; 24 
µmol) of Et3N. The reaction mixture was stirred at room temperature for 3.5 h and 
then concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (15 × 2 cm). Elution with 1:15 methanol–
chloroform afforded 3.27 as a colorless solid (mixture of epimers): yield 10 mg 
(79%); silica gel TLC Rf 0.36 (9:1 chloroform–methanol); 1H NMR (CD3OD) δ 
2.30 (s, 3H), 2.91 (dd, 1H, J = 13.6 and 6.0 Hz), 3.08 (dd, 1H, J = 13.5 and 9.9 
Hz), 3.46 (m, 8H), 3.74 (s, 3H), 3.83 (ddd, 1H, J = 6.7, 5.3 and 2.2 Hz), 4.37 (dd, 
1H, J = 9.9 and 6.1 Hz), 4.51 (m, 3H); 5.86 (d, 1H, J = 3.1 Hz), 6.84 (d, 2H, J = 
8.6 Hz), 7.16 (d, 2H, J = 8.5 Hz), 8.17 (s, 1H) and 8.27 (s, 1H); 13C NMR 
(CD3OD) δ 30.2, 38.6, 49.9, 52.1, 55.7, 62.3, 74.7, 85.1, 91.9, 114.9, 121.6, 
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130.9, 131.4, 139.2, 150.6, 152.9, 156.2, 160.2, 173.1 and 196.2; mass spectrum 
(ESI), m/z 530.2023 (M + H)+ (C24H31N6O6S requires m/z 530.2020). 
 
9-[3′-Deoxy-3′-(2-thio-3-(4- methoxyphenyl)propanamido)-β-D-
ribofuranosyl]-6-(N,N′- dimethylamino)purine (3.4). 
A solution of 7.0 mg (13 µmol) of compound 9 in1.2 mL of dry MeOH was 
saturated with NH3 and the reaction mixture was stirred at room temperature for 2 
h. To the reaction mixture were added 0.8 mL of 50 mM aq NH4OAc buffer and ~ 
5 mg of tris(2-carboxyethyl)phosphine, and the mixture was purified using a 
semipreparative C18 reversed phase column (250 × 10 mm). The column was 
washed with 1 à 63% CH3CN in 50 mM NH4OAc, pH 4.5, over a period of 45 
min at a flow rate of 3.5 mL/min (monitoring at 260 nm). Fractions containing the 
desired product eluted at 32.0 min and were collected, frozen, and lyophilized to 
give 3.4 as a colorless solid: yield 4.8 mg (74%); 1H NMR (DMSO-d6) δ 2.75 (m, 
4H), 3.08 (m, 3H), 3.54 (m, 4H), 3.71 (s, 3H), 3.71 (s, 3H), 3.74 (m, 3H), 3.99 (m, 
1H), 4.35 (br s, 12H), 4.45 (m, 2H), 5.08 (t, 1H, J = 5.4 Hz), 5.20 (t, 1H, J = 5.4 
Hz), 5.94 (d, 1H, J = 3.1 Hz), 5.98 (d, 1H, J = 2.6 Hz), 6.03 (m, 1H), 6.13 (d, 1H, 
J = 5.0 Hz), 6.82 (d, 2H, J = 2.9 Hz), 6.84 (d, 2H, J = 2.9 Hz), 7.13 (d, 4H, J = 8.6 
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Hz), 8.09 (d, 1H, J = 8.1 Hz), 8.13 (d, 1H, J = 7.4 Hz), 8.23 (s, 1H), 8.23 (s, 1H), 
8.42 (s, 1H) and 8.44 (s, 1H); 13C NMR (DMSO-d6) δ 41.08, 41.09, 42.5, 42.7, 
50.3, 50.4, 54.9, 55.0, 60.8, 61.0, 73.01, 73.02, 83.4, 83.5, 89.31, 89.32, 113.50, 
113.55, 119.60, 119.61, 130.0, 130.1, 130.47, 130.55, 137.8, 149.6, 151.8, 154.2, 
157.8, 157.9, 172.0 and 172.4; mass spectrum (MALDI), m/z 489.3 (M + H)+ 
(theoretical m/z 489.2); mass spectrum (APCI), m/z 489.1921 (M + H)+ 
(C22H29N6O5S requires m/z 489.1920). 
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CHAPTER 4 
SYNTHESIS OF MESOXALIC ACID HYDRAZONES 
4.1. INTRODUCTION  
 Due to its central role in the viral replication process the reverse 
transcriptase enzyme of human immunodeficiency virus (HIV) has been the target 
of a large number of anti-HIV therapeutic agents. The p66 subunit of HIV-1 
reverse transcriptase (HIV-1 RT) has two active sites.99 The polymerase site 
catalyzes RNA/DNA-dependent DNA polymerization and the RNase active site is 
responsible for selective hydrolysis of the RNA strands from RNA–DNA 
heteroduplexes. There are two kinetically different pathways for RNA hydrolysis, 
namely polymerase-dependent RNase activity and polymerase-independent 
RNase activity.100 RNase activity is very important for the two DNA strand 
transfer reactions that occur during the reverse transcription process.100 The strand 
transfer reactions involve translocation of a nascent DNA strand from one 
template strand to another.  
 In an automated screening of a library of compounds, 4-
chlorophenylhydrazone of mesoxalic acid (CPHM) was identified as an inhibitor 
of the DNA strand transfer reactions catalyzed by the reverse transcriptase with an 
IC50 value of 4.5 µM (Figure 4.1).101 The structure-activity relationship studies 
revealed that both the carboxylic acid moieties are essential for the inhibitory 
activity. Initially, it was proposed that CPHM chelates the Mg2+ ion present at the 
RNase active site and blocks the hydrolysis of RNA from RNA–DNA duplexes. 
Inhibition of the RNase activity prevents the transfer of the newly synthesized 
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DNA strand to a new template. CPHM was also shown to be specific for the 
reverse transcriptase from HIV-1.102  
 
Figure 4.1. Structure of 4-chlorophenylhydrazone of mesoxalic acid (CPHM). 
 
 In 2002, Shaw-Reid and coworkers studied the mode of action of CPHM 
using mutant HIV-1 RT enzymes.103 CPHM inhibited both the polymerase and the 
RNase activity of wild type HIV-1 RT but it did not show any activity against a 
polymerase active site mutant (D185N). Interestingly, its activity against an 
RNase active site mutant (D443N) was similar to that against the wild-type 
enzyme. CPHM also failed to inhibit the isolated RNase H domain chimera of 
HIV-1 RT. This data clearly suggested that CPHM binds near the polymerase 
active site and causes inhibition of RNase activity, possibly through allosteric 
effects. In cellular assays, however, CPHM did not show any antiviral activity. 
This was probably due to the inefficient uptake of this drug across the cell 
membrane. 
 Development of new inhibitors of HIV-1 RT might be useful in 
elucidating the mechanism of several steps of the viral reverse transcription 
process. Discovery of more potent inhibitors might also lead to new anti-viral 
therapies. We synthesized a series of analogues of CPHM (Figure 4.2) with 
Cl
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various substituents on the aromatic ring. Our collaborators designed these 
analogues using molecular docking simulations based on their ability to bind to 
the polymerase active site. 
 
Figure 4.2. Structures of CPHM analogues prepared. 
 
4.2 RESULTS 
Hydrazones 4.1a, 4.1b and 4.1c were prepared in a single step by 
condensing the corresponding arylhydrazines with disodium mesoxlate in the 
presence of an acid catalyst (Scheme 4.1). Compound 1c was subsequently 
esterified with ethanol and catalytic conc. H2SO4 to afford the diester 4.2 in 80% 
yield. Reduction of the nitro group with stannous chloride followed by acetylation 
of the resulting amine gave intermediate 4.4. Ester hydrolysis of the diester 4.4 
using aqueous LiOH afforded the diacid 4.1d in 74 % yield (Scheme 4.2).104  
 
HN
N
CO2H
CO2H
R1
R3
4.1a R1 = CN, R2 = H, R3 = H 
4.1b R1 = Cl, R2 = H, R3 = CH3
4.1c R1 = NO2, R2 = H, R3 = H
4.1d R1 = NHAc, R2 = H, R3 = H
4.1e R1 = OBn, R2 = H, R3 = H 
4.1f  R1 = Cl, R2 = CH3, R3 = H
4.1g R1 = OMe, R2 = H, R3 = H
R2
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Scheme 4.1. Synthesis of CPHM analogues 4.1a, 4.1b and 4.1c.104 
 
Scheme 4.2. Synthesis of 4-N-acetyl analogue 4.1d.104 
 
Analogue 4.1e was synthesized from 4-O-benzylaniline hydrochloride by 
diazonium coupling with diethyl malonate to form intermediate 4.5, followed by 
hydrolysis of the diester using LiOH (Scheme 4.3).104 Similarly, 4-chloro-3- 
 
Scheme 4.3. Synthesis of 4-O-benzyl analogue 4.1e.104 
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Scheme 4.4. Synthesis of 4-chloro-3-methyl analogue 4.1f. 
 
methylaniline was diazo-coupled with diethyl malonate and the intermediate 4.6 
was subjected to ester-hydrolysis to produce diacid 4.1f in 70% overall yield 
(Scheme 4.4). The synthesis of the 4-O-methyl analogue 4.1g was achieved using 
a slightly different route. Diazo coupling of p-anisidine with dibenzyl malonate 
4.7 (prepared from malonic acid)105 afforded intermediate 4.8 in 56% yield. 
Reductive debenzylation using Pd(OH)2/C provided analogue 4.1g in 47% yield 
(Scheme 4.5).104 
 
Scheme 4.5. Synthesis of 4-O-methyl analogue 4.1g.104 
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4.3. DISCUSSION 
Syntheses of the analogues 4.1a–c were achieved in one step from the 
corresponding hydrazones, which were commercially available. Reduction of the 
nitro group to the amine group in Scheme 4.2 was much cleaner when the diacid 
moiety was protected as the ethyl esters. Analogues 4.1e–g were prepared by 
condensing diazotized aniline derivatives with malonate esters and subsequent 
deprotection of the esters. For the synthesis of 4-O-methyl analogue (4.1g), 
dibenzyl malonate was used instead of diethyl malonate. The diethyl analogue of 
4.8 never afforded the desired product (4.1g) when subjected to saponification 
conditions, most probably due to oxidative decomposition. Reductive removal of 
the benzyl groups was employed to circumvent this problem (Scheme 4.5). These 
analogues were sent to our collaborators for biochemical evaluation.  
 
4.4. EXPERIMENTAL 
Chemicals and solvents were of reagent grade and were used without 
further purification. All reactions involving air or moisture sensitive reagents or 
intermediates were performed under an argon atmosphere. Flash chromatography 
was carried out using Silicycle 200–400 mesh silica gel. Analytical TLC was 
carried out using 0.25 mm EM Silica Gel 60 F250 plates that were visualized by 
irradiation (254 nm) or by staining with p-anisaldehyde stain. 1H and 13C NMR 
spectra were obtained using an Inova 400 MHz Varian instrument. Chemical 
shifts were reported in parts per million (ppm, δ) referenced to the residual 1H 
resonance of the solvent (CDCl3, 7.26 ppm; DMSO-d6, 2.50 ppm). 13C spectra 
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were referenced to the residual 13C resonance of the solvent (CDCl3, 77 ppm; 
DMSO-d6, 39.5 ppm). Splitting patterns were designated as follow: s, singlet; br, 
broad; d, doublet; dd, doublet of doublet; dt, doublet of triplet; m, multiplet. High 
resolution mass spectra were obtained at the Arizona State University High 
Resolution Mass Spectrometry Laboratory or at the Ohio State University Mass 
Spectrometry Facility. 
 
2-(2-(4-Cyanophenyl)hydrazono)malonic Acid (4.1a). 
To a suspension containing 180 mg (1.00 mmol) of disodium ketomalonate in 3 
mL of 1:2 ethanol–water was added 170 mg (1.00 mmol) of 4-
cyanophenylhydrazine hydrochloride with vigorous stirring. The pH of the 
resulting mixture was adjusted to ~5 by adding 1 N aq NaHSO4 soln and the 
reaction mixture was stirred at 23 °C for 12 h. The mixture was filtered and the 
precipitate was washed with cold acidic (pH ~4) water. The precipitate was 
dissolved in 40 mL of ethyl acetate and was extracted with three 20-mL portions 
of 1 N aq NaOH soln. The combined NaOH extract was washed with two 10-mL 
portions of ethyl acetate, cooled in an ice bath and acidified to pH ~3 with 3 N 
HCl. The formed precipitate was filtered, washed with cold acidic (pH ~4) water 
and air-dried to obtain 4.1a as a pale yellow solid: yield 182 mg (78%); mp >200 
°C; silica gel TLC Rf 0.45 (4:1 chloroform–methanol); 1H NMR (DMSO-d6) δ 
7.49 (d, 2H, J = 8.8 Hz), 7.77 (d, 2H, J = 8.8 Hz) and 13.55 (br s, 1H); 13C NMR 
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(DMSO-d6) δ 104.3, 115.2, 115.2, 119.2, 125.6, 133.8, 133.8, 146.3, 165.0 and 
165.3; mass spectrum (APCI), m/z 232.0342 (M − H)− (C10H6N3O4 requires 
232.0358). 
 
2-(2-(4-Chloro-2-methylphenyl)hydrazono)malonic Acid (4.1b). 
To a suspension containing 180 mg (1.00 mmol) of disodium ketomalonate in 3 
mL of 1:2 ethanol–water was added 198 mg (1.00 mmol) of 4-chloro-2-
methylphenylhydrazine with vigorous stirring. The pH of the resulting mixture 
was adjusted to ~5 by adding 1 N aq NaHSO4 soln and the reaction mixture was 
stirred at 23 °C for 12 h. The mixture was filtered and the precipitate was washed 
with cold acidic (pH ~4) water. The precipitate was dissolved in 40 mL of ethyl 
acetate and extracted with three 20-mL portions of 1 N aq NaOH soln. The 
combined NaOH extract was washed with two 10-mL portions of ethyl acetate, 
cooled in an ice bath and acidified to pH ~3 with 3 N HCl. The formed precipitate 
was filtered, washed with cold acidic (pH ~4) water and air-dried to obtain 4.1b 
as a yellow solid: yield 132 mg (51%); mp >200 °C; silica gel TLC Rf 0.33 (4:1 
chloroform–methanol); 1H NMR (DMSO-d6) δ  2.23 (s, 3H), 7.26 (m, 2H) and 
7.51 (m, 1H); 13C NMR (DMSO-d6) δ 16.9, 114.7, 125.1, 125.4, 126.0, 127.3, 
130.4, 140.4, 165.6 and 169.0; mass spectrum (APCI), m/z 255.0176 (M − H)− 
(C10H8N2O4Cl requires 255.0173). 
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2-(2-(4-Nitrophenyl)hydrazono)malonic Acid (4.1c).104  
To a suspension containing 180 mg (1.00 mmol) of disodium ketomalonate in 3 
mL of 1:2 ethanol–water was added 208 mg (1.10 mmol) of 4-
nitrophenylhydrazine hydrochloride with vigorous stirring. The pH of the 
resulting mixture was adjusted to ~5 by adding 1 N aq NaHSO4 soln and the 
reaction mixture was stirred at 23 °C for 12 h. The mixture was filtered and the 
precipitate was washed with cold acidic (pH ~4) water. The precipitate was 
dissolved in 40 mL of ethyl acetate and extracted with three 20-mL portions of 1 
N aq NaOH soln. The combined NaOH extract was washed with two 10-mL 
portions of ethyl acetate, cooled in an ice bath, acidified to pH ~3 with 3 N HCl 
and re-extracted with three 40-mL portions of ethyl acetate. The combined 
organic layer was then washed with 20 mL of brine, dried over anhydrous 
Na2SO4, filtered and concentrated under diminished pressure to afford 4.1c as a 
yellow solid: yield 230 mg (91%); mp 196–198 °C (dec); silica gel TLC Rf 0.40 
(4:1 chloroform–methanol); 1H NMR (DMSO-d6) δ 7.56 (d, 2H, J = 9.2 Hz), 8.23 
(d, 2H, J = 9.2 Hz) and 12.84 (br s, 1H); 13C NMR (DMSO-d6) δ 115.0, 115.0, 
125.6, 125.6, 126.8, 142.2, 148.1, 163.5 and 165.0; mass spectrum (APCI), m/z 
252.0266 (M − H)− (C9H6N3O6 requires 252.0257). 
	   145 
 
2-(2-(4-Nitrophenyl)hydrazono)malonic Acid Diethyl Ester (4.2).104  
To a solution of 235 mg (0.760 mmol) of 4.1c in 15 mL of ethanol was added 6–7 
drops of H2SO4 and the reaction mixture was heated to reflux for 16 h. The cooled 
reaction mixture was concentrated under diminished pressure and the residue was 
diluted in 40 mL of ethyl acetate. The organic layer was washed with two 20-mL 
portions of sat aq NaHCO3, 10 mL of brine, then dried over anhydrous Na2SO4, 
filtered and concentrated under diminished pressure. The resulting residue was 
purified by flash chromatography on a silica gel column (15 × 3 cm). Elution with 
50:1 chloroform–methanol gave 4.2 as a light yellow solid: yield 230 mg (80%); 
mp 64–66 °C; silica gel TLC Rf 0.72 (1:1 hexanes–ethyl acetate);  1H NMR 
(CDCl3) δ 1.38 (m, 6H), 4.36 (m, 4H), 7.38 (d, 2H, J = 9.2 Hz), 8.24 (d, 2H, J = 
9.2 Hz) and 12.72 (br s, 1H); 13C NMR (CDCl3) δ 14.0, 14.2, 61.8, 62.1, 115.0, 
115.0, 124.3, 125.7, 125.7, 143.7, 143.9, 162.6 and 162.7; mass spectrum (ESI), 
m/z 332.0844 (M + Na)+ (C13H15N3O6Na requires 332.0859). 
 
2-(2-(4-Aminophenyl)hydrazono)malonic Acid Diethyl Ester (4.3). 
A suspension containing 44.0 mg (0.14 mmol) of 4.2 and 160 mg (0.71 mmol) of 
SnCl2•2H2O in 2 mL of absolute ethanol was purged with argon for 15 min. The 
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reaction mixture was heated to 70 °C for 12 h under an argon atmosphere. The pH 
of the cooled reaction mixture was adjusted to ~9 by addition of sat aq NaHCO3 
soln and the resulting mixture was stirred at 23 °C for 1 h. The reaction mixture 
was then extracted with three 20-mL portions of ethyl acetate. The combined 
organic layer was washed with three 20-mL portions of brine, dried over 
anhydrous Na2SO4, filtered and concentrated under diminished pressure. The 
residue was purified by flash chromatography on a silica gel column (12 × 2 cm). 
Elution with 1:1 hexanes–ethyl acetate gave 4.3 as an orange solid: yield 30 mg 
(75%); mp 91 °C; silica gel TLC Rf 0.44 (1:1 hexanes–ethyl acetate); 1H NMR 
(CDCl3) δ 1.36 (m, 6H), 3.68 (br s, 2H), 4.32 (m, 4H), 6.67 (d, 2H, J = 8.8 Hz), 
7.17 (d, 2H, J = 8.8 Hz) and 12.99 (br s, 1H); 13C NMR (CDCl3) δ 14.3, 14.4, 
60.9, 61.1, 115.9, 115.9, 117.2, 117.6, 117.6, 134.1, 144.1, 163.8 and 164.2; mass 
spectrum (APCI), m/z 280.1299 (M + H)+ (C13H18N3O4 requires 280.1297). 
 
2-((4-Acetylaminophenyl)hydrazono)malonic Acid Diethyl Ester (4.4).104 
To a solution containing 20.0 mg (72 µmol) of 4.3 and 57.0 µL (56 mg; 0.72 
mmol) of pyridine in 2 mL of anhydrous CH2Cl2 was added 36.0 µL (39 mg; 0.36 
mmol) of acetic anhydride and the reaction mixture was stirred at 23 °C for 8 h. 
The reaction mixture was concentrated under diminished pressure and diluted in 
15 mL of ethyl acetate. The organic layer was washed with three 5-mL portions of 
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1 N HCl, 5 mL of satd aq NaHCO3 soln, 5 mL of brine, then dried over anhydrous 
Na2SO4, filtered and concentrated under diminished pressure. The residue was 
purified by flash column chromatography on a silica gel column (12 × 2 cm). 
Elution with 1:1 hexanes–ethyl acetate gave 4.4 as yellow solid: yield 23 mg 
(100%); mp 154–156 °C; silica gel TLC Rf 0.28 (1:1 hexanes–ethyl acetate); 1H 
NMR (CDCl3) δ 1.36 (m, 6H), 2.15 (s, 3H), 4.32 (m, 4H), 7.26 (d, 2H, J = 8.4 
Hz), 7.52 (d, 2H, J = 8.4 Hz), 7.71 (br s, 1H) and 12.84 (s, 1H); 13C NMR 
(CDCl3) δ 14.2, 14.4, 24.6, 61.3, 61.4, 116.1, 116.1, 119.6, 121.1, 121.1, 135.1, 
138.2, 163.66, 163.68 and 168.5; mass spectrum (APCI), m/z 322.1403 (M + H)+ 
(C15H20N3O5 requires 322.1403). 
 
2-((4-Acetylamino-phenyl)-hydrazono)malonic Acid (4.1d).104 
To a solution containing 23.0 mg (72 µmol) of 4.4 in 1 mL THF was added 
dropwise a solution containing 8.0 mg (0.3 mmol) of LiOH in 0.5 mL of water. 
The reaction mixture was stirred at 23 °C for 16 h. The reaction was diluted with 
5 mL of Et2O and 10 mL of water and the phases were separated. The aqueous 
layer was washed with two 5-mL portions of ethyl acetate, cooled in an ice bath, 
acidified to pH ~3 with 1 N HCl and extracted with three 10-mL portions of ethyl 
acetate. The combined organic layer was then washed with 10 mL of brine, dried 
over anhydrous Na2SO4, filtered and concentrated under diminished pressure to 
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afford 4.1d as a yellow solid: yield 14 mg (74%); mp 176–178 °C (dec); silica gel 
TLC Rf 0.19 (4:1 chloroform–methanol); 1H NMR (DMSO-d6) δ 2.03 (s, 3H), 
7.45 (d, 2H, J = 8.8 Hz), 7.61 (d, 2H, J = 8.8 Hz), 9.99 (s, 1H) and 13.24 (s, 1H); 
13C NMR (DMSO-d6) δ 24.0, 116.4, 116.4, 116.9, 119.9, 119.9, 136.6, 136.9, 
164.6, 168.2 and 168.6; mass spectrum (APCI), m/z 264.0627 (M−H)− 
(C11H10N3O5 requires 264.0620). 
 
2-((4-Benzoxyphenyl)hydrazono)malonic Acid Diethyl Ester (4.5).104 
To a solution containing 2.36 g (10.0 mmol) of 4-O-benzylaniline hydrochloride 
in 51 mL of acetic acid was added 2.5 mL of conc HCl and the reaction mixture 
was cooled to 0 °C. To the cooled reaction mixture was added a solution of 0.90 g 
(13.0 mmol) of sodium nitrite in 26 mL water and resulting mixture was stirred at 
0 °C for 30 min. The mixture was then added dropwise into a previously prepared 
mixture of 1.51 mL (1.44 g; 10.0 mmol) of diethyl malonate and 31.0 g (0.38 
mol) of sodium acetate in 250 mL water. The reaction mixture was stirred at 23 
°C for 24 h and then filtered.  The precipitate was washed with water, air dried 
and purified by flash column chromatography on a silica gel column (15 × 4 cm). 
Elution with 2:1 hexanes–ethyl acetate afforded 4.5 as yellow solid: yield 2.49 g 
(67%); mp 70-72 °C; silica gel TLC Rf 0.69 (1:1 hexanes–ethyl acetate); 1H NMR 
(CDCl3) δ 1.26 (m, 6H), 4.23 (m, 4H), 4.93 (m, 2H), 6.86 (m, 2H), 7.23 (m, 7H) 
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and 12.81 (s, 1H); 13C NMR (CDCl3) δ 14.1, 14.3, 60.9, 61.1, 70.3, 115.8, 115.8, 
116.8, 116.8, 118.6, 127.4, 127.4, 128.0, 128.6, 128.6, 136.8, 153.7, 156.2, 163.4 
and 163.8; mass spectrum (APCI), m/z 371.1621 (M + H)+ (C20H23N2O5 requires 
371.1607). 
 
2-((4-Benzoxyphenyl)hydrazono)malonic Acid (4.1e).104 
To a solution containing 493 mg (1.33 mmol) of 4.5 in 12 mL THF was added 
dropwise a solution of 160 mg (6.66 mmol) of LiOH in 6 mL of water and the 
reaction mixture was stirred at 23 °C for 16 h. The reaction was diluted with 20 
mL of Et2O and 25 mL of water and the phases were separated. The aq layer was 
washed with two 10-mL portions of ethyl acetate, cooled in an ice bath and 
acidified to pH ~3 with 3 N HCl. The formed precipitate was filtered, washed 
with cold acidic (pH ~4) water and air dried to obtain 4.1e as a yellow solid: yield 
300 mg (72%); mp 153 °C (dec); silica gel TLC Rf 0.43 (4:1 chloroform–
methanol); 1H NMR (DMSO-d6) δ 5.10 (s, 2H), 7.14 (m, 2H), 7.40 (m, 7H) and 
13.30 (br s, 1H); 13C NMR (DMSO-d6) δ 69.5, 115.7, 115.7, 116.2, 117.5, 117.5, 
127.7, 127.7, 127.9, 128.4, 128.4, 135.4, 136.9, 136.9, 156.0, 164.6 and 168.8; 
mass spectrum (APCI), m/z 313.0827 (M − H)− (C16H13N2O5 requires 313.0824). 
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 2-(2-(4-Chloro-3-methylphenyl)hydrazono)malonic Acid Diethyl Ester (4.6). 
To a solution containing 142 mg (1.00 mmol) of 4-chloro-3-methylaniline in 5.1 
mL of acetic acid was added 0.3 mL of conc HCl and the mixture was cooled to 0 
°C. To the cold mixture was added a solution of 89.0 mg (1.30 mmol) of sodium 
nitrite in 2.5 mL water and the reaction mixture was stirred at 0 °C for 30 min. 
The reaction mixture was then poured into a previously prepared mixture of 0.13 
mL (120 mg; 0.86 mmol) of diethyl malonate and 2.54 g (31.0 mmol) of sodium 
acetate in 20 mL of water. The reaction mixture was stirred at 23 °C for 24 h and 
filtered. The precipitate was washed with water, air dried and purified by flash 
chromatography on a silica gel column (14 × 2 cm). Elution with 25:1 
chloroform–methanol gave 4.6 as light yellow solid: yield 250 mg (89%); mp 46 
°C; silica gel TLC Rf 0.72 (1:1 hexanes–ethyl acetate); 1H NMR (CDCl3) δ 1.39 
(m, 6H), 2.39 (m, 3H), 4.35 (m, 4H), 7.10 (m, 1H), 7.26 (m, 2H) and 12.75 (br s, 
1H); 13C NMR (CDCl3) δ 14.1, 14.3, 20.3, 61.3, 61.5, 114.2, 117.7, 120.4, 129.94, 
129.93, 137.4, 140.4, 163.3 and 163.5; mass spectrum (APCI), m/z 313.0951 
(M+H)+ (C14H18N2O4Cl requires 313.0955). 
 
2-((4-Chloro-3-methylphenyl)hydrazono)malonic Acid (4.1f). 
To a solution of 75.0 mg (0.24 mmol) of 4.6 in 2.5 mL of THF was added 
dropwise a solution of 24.0 mg (0.96 mmol) of LiOH in 1.25 mL of water and the 
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reaction mixture was stirred at 23 °C for 16 h. The reaction mixture was diluted 
with 10 mL of Et2O and 20 mL of water and the phases were separated. The 
aqueous layer was washed with two 8-mL portions of ethyl acetate, cooled in an 
ice bath and acidified to pH ~3 with 1 N HCl. The formed precipitate was filtered, 
washed with cold acidic (pH ~4) water and air dried to obtain 4.1f as a yellow 
solid: yield 45 mg (79%); mp 150–152 °C (dec); silica gel TLC Rf 0.38 (4:1 
chloroform–methanol); 1H NMR (DMSO-d6) δ and 2.33 (s, 3H), 7.33 (m, 1H), 
7.40 (m, 1H), 7.46 (m, 1H) and 12.75 (br s, 1H);	  13C NMR (DMSO-d6) 19.8, 
114.8, 118.0, 119.8, 128.4, 129.7, 136.6, 140.8, 164.2 and 167.3; mass spectrum 
(APCI), m/z 255.0175 (M − H)− (C10H8N2O4Cl requires 255.0173). 
  
Dibenzyl Malonate (4.7).105 
To a solution containing 4.02 g (38.6 mmol) of malonic acid and 9.40 mL (9.00 g; 
91 mmol) of benzyl alcohol in 15 mL of toluene was added 5 drops of H2SO4 and 
the reaction mixture was heated to reflux using a Dean Stark apparatus for 2 h. 
The cooled reaction mixture was concentrated under diminished pressure and the 
residue was redissolved in 80 mL of ethyl acetate. The ethyl acetate layer was 
washed with two 30 mL-portions of sat aq NaHCO3 soln, one 20-mL portion of 
brine, dried over anhydrous Na2SO4, filtered and concentrated under diminished 
pressure. The residue was purified by flash chromatography on a silica gel 
column (20 × 4 cm). Elution with 4:1 hexanes–ethyl acetate gave 4.7 as a 
colorless oil: yield 9.01 g (82%); silica gel TLC Rf 0.57 (2:1 hexanes–ethyl 
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acetate); 1H NMR (CDCl3) δ 3.48 (s, 2H), 5.18 (s, 4H) and 7.35 (m, 10H); 13C 
NMR (CDCl3) δ 41.7, 67.4, 67.4, 128.4, 128.4, 128.4, 128.4, 128.5, 128.5, 128.7, 
128.7, 128.7, 128.7, 135.3, 135.3, 166.3 and 166.3. 
 
2-((4-Methoxyphenyl)hydrazono)malonic Acid Dibenzyl Ester (4.8).  
To a mixture containing 0.62 g (5.00 mmol) of p-anisidine in 1.25 mL of conc 
HCl was added 2.5 g of ice and the mixture was cooled to 0 °C. To the cold 
mixture was added dropwise a solution of 0.35 g (5.11 mmol) of sodium nitrite in 
0.85 mL water and the reaction mixture was stirred at 0 °C for 20 min. The 
resulting mixture was then poured into a previously prepared mixture of 1.40 g 
(4.90 mmol) of dibenzyl malonate (4.7), 0.95 g (11.6 mmol) of sodium acetate 
and 1.5 mL of water in 10 mL of ethanol. The reaction mixture was stirred at 23 
°C for 12 h and then concentrated under diminished pressure. The residue was 
diluted in 40 mL ethyl acetate. The organic layer was washed with two 15-mL 
portions of water, 10 mL of brine, then dried over anhydrous Na2SO4, filtered and 
concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (15 × 3 cm). Elution with 2:1 hexanes–
ethyl acetate gave 4.8 as orange oil: yield 1.21 g (56%); silica gel TLC Rf 0.72 
(1:1 hexanes–ethyl acetate); 1H NMR (CDCl3) δ 3.81 (s, 3H), 5.34 (s, 4H), 6.91 
(m, 2H), 7.37 (m, 12H) and 13.00 (br s, 1H); 13C NMR (CDCl3) δ 55.6, 66.6, 66.6, 
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114.8, 114.8, 117.1, 117.1, 118.0, 127.9, 127.9, 128.00, 128.00, 128.05, 128.3, 
128.5, 128.5, 128.7, 128.7, 135.5, 135.5, 136.3, 157.4, 163.3 and 163.6; mass 
spectrum (APCI), m/z 419.1616 (M + H)+ (C24H23N2O5 requires 419.1607). 
 
2-((4-Methoxyphenyl)hydrazono)malonic Acid (4.1g).104 
Hydrogen gas was bubbled through a stirred suspension containing 298 mg (0.71 
mmol) of 4.8 and 15 mg of 20% palladium hydroxide in 15 mL of ethyl acetate 
for 25 min. The reaction mixture was filtered through a Celite pad and the pad 
was washed with ethyl acetate. The filtrate was concentrated under diminished 
pressure to a volume of 30 mL and extracted with three 15-mL portions of 1 N aq 
NaOH soln. The combined NaOH extract was washed with two 10-mL portions 
of ethyl acetate, cooled in an ice bath, acidified to pH ~3 with 3 N HCl and re-
extracted with three 15-mL portions of ethyl acetate. The combined organic layer 
was then washed with one 20-mL portion of brine, dried over anhydrous Na2SO4, 
filtered and concentrated under diminished pressure to afford 4.1g as a yellow 
solid: yield 80 mg (47%); mp 128–130 °C (dec); silica gel TLC Rf 0.86 (4:1 
chloroform–methanol); 1H NMR (DMSO-d6) δ 3.75 (s, 3H), 6.98 (d, 2H, J = 8.4 
Hz), 7.49 (d, 2H, J = 8.4 Hz) and 13.30 (br s, 1H); 13C NMR (DMSO-d6) δ 55.4, 
114.7, 114.7, 115.8, 115.8, 117.6, 135.1, 157.1, 164.5 and 169.0; mass spectrum 
(ESI), m/z 237.0503 (M − H)− (C10H9N2O5 requires 237.0511). 
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